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The innate immune system is the first line of defence against infection. It is comprised of 
physicochemical barriers and a variety of cell types including macrophages and dendritic 
cells. Pathogens express specific pathogen associated molecular patterns (PAMP) which 
are recognised by pattern recognition receptors (PRR) on macrophages to initiate an innate 
immune response. Gram-negative bacteria such as Salmonella enterica serovar 
Typhimurium express a range of bacterial PAMPs recognised by Toll-like receptors (TLRs) 
including lipopolysaccharides (LPS) recognised by TLR-4 and lipoproteins by TLR-2. The 
activation of TLRs results in activation of nuclear factor κB (NF-κB) to drive transcription of 
mRNA coding for pro-inflammatory proteins such as tumor necrosis factor α (TNF-α) and 
pro-interleukin (IL) 1β. Myeloid cells also possess intracellular PRRs including the 
nucleotide-binding domain and leucine-rich repeat (NLR) family. NLR family CARD domain-
containing protein 4 (NLRC4) and NLR family pyrin domain-containing protein 3 (NLRP3) are 
the main NLRs engaged in recognising S. Typhimurium infection, leading to formation of the 
inflammasome. 
The inflammasome is a macromolecular complex assembled in the cytoplasm, and usually 
contains a NLR, the structural protein apoptosis-associated speck-like protein containing a 
CARD (ASC) and effector enzymes such as cysteine-dependent aspartate-directed protease 
(caspase) -1 and caspase-8. This structure is responsible for processing the cytokines pro-
IL-1β and pro-IL-18 to their mature form and is involved in triggering a pro-inflammatory 
process of cell death termed pyroptosis. The formation of the inflammasome therefore 
results in cell death and secretion of proinflammatory cytokines which play important roles in 
controlling infections. Inflammasome activity must be tightly coordinated, as its dysregulation 
is associated with a variety of auto-inflammatory and auto-immune diseases. 
The signalling events leading to inflammasome assembly are poorly understood and the 
molecules involved in fine-tuning its activity are only beginning to be discovered. The aim of 
 
 
this thesis was to discover new molecules involved in inflammasome activation and/or in 
keeping its activity in check. To achieve this goal, I performed S. Typhimurium infection 
assays in primary bone marrow derived macrophages (BMDM) derived from C57BL/6 mice 
wild type (WT) and compared the resulting cellular viability, intracellular bacteria counts and 
IL-1β production to that of BMDMs derived from C57BL/6 mice lacking proteins involved 
with, or suspected to be involved with, innate immune activity. Amongst the proteins I 
studied, caspase recruitment domain 9 (CARD9) inhibited inflammasome-mediated IL-1β 
production. Multiple independent genome-wide association studies link this protein to 
inflammatory pathologies such as Crohn’s disease, but its role in canonical inflammasomes 
was largely unexplored. 
To investigate how CARD9 inhibits inflammasome-mediated IL-1β production I have 
conducted assays in WT and Card9-/- BMDMs, including stimulation of specific NLRs with 
their purified ligands, infection with bacterial strains deficient in NLRC4 activation, and 
infection assays in presence of pharmacological inhibitors. By employing these approaches, 
I observed that CARD9 has a negative role on NLRP3-dependent IL-1β 
production.  Specifically, in response to activation of the NLRP3 by Salmonella infection, 
CARD9 negatively regulates pro-IL-1β transcription, and decreases IL-1β processing by 
inhibiting spleen tyrosine kinase (SYK)-mediated NLRP3 activation and represses caspase-8 
activity in the inflammasome. CARD9 expression is suppressed in the course of S. 
Typhimurium infection which may act as a mechanism to increase IL-1β production during 
the infection. 
In conclusion, I have established a connection between CARD9 and IL-1β production by the 
canonical NLRP3 inflammasome and elucidated some of the mechanisms involved in this 
process. I have also found evidence that other proteins are likely to be involved in 
inflammasome regulation and the elucidation of their roles will be addressed in future 
studies.  
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1.1. Innate immunity 
Microbial diversity is unprecedented, with an estimated one trillion species occupying a wide 
range of environments (Locey and Lennon, 2016). The human body, in particular, is 
inhabited by 10,000 different microbial species (Huttenhower et al., 2012) with an estimated 
ratio of human to bacterial cells of one to one (the more dramatic and often cited one to ten 
ratio lacks empirical support) (Sender et al., 2016). Most of these bacteria reside in the 
gastrointestinal tract and are either commensal or symbiotic. Commensal microorganisms 
benefit from the host while the host is neither harmed nor benefitted. Symbionts are 
microorganisms that have co-evolved with the host in a mutually beneficial way. They are 
provided with a favourable habitat and, through the host’s diet, non-digestible material which 
they degrade to produce energy and nutrients essential for their growth. In turn, certain end-
products of this fermentation, such as short chain fatty acids and vitamins, play important 
physiological, metabolic and protective roles in the host’s gut health. Furthermore, symbiotic 
bacteria compete with pathogenic bacteria for nutrients and space preventing them from 
colonising the gastrointestinal tract (Pickard et al., 2017).  
In addition to commensals and symbionts, we are also exposed to a large number of 
microbes with pathogenic potential, which, however, rarely cause disease. This is not only 
due to competition with the gut microbiota as mentioned above, but also due to the 
protective effect of the innate immune system. This system is the first line of defence against 
invading organisms and is formed by numerous components such as physical and chemical 
barriers, nonspecific antimicrobial molecules and numerous cell types such as macrophages 
and dendritic cells. Although it is nonspecific and conserved throughout evolution, it is highly 
efficient at eliminating threats before compromising the host’s health. 
Different cells of the innate immune system recognise bacteria by using pattern recognition 
receptors (PRR), which detect conserved pathogen associated molecular patterns (PAMP) 
of foreign origin and danger associated molecular patterns (DAMP) of host origin. Once 
activated, PRRs trigger specific cellular signalling events leading to a pro-inflammatory 
response important for clearing the infection (Janeway and Medzhitov, 2002; Schroder and 
Tschopp, 2010). At the heart of this response lies the production of cytokines and 
chemokines together with the induction of various forms of programmed host’s cell death 
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(Figure 1.1). In the context of a wide range of infectious agents, programmed cell death is 
beneficial to the host: an infected cell “commits suicide” and interrupts the pathogen’s life 
cycle and/or alerts neighbouring cells to the pathogen (Grootjans et al., 2017; Lamkanfi and 
Dixit, 2014). 
Apoptosis is the most well-defined form of programmed cell death triggered by both intrinsic 
and extrinsic signals, occurring both in physiological conditions (for instance during 
development), and in pathologies including infections. Morphologically, apoptotic cells 
undergo shrinkage due to enzymatic cleavage of cytoskeletal proteins, membrane blebbing, 
chromatine condensation and nuclear fragmentation (Kerr et al., 1972). This death program 
is executed by different cysteine-aspartic protease (caspase) enzymes. An important feature 
of this process is the translocation of phosphatidylserine (PS) to the outer leaflet of the 
plasma membrane, acting as a signal for phagocytes to “clear” the apoptotic cell (Fadok et 
al., 1992). This process is considered immunologically silent as apoptotic cells do not 
generally release their intracellular contents and are quickly cleared by phagocytosis. 
Unlike the immunologically silent apoptosis, pyroptosis is an orchestrated form of cell death 
that involves the production and release of pro-inflammatory cytokines interleukin (IL)-1 and 
IL-18. Although the mechanisms of cytokine release are not clear, it is possible that the 
release of intracellular contents including cytokines occurs after the loss of membrane 
integrity.  Pyroptosis is triggered by caspase 1 cleavage of the protein gasdermin D to its 
active form which create pores in the cellular membrane (Aglietti et al., 2016; Kayagaki et al., 
2015; Shi et al., 2015). This results in rapid cytoplasmic swelling with subsequent cell 
rupture and release of intracellular contents that can act as danger signals to “alert” 
neighboring cells (Cunha and Zamboni, 2013). This form of cell death is associated with the 
formation of macromolecular complexes known as inflammasomes. Pyroptosis is thought to 
be important for host protection against a number of intracellular pathogens, as the rupture 
of the cell in an inflammatory context releases the invading pathogen into the extracellular 
space where it can be destroyed by other immune cells, such as neutrophils (Lamkanfi and 
Dixit, 2014; Miao et al., 2010). 
Necroptosis is a form of cell death typically associated with pathological processes where 
cells are rapidly stressed. Necroptosis involves rapid cytoplasmic swelling resulting in 
plasma membrane and organelle breakdown and is thought to trigger inflammation due the 
release of DAMPs. Mechanistically, this form of cell death involves proteins such as 
caspase-8, receptor-interacting serine/threonine-protein kinase (RIPK)-1, RIPK-3 and mixed 
lineage kinase domain-like (MLKL) (Grootjans et al., 2017; Krysko et al., 2008). Necroptosis 
can also be triggered by infectious agents and play a role in clearing the infection. For 
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instance, RIPK3-dependent necroptosis is thought to be important in the clearance of 
cytomegalovirus infections (Upton et al., 2008). 
 
 
Figure 1.1: Programmed cell-death. Overview of apoptosis, necroptosis and pyroptosis, 
with some of the key-players highlighted.  
 
1.2. Toll-like Receptors 
The family of Toll-like receptors (TLRs) consists of transmembrane proteins usually 
expressed in myeloid cells such as macrophages and dendritic cells. Twelve of these 
receptors have been so far identified in mammals and are located either on the surface of 
the plasma membrane (TLR 1, 2, 4, 5, 6, 10 and 11) or in endosomes (TLRs 3, 4, 7, 8, 9, 12 
and 13). TLRs can initiate and modulate important biological responses, such as phagocyte 
activation and induction of inflammation, therefore contributing to the resolution of infection 
(Monie et al., 2009). 
Different TLRs recognizes different PAMPs. For example, TLR4 recognises  
lipopolysaccharide (LPS) present in the outer membrane of Gram negative bacteria 
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(Hoshino et al., 1999; Poltorak et al., 1998). TLR5 and TLR11 recognises bacterial flagellar 
proteins (Feuillet and Medjane, 2006; Hayashi et al., 2001; Mathur et al., 2012). TLR9 
recognises non-methylated CpG motifs, a common feature in the DNA of numerous 
microorganisms (Hemmi et al., 2000; Klinman et al., 1996). TLR2 and TLR1 heterodimers 
recognise triacylated proteins (Takeuchi et al., 2002) while diacylated proteins are 
recognised by TLR2 and TLR6 heterodimers (Takeuchi et al., 2001). Viral single stranded 
(ss) DNA is recognised by either TLR7 or TLR8 (Heil, 2004; Lund et al., 2004). Profilin from 
Toxoplasma gondii is recognised by TLR11 and TLR12 dimers (Koblansky et al., 2013). 
Finally, bacterial rRNA is recognised by TLR13 (Oldenburg et al., 2012). Table 1.1 and 
Figure 1.2 summarise the different TLRs discussed above. 
 
Table 1.1: TLRs and their main adaptor(s), cellular location and PAMPs.  
Toll-like 
receptor 








Lipoproteins (Heterodimer with TLR1 or TLR6) 












Diacylated lipoproteins (Dimer TLR6/TLR2) 
TLR7 MyD88 Endosomes ssRNA 
TLR8 MyD88 Endosomes ssRNA 









TLR12(*) MyD88 Endosomes Profilin 
TLR13(*) MyD88 Endosomes Bacterial 23S rRNA 
 (*) Absent in humans. 
 
Upon activation, the TLRs form homo- or heterodimers and recruit the adaptors Myeloid 
Differentiation primary response gene 88 (MyD88) or TIR-domain-containing adapter-
inducing interferon- (TRIF), in some cases via the adaptors MAL (MyD88-adaptor-like) or 
TRAM (TRIF-related adaptor molecule), respectively. With the exception of TLR3, every TLR 
signals through MyD88, while the TRIF branch is only activated by TLR3 and TLR4 (Kawai 
and Akira, 2011). MyD88 ultimately leads to activation of nuclear factor-B (NF-B) and 
mitogen-associated protein kinases (MAPK) and TRIF-dependent pathways leads to 
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activation of NF- and interferon regulatory transcription factor 3 (IRF3) (Kawai and Akira, 
2010). 
 
Figure 1.2: Toll-like receptors, their cellular localization and main adaptors. 
 
Downstream to MyD88 and TRIF, NF-B is the main family of transcription factors activated 
by PAMPs. NF-B is a homo- or heterodimer that can be formed by the subunits RelA, c-
Rel, RelB, p50 and p52, all of which contain a Rel Homology Domain (RHD), allowing them 
to interact with the DNA. In resting cells, the NF-B dimer is sequestered in the cytosol by 
the protein Inhibitor of NF-κB (IB), that masks NF-B nuclear leading sequence (NLS), 
blocking its interaction with nuclear importins (Jacobs and Harrison, 1998). Upon activation, 
IB is phosphorylated by the IB kinases (IKK) IKK1/IKK2 complex, followed by 
ubiquitination and degradation in the proteasome (Tergaonkar, 2006). This causes NF-B to 
translocate to the nucleus where it can interact with enhancers such as p300/CBP (CREB-
binding protein), allowing the transcription of target genes to occur. Over time, newly 
synthetized IB is translocated to the nucleus, where it binds to NF-B and interacts with 





Figure 1.3: The NF-B pathway, as exemplified by TLR4 activation. TLR4 activation 
leads to Mal/MyD88-dependent activation of NF-B signalling. On a later stage, the receptor 
undergoes endocytosis leading to TRAM/TRIF-dependent activation of IRF3 and NF-B. 
 
The TLR4 signalling pathway is unique in that it can be both TRIF- and MyD88-dependent. 
LPS is solubilized by the LPS-binding protein (LBP) (Tobias et al., 1986), and transferred to 
the receptor cluster of differentiation (CD)-14 present in the membrane of numerous myeloid 
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cells (Wright et al., 1990). The LPS/CD-14 complex interacts with TLR4 and the MD-2 co-
receptor resulting in the recruitment of the adaptor MAL. MAL, in turn, mediates the 
interaction with MyD88, triggering the recruitment of IL-1 associated protein kinases (IRAK) 
and early phase NF-B translocation (Burns et al., 1998; Horng et al., 2002; Shimazu et al., 
1999), upregulating the transcription of genes that code for proteins such as NLRP3, pro-IL-
1β, cyclooxygenase-2 (COX-2) and TNF-α (Bauernfeind et al., 2009; Hiscott et al., 1993; 
Libermann and Baltimore, 1990; Shakhov et al., 1990; Ueda and Yamamoto, 1995). Next, 
TLR4 is endocytosed allowing TRIF to be recruited through the adaptor TRAM. This results 
in a delayed stimulation of NF-B and the IRF3 pathway, which upregulates the transcription 
of genes such as Ifna, Ifnb and Rantes (Fitzgerald et al., 2003; Kagan et al., 2008; Lin et al., 
1999; Yamamoto et al., 2002; Yoneyama et al., 1998) (Figure 1.3).  
 
1.3. Nucleotide-binding domain and leucine-rich repeat-containing proteins 
Nucleotide-binding domain and leucine-rich repeat-containing (NLR) proteins are located in 
the cytoplasm of a variety of cell types and can act as PRRs by recognizing PAMPs and 
DAMPs or by modulating a variety of signalling pathways associated with innate immunity, 
such as the formation of the inflammasome. Members of this family usually contain C-
terminal LRR and a N-terminal nucleotide-binding domain, either a caspase-recruitment 
domain (CARD) or PYRIN domain (PYD), although some members possess a baculovirus 
inhibitor repeat (BIR) domain or a domain with no clear homology to any described domain. 
Members of this family also contain the NACHT domain, named after some of its constituent 
proteins: NAIP, CIITA, HET-E and TP1 (acronyms for neuronal apoptosis inhibitory protein, 
MHC class II transcriptional activator, incompatibility locus protein from Podospora anserina, 
and telomerase-associated protein) (Koonin and Aravind, 2000), that bind oligonucleotides 
to initiate oligomerization. Table 1.2 (modified from Proell et al., 2008) lists some of the 




Table 1.2: NLR proteins and their domains. Caspase-recruitment domain (CARD), Pyrin 
Domain (PYD), baculovirus inhibitor repeat (BIR), domain present in NAIP, CIITA, HET-E 


























In addition to NLRs, absent in melanoma-2 (AIM2)-like receptor (ALR) and RIG-I-like 
receptor (RLR) are also intracellular PRRs involved in the recognition of intracellular nucleic 
acids (Rathinam and Fitzgerald, 2016; Yoneyama et al., 2015). 
 
1.3.1. The inflammasome 
One of the most important functions of both NLRs and ALRs is the recognition of PAMPs 
and DAMPs which trigger signalling events leading to the assembly of the inflammasome. 
Ultimately the inflammasome is observed as a speck-like macromolecular protein complex 
(which appears as a ring-shaped structure in super resolution microscopy of the endogenous 
complex) in the cytoplasm of the cell (Man et al., 2014). It contains a polymer of the adaptor 
apoptosis-associated speck-like protein containing a CARD (ASC), acting as a platform for 
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the activation of caspase-1, which in turn catalyses the conversion of pro-IL-1β and pro-IL-
18 to their active forms IL-1β and IL-18, respectively (Martinon et al., 2002). Inflammasome 
assembly also results in cleavage of gasdermin D that create pores in the cellular membrane 
executing pyroptosis (Aglietti et al., 2016; Kayagaki et al., 2015; Lamkanfi and Dixit, 2014; 
Man et al., 2014; Masumoto et al., 1999; Shi et al., 2015). The ring-shaped structure 
containing a NLR, ASC and caspase-1 is known as a canonical inflammasome (Figure 1.4). 
The less well characterised non-canonical inflammasomes may or may not contain ASC and 
a contains a non-caspase-1 enzyme, such as caspase-8 or caspase-11 (human caspase 
4/5) and are assembled in specific contexts. For example, the caspase-8 non-canonical 
inflammasome is assembled during fungal infections as a result of dectin-1 activation, a C-
type lectin (Gringhuis et al., 2012), whereas the caspase-11 non-canonical inflammasome is 
formed upon recognition of intracellular LPS (Kayagaki et al., 2013, 2011). Currently, the 
following canonical inflammasomes were described: NLRP1, NLRP3, NLRC4, AIM2, NLRP9 
and Pyrin (Agostini et al., 2004; Fernandes-Alnemri et al., 2009; Mariathasan et al., 2004; 
Martinon et al., 2002; Xu et al., 2014; Zhu et al., 2017). 
 
 
Figure 1.4: The inflammasome. Ring-shaped model as suggested by super resolution 
microscopy in physiological conditions. Multiple molecules of ASC form a platform on the 
outer surface of the inflammasome, with caspase-1 enzymes located in the core of the 
structure and NLR molecules between ASC and caspase-1. 
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The exact structure of the inflammasome is currently a topic of debate. Super resolution 
microscopy experiments conducted in cells using antibodies against proteins present in the 
endogenous inflammasome reveal a ring-shaped structure formed by polymeric ASC, with 
NLRs on the inside surface and caspase-1 and caspase-8 forming the core of this structure. 
Pro-IL-1β is also seen in the core, in contact with the enzymatically active caspases (Man et 
al., 2014) (Figure 1.4). The same structure is not observed in vitro and in cells 
overexpressing some of the components of the inflammasome. In these systems, cryo-
electron microscopy reveals PYD domains from AIM2 and NLRP3 nucleate ASC, allowing 
ASC to recruit multiple copies of caspase-1 through CARD-CARD interactions, forming 
characteristic filamentous structures (Lu et al., 2014). Although rings are seen in THP-I cells 
not overexpressing any proteins, the investigators claim these ring structures are artefactual 
(Lu et al., 2014). 
In vivo, different inflammasomes play a key role against a number of pathogens. Pyroptosis 
of infected cells could contribute to controlling the infection by exposing intracellular 
pathogens to circulating phagocytes, in a IL-1β and IL-18 rich-environment (Lamkanfi and 
Dixit, 2014). These cytokines have a very potent inflammatory potential (Slaats et al., 2016). 
IL-18 enhances the induction of Th1 polarization, priming natural killer (NK) cells to produce 
more interferon (IFN)- which is of extreme importance in clearing intracellular pathogens 
(Chaix et al., 2008; Slaats et al., 2016). IL-1β is responsible for inducing COX2 expression, a 
key enzyme in the synthesis of the eicosanoid prostaglandin E2 (PGE2) responsible for 
enhancing Th17 polarization by upregulating IL-17 in CD4+ cells (Boniface et al., 2009). IL-
1β upregulates the production of IL-6, another cytokine involved in Th17 polarization (Korn 
et al., 2008).  
The production of pro-inflammatory cytokines such as IL-1β and IL-18 by the inflammasome 
must be tightly regulated. Deficient production of these cytokines is detrimental to the host in 
the context of infections caused by bacterial pathogens such as Salmonella enterica serovar 
Typhimurium (Sebastiani et al., 2002; Srinivasan et al., 2007), and excessive production of 
these cytokines are associated with a worse outcome in several infectious diseases such as 
tuberculosis (G. Zhang et al., 2014). Unresolved and/or excessive inflammation caused by 
inflammasome activation is linked to several inflammatory diseases such as vitiligo, 
psoriasis, type I diabetes, colitis and Chron’s disease (Cobrin and Abreu, 2005; Siegmund et 
al., 2001; Zhong et al., 2013). For example, the missense mutation c.1009A>T, encoding 
p.Thr337Ser in the nucleotide binding domain of the NLRC4 gene causes an early-onset 
recurrent fever flares and macrophage activation syndrome, with spontaneous 
inflammasome formation and exacerbated IL-1β and IL-18 production (Canna et al., 2014). 
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Another NLRC4 gain-of-function mutation described occurs in the HD1 domains of the 
protein, substituting the amino acid valine at the 341 position for an alanine, and causing 
chronic inflammation and enterocolitis (Romberg et al., 2014). Several mutations in the 
NLRP3 gene are also linked to a variety of diseases, such as Muckle-Wells Syndrome, 
familial cold autoinflammatory syndrome, and other diseases featuring symptoms such as 




NLRP3 (also known as Cryopyrin, and NACHT, LRR and PYD domains-containing protein 
(NALP) 3) is a cytoplasmic 118 kDa protein containing a N-terminal PYD domain, a NACHT 
domain and a C-terminal LRR. It was first discovered in the context of familial cold auto-
inflammatory syndrome and Muckle-Wells syndrome which are both pathological conditions 
associated with excessive inflammation (Hoffman et al., 2001). 
NLRP3 is involved in assembling a canonical inflammasome containing ASC, caspase-1 and 
caspase-8 (Agostini et al., 2004; Gurung et al., 2014; Man et al., 2013) in response to a wide 
array of pathogens including gram-negative and gram-positive bacteria such as 
Staphylococcus aureus, Listeria monocytogenes, Escherichia coli, S. Typhimurium, fungi 
such as Candida albicans, viruses such as influenza A, and parasites including the helminth 
Schistosoma mansoni and the amoeba Entamoeba histolytica. NLRP3 is, therefore, a rather 
promiscuous sensor, able to respond to infectious agents that are evolutionary distant from 
one another (Table 1.3). This suggests that NLRP3 is unlikely to detect specific PAMPs but, 
instead, recognizes DAMPs of endogenous origin, secondary to cellular or tissue injury 





Table 1.3: Examples of pathogens that can activate the NLRP3 inflammasome. 
Microorganism Type Reference 
Adenovirus dsDNA virus (Muruve et al., 2008) 
Aspergillus fumigatus Fungus (Saïd-Sadier et al., 2010) 
Candida albicans Fungus (Gross et al., 2009) 
Chlamydia pneumoniae Gram-negative bacteria (He et al., 2010) 
Chlamydia trachomatis Gram-negative bacteria (Abdul-Sater et al., 2009) 
Dermatophagoides pteronyssinus Arthropod (Dai et al., 2011) 
Encephalomyocarditis virus ssRNA virus (Rajan et al., 2011) 
Entamoeba histolytica Protozoa (Mortimer et al., 2015) 
Escherichia coli Gram-negative bacteria (Brereton et al., 2011) 
Influenza A virus ssRNA virus (Allen et al., 2009) 
Klebsiella pneumoniae Gram-negative bacteria (Willingham et al., 2009) 
Listeria monocytogenes Gram-positive bacteria (Kim et al., 2010) 
Modified Vaccinia Virus Ankara dsDNA virus (Delaloye et al., 2009) 
Mycobacterium marinum Mycobacteria (Carlsson et al., 2010) 
Mycobacterium tuberculosis Mycobacteria (Mishra et al., 2010) 
Neisseria gonorrhoeae Gram-negative bacteria (Duncan et al., 2009) 
Porphyromonas gingivalis Gram-negative bacteria (Huang et al., 2009) 
Salmonella enterica serovan Typhimurium Gram-negative bacteria (P. Broz et al., 2010) 
Schistosoma mansoni Helminth parasite (Ritter et al., 2010) 
Staphylococcus aureus Gram-positive bacteria (Craven et al., 2009) 
Trypanosoma cruzi Protozoa (Gonçalves et al., 2013) 
Vesicular stomatitis virus ssRNA virus (Rajan et al., 2011) 
Vibrio cholerae Gram-negative bacteria (Toma et al., 2010) 
Vibrio vulnificus Gram-negative bacteria (Toma et al., 2010) 
 
 
The list of DAMPs capable of triggering NLRP3 inflammasome assembly is also very long 
and includes ATP, cholesterol and uric acid crystals, glucose, amyloid β, hyaluronan, and 
low intracellular potassium concentration as triggered by foreign molecules such as the 
ionophore nigericin (Davis et al., 2011b; Mariathasan et al., 2006; Martinon et al., 2006; 
Pétrilli et al., 2007). It is likely that NLRP3 does not directly interact with these DAMPs, but 
no co-receptor protein has been described thus far. The bacterial ligands responsible for 
NLRP3 activation are only now beginning to emerge, a consistent theme is that potassium 
efflux is important in NLRP3 activation in Salmonella infections: blocking K+ efflux reduces 
IL-18 production, indicative of an adverse effect on inflammasome activity (Franchi et al., 
2007). The glycolytic enzyme hexokinase can also act as a stress sensor in some 
conditions. This enzyme is usually located in the mitochondrial outer membrane and it is also 
capable of interacting with N-acetylglucosamine due to its similarity with D-glucose. This 
interaction causes the release of hexokinase from the mitochondria to the cytosol where it 
triggers NLRP3 inflammasome formation via an unknown mechanism that does not involve 
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K+ efflux (Wolf et al., 2016). There is also evidence to suggest that bacterial mRNA may act 
as an NLRP3 activator, although it is still unclear how relevant this response is in the context 
of bacterial infections (Sander et al., 2011). 
The production of reactive oxygen species (ROS) by the complex NADPH oxidase appears 
to be key for the activation of the NLRP3 inflammasome. For instance, ATP activates the 
NLRP3 inflammasome via the purinergic receptor P2X7R leading to the production of ROS 
by NADPH oxidase, as shown by the lower IL-1β production upon NADPH oxidase 
pharmacological inhibition or when ROS scavengers are present (Cruz et al., 2007; 
Hewinson et al., 2008). Similarly, ROS produced by NADPH oxidase appears to be involved 
in the activation of the NLRP3 inflammasome by a variety of other stimuli, such as nigericin, 
silica and asbestos, as well as infectious agents (Cassel et al., 2008; Dostert et al., 2008; 
Hewinson et al., 2008; Tóth et al., 2017). ROS production is also potentially involved in the 
oxidation of mitochondrial DNA, which is released from the mitochondria in stress situations 
and activates the NLRP3 inflammasome (Shimada et al., 2012). 
In vitro in mouse cells, a “licensing step” is required before DAMPs can induce NLRP3 
inflammasome formation in macrophages and dendritic cells. In this step, the transcription of 
Nlrp3, as well as Il1b, is upregulated by activation of the NF-B pathway, as NLRP3 is only 
weakly expressed in those cells under physiological conditions (Bauernfeind et al., 2009). 
Nevertheless, NLRP3 expression is not negligible (Heng and Painter, 2008; Hoffman et al., 
2001), and transcriptional regulation is not the only event that occurs during the licensing 
step. This has been demonstrated in experiments where LPS priming was done too fast for 
protein synthesis to occur, or was performed in the presence of protein synthesis inhibitors 
or transcription inhibitors (Fernandes-Alnemri et al., 2013; Juliana et al., 2012; Lin et al., 
2014; Walle et al., 2014). During non-transcriptional priming, deubiquitination was described 
as necessary for NLRP3 activation. In resting cells, the NLRP3 pool is kept in an inactive 
state by ubiquitination at the LRR domain, a post-translational modification involving the 
binding of the 8.5 kDa protein ubiquitin to an amino acid side-chain. Upon TLR4 stimulation 
and signalling through MyD88/IRAK1, the NLRP3 pool is deubiquitinated by the K63 
deubiquitinase BRCA1/BRCA2-Containing Complex Subunit 3 (BRCC3), allowing NLRP3 
activation to occur (Fernandes-Alnemri et al., 2013; Juliana et al., 2012; Lin et al., 2014; Py 
et al., 2013). 
At the end of this priming step, the intracellular concentration of NLRP3 is greatly enhanced 
and the protein is found in a de-ubiquitinated state, ready to respond to several DAMPs. 
Although we still do not have a complete picture of the signalling events involved in NLRP3 
inflammasome activation, studies on the post-translational modifications (PTM) of 
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inflammasome components have provided some evidence. In primed macrophages, 
stimulation of the NLRP3 inflammasome causes ASC to be phosphorylated at tyrosine 144 
via spleen tyrosine kinase (SYK), enhancing the assembly of the ASC speck and 
subsequent cytokine production. Interestingly, this phosphorylation is not mediated by SYK 
in dendritic cells and suggests that the signalling events in inflammasome formation is cell 
type-dependent (Hara et al., 2013). It is currently unclear how SYK controls ASC 
phosphorylation, with evidence suggesting that SYK can either directly bind and 
phosphorylate ASC (Lin et al., 2015), or it can act via phosphorylation and activation of 
proline-rich tyrosine kinase 2 (Pyk2), which in turn binds and phosphorylates ASC (Chung et 
al., 2016). In addition to SYK and Pyk2, Bruton Tyrosine Kinase (BTK) was also linked to 
NLRP3 inflammasome activity. BTK was found to interact and promote ASC speck formation 
in a variety of cell lines, and in vivo BTK inhibitors were capable of protecting mice from 
ischaemic brain injury, a pathology linked to NLRP3 (Ito et al., 2015). 
Different PTMs can also inhibit inflammasome activity. For example, direct phosphorylation 
of NLRP3 by protein kinase A (PKA) negatively regulates inflammasome activity. Upon 
PGE2 stimulation, PKA is activated and catalyses the phosphorylation of NLRP3 at serine 
295, disrupting inflammasome activity (Mortimer et al., 2016). The nitrosylation of cysteine 
residues is a PTM responsible for modulating the function of several proteins including 
proteins related to innate immunity. It is caused by an increase in the local nitric oxide (NO) 
concentration due to enhanced nitric oxide synthase (NOS) activity (Hess and Stamler, 
2012). NLRP3 was found to be inhibited by NO-induced S-nitrosylation, explaining the 
antagonistic effect that IFN- has in inflammasome signalling. This is because IFN- 
enhances the expression of inducible NOS (iNOS), therefore increasing intracellular NO 
concentration and inhibiting the inflammasome (Hernandez-Cuellar et al., 2012; Mishra et 
al., 2012). How exactly this inhibition occurs is largely unknown. For example, there is no 
data on which cysteine residues are modified and whether S-nitrosylation inhibits speck 
formation, caspase recruitment or cytokine maturation. 
Further fine-tuning of the NLRP3 inflammasome is achieved by autophagy of inflammasome 
components. In particular, NLRP3 and AIM2 inflammasomes can be targeted for autophagy 
via ubiquitination of ASC which is recognized by p62 and directed for engulfment and 
subsequent degradation by the autophagosome (Shi et al., 2012). This suggests that the 
relationship between inflammasome activation and autophagy is antagonistic, a hypothesis 
that is further strengthened by the observation that caspase-1 can inhibit autophagy by 




Molecules capable of negatively and positively regulating inflammasome activity by 
modulating the first and second steps of NLRP3 activation are still being discovered. For 
instance, A20 is a protein known to increase the susceptibility to rheumatoid arthritis with a 
mechanism linked to negative regulation of Nlrp3 transcription. Patients with an aberrant A20 
have a higher NLRP3 expression and consequentially a lower NLRP3 activation threshold 
(Walle et al., 2014). In contrast, the small heterodimer partner (SHP) acts as a negative 
regulator of the second phase of NLRP3 activation by inhibiting the binding of NLRP3 to 
ASC, thus preventing speck formation (Yang et al., 2015). 
Figure 1.5 summarises some of the events in NLRP3 inflammasome activation. 
 
 
Figure 1.5: The NLRP3 inflammasome. Upon stimuli by molecules involved in cellular and 
tissue damage, NLRP3 recruits ASC and enzymes such as caspase-1 to form the NLRP3 





NLRC4 (also known as IPAF or CARD12) is a CARD-containing NLR constitutively 
expressed as different splice variants in different cell types with the 116 kDa variant the most 
commonly expressed in immune cells (Masumoto et al., 2003; Poyet et al., 2001). NLRC4 is 
involved in the assembly of a canonical inflammasome containing ASC, caspase-1 and 
caspase-8 (Man et al., 2013; Mariathasan et al., 2004) and interestingly NLRC4 is also 
capable of directly interacting with caspase-1, an interaction that is possibly involved in 
speck-independent pyroptosis (Petr Broz et al., 2010b). Unlike NLRP3, NLRC4 
inflammasome formation does not require a priming step due the fact that NLRC4 is 
constitutively expressed in a variety of immune cells such as macrophages and dendritic 
cells (Heng and Painter, 2008; Mariathasan et al., 2004).  
This inflammasome is involved in the innate immune response against pathogens such as S. 
Typhimurium, Shigella flexneri, Anaplasma phagocytophilum, Pseudomonas aeruginosa, 
Burkholderia thailandensis, Legionella pneumophila (Lamkanfi and Dixit, 2012; Pedra et al., 
2007) (Table 1.4). In contrast to the very broad activation repertoire of NLRP3, NLRC4 can 
recognise either directly or indirectly a small set of PAMPs commonly present in intracellular 
flagellated or type 3 secretion system (T3SS)-containing bacterial pathogens, such as 
flagellin (Franchi et al., 2006; Miao et al., 2006).  
 
Table 1.4: Example of pathogens capable of activating the NLRC4 inflammasome. 
Microorganism Type Reference 
Anaplasma phagocytophilum Gram-negative bacteria (Pedra et al., 2007) 
Burkholderia thailandensis Gram-negative bacteria (Miao et al., 2010) 
Klebsiella pneumoniae Gram-negative bacteria (Cai et al., 2012) 
Legionella pneumophila Gram-negative bacteria (Amer et al., 2006) 
Listeria monocytogenes Gram-positive bacteria (Wu et al., 2010) 
Pseudomonas aeruginosa Gram-negative bacteria (Sutterwala et al., 2007) 
Salmonella enterica serovar Typhimurium Gram-negative bacteria (Mariathasan et al., 2004) 
Shigella flexneri Gram-negative bacteria (Suzuki et al., 2007) 
Yersinia pseudotuberculosis Gram-negative bacteria (Brodsky et al., 2010) 
 
 
The recognition of bacterial PAMPs by NLRC4 is indirect and mediated by the N-terminal 
BIR-containing family of neuronal apoptosis inhibitory proteins (NAIP). Four NAIP 
paralogues are constitutively expressed in mice (NAIP 1, 2, 5 and 6) whereas only one NAIP 
17 
 
protein is expressed in human cells (Diez et al., 2003). In mice, NAIP1 recognises the 
needle protein of the T3SS, NAIP2 recognises the basal rod component of the T3SS, NAIPs 
5 and 6 recognise flagellin and the single NAIP expressed in humans is responsible for 
recognition of the T3SS needle protein (Kofoed and Vance, 2011; Rayamajhi et al., 2013; 
Yang et al., 2013; Zhao et al., 2016, 2011). In vitro structural studies of NAIP/NLRC4 
interaction allowed researchers to develop models explaining the early stages of NLRC4 
inflammasome formation. In this model, the NAIP/ligand binding occurs at the nucleotide-
binding domain (NBD) and it is required for the subsequent NAIP/NLRC4 co-oligomerization 
(Tenthorey et al., 2014), as illustrated by NAIPs 2 and 5. A single NAIP molecule interacts 
with flagellin, which then interacts with NLRC4 and induces a change from the closed auto-
inhibitory conformation to an open active conformation. The open conformation propagates 
the recruitment of multiple copies of NLRC4 and culminates in the formation a stacked open 
disk-like filamentous structure capable of recruiting caspase-1 (Diebolder et al., 2015; Halff 
et al., 2012; Hu et al., 2015, 2013; Tenthorey et al., 2017; Zhang et al., 2015). 
Many of the events that lead to the activation of the NLRC4 inflammasome are not well 
characterized, but PTMs are likely to play a role in this process. Protein Kinase C isoform δ 
(PKC)-dependent NLRC4 phosphorylation occurs in a conserved serine residue (Ser 533) 
in response to flagellin and S. Typhimurium. This phosphorylation event is triggered by 
flagellin, but does not depend on NAIP5 (Matusiak et al., 2015; Qu et al., 2012). It is unlikely 
however that this phosphorylation event is required for NLRC4 inflammasome formation at 
all times, since NAIP2-dependent NLRC4 activation occurs independently of PKC (Suzuki 
et al., 2014). 




Figure 1.6: The NLRC4 inflammasome. PAMPs from intracellular bacteria are recognized 
by NAIPs to engage NLRC4 which subsequently recruits ASC resulting in the assembly of 
the NLRC4 inflammasome which stimulates pyroptosis and pro-IL-1β processing. 
Alternatively, pyroptosis may occur independently of ASC. 
 
1.3.4. NLRP1a-c 
Also known as NALP1, NLRP1 interacts with ASC and caspase-1 to form a canonical 
inflammasome in response to signals such as Bacilus anthracis Lethal Toxin (LeTx), ATP 
depletion and Toxoplasma gondii infection (Boyden and Deitrich, 2006; Cirelli et al., 2014; 
Liao and Mogridge, 2013; Martinon et al., 2002). In mice the Nlrp1 gene has suffered 
duplication events throughout evolution and different strains have up to three paralogue 
genes (Nlrp1 a, b and c) with different expression patterns and allelic variants, each 
responding to different signals with different affinities (Boyden and Deitrich, 2006). 
Its structure is somewhat unique amongst NLRs: NLRP1 contains a N-terminal PYR domain 
(present in humans but not in mouse and rat), NACHT, NACHT associated domain (NAD), 
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LRR domain and CARD domain, in addition to the unusual “function to find” domain (FIIND) 
between the LRR and CARD domains (D’Osualdo et al., 2011). 
NLRP1 is “primed” by autoproteolysis at the FIIND domain, and the resulting fragments 
remain associated as inactive dimers until further stimulation occurs (Frew et al., 2012). In 
response to LeTx, specific alleles of Nlrp1b can be proteolytically cleaved at the N-terminal 
(Levinsohn et al., 2012), which in turn triggers the recruitment of ASC through the CARD 
domain of NLRP1 (Finger et al., 2012), caspase-1 activation and cytokine production 
(Cordoba-Rodriguez et al., 2004). In the context of ATP depletion, however, NLRP1 N-
terminal proteolysis is not required (Liao and Mogridge, 2013). This could be explained by 
the fact that some NLRP1 variants contain an ATP-binding domain that is exposed during 
ATP depletion, stimulating its auto-proteolytical activity and inflammasome formation 
(Neiman-Zenevich et al., 2014) (Figure 1.7). 
 
1.3.5. NLRC3 
Although their activation typically initiates inflammation, some NLRs can also have anti-
inflammatory properties. NLRC3 is such an example. This 114 kDa protein contains a N-
terminal NBD followed by a LRR. It is expressed in the cytoplasm of cells related to the 
immune system such as T-cells and macrophages, and acts as an inhibitor of MyD88-
dependent NF-B signalling (Conti et al., 2005). During MyD88 signalling, TNF receptor 
associated factor (TRAF) 6 is conjugated to the lysine 63 (K63) of ubiquitin, allowing it to 
activate the IKK complex (Deng et al., 2000). During LPS stimulation, NLRC3 negatively 
regulates the transcription of NF-kB related genes, such as Tnf, Il1b, Il6 and Il12, by 
inhibiting TRAF6 K63-ubiquitination (Schneider et al., 2012). 
In addition to NF-B, NLRC3 is also an inhibitor of the stimulator of interferon genes (STING) 
pathway. In the STING pathway, viral DNA is recognized by cyclic GMP-AMP synthase 
(cGAS), an enzyme that in turn catalyses the production of the second messenger cyclic 
GMP-AMP (cGAMP) in the cytoplasm. cGAMP then interacts with STING in the 
endoplasmatic reticulum, leading to its association with TANK-binding kinase-1 (TBK1). 
TBK1 then translocates to perinuclear regions and phosphorylates proteins such as IRF3 
and NF-B, modulating this way the transcription of immunologically relevant genes (Barber, 
2015; Gao et al., 2013). NLRC3 can physically interact with both STING and TBK1, blocking 




Figure 1.7: The NLRP1 inflammasome. The NLRP1 FIIND domain is involved in 
autoproteolysis, priming NLRP1 to respond to stimuli such as LeTx. Further proteolytic 






Figure 1.8: The STING pathway. Recognition of dsDNA by cGAS triggers the production of 
the second messenger cGAMP, responsible for activating STING and subsequent NF-B 




NLRX1 is a 108 kDa protein containing a NBD and a LRR domains, in addition to a N-
terminal mitochondrial targeting sequence (Tattoli et al., 2008), responsible for NLRX1 
localization at the mitochondrial outer membrane, where NLRX1 acts as a negative regulator 
of viral responses. During single-stranded RNA virus infections, the cytoplasmic receptor 
retinoic acid-inducible gene-I (RIG-I) recognizes foreign nucleic acids and activates the 
mitochondria antiviral signalling protein (MAVS). MAVS activates IRF3 and stimulates the 
formation of the CARD9/B-cell lymphoma/leukemia-10 (BCL10) complex, responsible for 
NF-B activation (Poeck et al., 2010; Seth et al., 2005; Yoneyama et al., 2004). In this 
context, NLRX1 is capable of physically interacting with MAVS, disrupting the RIG-I/MAVS 
interaction and inhibiting the pathway (Allen et al., 2011; Moore et al., 2008). NLRX1 also 
inhibits the NF-B pathway by blocking TRAF3 and TRAF6 (Allen et al., 2011). Interestingly, 
NLRX1 is itself a target of negative regulation by the protein FAS-associated factor-1 
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(FAF1), which competes for NLRX1 binding and consequentially increases MAVS signalling 
(Kim et al., 2017) (Figure 1.9).  
 
 
Figure 1.9: RIG-I pathway. ssRNA is recognized by RIG-I and ultimately leads to NF-kB 
and IRF3 activation. NLRX1 blocks the IRF3 branch of the pathway by inhibiting RIG-I and 
MAVS interaction and the NF-B branch by interacting with TRAF3 and TRAF6. 
 
A study using genome wide small interfering RNA (siRNA) analysis identified NLRX1 as an 
early-stage regulator of human immunodeficiency virus 1 (HIV-1) replication (Zhou et al., 
2008), a pathogen known to stimulate the STING pathway discussed above (Gao et al., 
2013). In this context NLRX1 assumes a role similar to that of NLRC3. The reverse-
transcribed DNA of HIV-1 triggers STING activation and subsequent association with TBK1, 
leading to the expression of proteins such as IFN-, RANTES (regulated on activation, 
normal T-cell expressed and secreted) and IL-6. This process is disrupted by NLRX1 which 







Studies in human-derived cell lines suggested a role for NLRC5 in controlling type I 
interferon-responses to viruses. This is because, first, NLRC5 is upregulated in response to 
double stranded RNA stimulation, second, knocking this protein down by interfering RNA 
technology reduced type I interferon responses and, third, its overexpression and 
oligomerization stimulated those responses (Kuenzel et al., 2010; Neerincx et al., 2010). A 
different study however identified NLRC5 as a negative regulator of NF-B signalling. In 
particular, NLRC5 acted by competing with NF-B essential modulator (NEMO) for 
IKK/IKK interaction, inhibiting their phosphorylation and kinase activity which is necessary 
for NF-B signalling (Cui et al., 2010). The same study also identified NLRC5 as a negative 
regulator of type I interferon responses, possibly by inhibiting the cytoplasmic sensors RIG-I 
and the RLR melanoma differentiation-associated protein 5 (MDA5). Equally, generation of 
Nlrc5-/- mice by different groups also raised conflicting reports regarding NLRC5 role in NF-
B and type I interferon responses (Kumar et al., 2011; Tong et al., 2012). 
In terms of inflammasome biology, a study reported that NLRC5 possesses inflammasome-
like activity, and the fact that ASC and caspase-1 are required for that activity strongly 
suggests that NLRC5 can form a canonical inflammasome (Davis et al., 2011a). 
Mechanistically, the authors suggested that NLRC5 collaborates with NLRP3 to trigger 
inflammasome formation in response to bacterial PAMPs, most likely by physically 
interacting with NLRP3 through NLRC5’s NBD. The study however was performed in human 
macrophage cell lines either overexpressing or having NLRC5 knocked down. Moreover, the 
physical interaction between NLRC5 and NLRP3 was demonstrated in the HEK293T 
overexpression system. In this system, high concentration of one of the proteins can lead to 
“forced” non-physiological interactions. These findings should, therefore, be interpreted with 
caution and further confirmation for the occurrence of this inflammasome is required. 
 
1.3.8. NLRP6 
NLRP6 contains a N-terminal PYD followed by NACHT and LRR domains and was originally 
described as an activator of caspase-1 and NF-B signalling, and colocalises with ASC in 
speck structures (Grenier et al., 2002). However, the study in question used a HEK293T 
overexpression model and later studies using BMDMs from genetically altered mice 
demonstrated that Nlrp6-/- cells have enhanced NF-B signalling and unaltered IL-1β 
production upon L. monocytogenes, E. coli and S. Typhimurium infections (Anand et al., 
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2012). Currently, evidence for the existence of the NLRP6 inflammasome in more 
physiological settings is lacking. 
 
1.3.9. NOD1 and NOD2 
The first NLRs described, NOD1 (NLRC1, CARD4) and NOD2 (NLRC2, CARD15) are 
cytoplasmic proteins containing a CARD domain followed by a second CARD (NOD2 only), 
NACHT, NAD and LRR domains (Girardin et al., 2001). NOD1 recognizes meso-
diaminopilemic acid (DAP), a structure found in the cell wall of gram-negative bacteria, 
whereas NOD2 recognizes muramyl dipeptide (MDP), a motif found in the cell wall of both 
gram-positive and gram-negative bacteria (Chamaillard et al., 2003; Girardin et al., 2003).  
Bacterial wall components are transported from endosomal compartments by the solute 
carrier family 15 (SLC15) A3 and SLC15A4, allowing them to be recognized by NOD1 and 
NOD2 (Kim et al., 2008). These NLRs then oligomerize and interact with RIPK2 and X-linked 
IAP (XIAP) (Abbott et al., 2004; Krieg et al., 2009), which promotes IKK activation resulting 
in NF-B signaling (Fritz et al., 2006). In addition to the NF-B pathway, NOD2 recruits the 
adaptor CARD9 to stimulate the MAPKs p38 and c-Jun N-terminal kinase (JNK) (Hsu et al., 
2007), via interaction with the NOD2 NACHT domain and the linker region between NACHT 
and CARD domains (Parkhouse et al., 2014). JNK and p38 regulate the activity of the 
transcription factor activator protein 1 (AP-1), which in turn acts on il1b transcription, further 
linking NOD2 to the priming event required for inflammasome activation (Arthur and Ley, 




Figure 1.10: NOD1/2 signalling. Components of the bacterial cell wall are recognized by 
NOD1/2, leading to RIPK2 and XIAP-dependent NF-kB activation. Additionally, NOD2 
activates p38 and JNK signalling via CARD9. 
 
1.3.10. AIM2 
AIM2 is an interferon-inducible 39 kDa protein containing a N-terminal PYD domain and a 
HIN domain (acronym for hematopoietic expression, interferon-inducible nature, and nuclear 
localization) (Schattgen and Fitzgerald, 2011). The ability of AIM2 to recognize cytoplasmic 
DNA was discovered by combining proteomic (proteins capable of interacting with DNA) and 
genomic (transcripts induced by IFN-) screens (Bürckstümmer et al., 2009). It is now 
established that AIM2 is one of the main receptors to trigger inflammasome formation in 
response to  cytoplasmic dsDNA in murine cells (Bürckstümmer et al., 2009; Fernandes-
Alnemri et al., 2009; Hornung et al., 2009). In human myeloid cells, however, AIM2 is not 
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involved in dsDNA sensing. This role is instead performed by cGAS/STING, which triggers 
cell death and subsequent activation of the NLRP3 inflammasome (Gaidt et al., 2017) 
The HIN domain of AIM2 contains two adjacent oligonucleotide and oligosaccharide-binding 
folds capable of interacting electrostatically with DNA. This interaction triggers the 
recruitment and oligomerization of ASC through the AIM2 PYD, forming a structure capable 
of recruiting caspase-1. This macromolecular structure, termed the AIM2 inflammasome, is 
responsible for dsDNA-induced cell death and maturation of pro-inflammatory cytokines 
such as IL-1β and IL-18 (Fernandes-Alnemri et al., 2009; Hornung et al., 2009; Rathinam et 
al., 2010). Interestingly, in addition to AIM2 activation in response to viral infections, certain 
microbial pathogens such as Francisella tularensis and L. monocytogenes can also activate 
this inflammasome (Rathinam et al., 2010; Warren et al., 2010)  (Figure 1.11). 
 
Figure 1.11: The AIM2 inflammasome. In murine cells, AIM2 recognizes cytoplasmic 
dsDNA, leading to assembly of the AIM2 inflammasome. 
 
1.4. Caspases 
Caspases are cysteine peptidases that cleave their substrate exclusively after an aspartic 
acid residue within a somewhat variable recognition motif (Pop and Salvesen, 2009). They 
were originally discovered in the context of cytokine maturation (Cerretti et al., 1992; 
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Nicholson et al., 1995) and play an important role in the development of innate immunity. Not 
only do they mediate the production of potent, biologically active pro-inflammatory cytokines, 
but they also drive different forms of host cell death. In humans, 12 caspases have been 
described so far (caspase-1 to caspase-10, caspase-12 and caspase-14). Based on their 
main function, caspases can be subdivided into three distinct groups: the pro-inflammatory 
caspases (caspase-1, -4, -5 and caspase-12), pro-apoptotic caspases (caspase-2, -3, -6, -7, 
-8, -9 and caspase-10) and those with no clear pro-inflammatory or pro-apoptotic function 
(caspase-14) (Table 1.5). (Julien and Wells, 2017; Shalini et al., 2014; van Raam and 
Salvesen, 2012).  
Structurally, caspases contain a C-terminal catalytic domain and a N-terminal prodomain 
usually containing a death fold motif, either a CARD (present in caspase-1, -2, -4, -5, -9, -11, 
and caspase-12) or a death effector domain (DED) (caspase -8 and caspase-10). The 
CARD or DED domains are involved in homotypic protein-protein interactions and, therefore, 
confer specificity in regard to their interaction partners. This allows the pro-apoptotic 
caspases to be further grouped into initiator caspases containing either CARD or DED 
domains (caspase-2, -8, -9 and caspase-10) and executioner caspases lacking specific pro-
domain motifs (caspase-3, -6 and caspase-7) (Shalini et al., 2014). 
 
Table 1.5: Caspases in humans and mice. 




Caspase-1 + + CARD Inflammation 
Caspase-2 + + CARD Apoptosis 
Caspase-3 + + - Apoptosis 
Caspase-4 + - CARD Inflammation 
Caspase-5 + - CARD Inflammation 
Caspase-6 + + - Apoptosis 
Caspase-7 + + - Apoptosis 
Caspase-8 + + DED Apoptosis 
Caspase-9 + + CARD Apoptosis 
Caspase-10 + - DED Apoptosis 
Caspase-11 - + CARD Inflammation 
Caspase-12 + + CARD Inflammation 





However useful, the classifications described above fail to consider the functional complexity 
and redundancy seen among caspases. A characteristic example is caspase-8 which was 
originally described as pro-apoptotic (Muzio et al., 1996). However, it was later found that, 
first, caspase-8 can be enzymatically active and cleave pro- IL-1β to its active form (Maelfait 
et al., 2008), and, second, it can regulate a distinct form of cell death termed necroptosis 
(Bell et al., 2008).  
 
1.4.1. Caspase-1 
The first and most well-studied pro-inflammatory caspase is caspase-1. Its first name was 
Interleukin Converting Enzyme (ICE) because it was originally described as an enzyme 
capable of converting pro-IL-1β into its mature form (Cerretti et al., 1992). Caspase-1 is 
expressed as a 45 kDa pro-enzyme containing a N-terminal CARD, a p20 subunit and a C-
terminal p10 subunit. Upon stimulation pro-caspase-1 oligomerizes to catalyise its own 
proteolysis and the resulting p20 and p10 fragments assemble into two p20/p10 
heterodimers to form the active caspase-1 tetramer (Wilson et al., 1994). Caspase-1 
activation is a process that depends on inflammasome assembly requiring ASC 
polymerization (Mariathasan et al., 2004; Srinivasula et al., 2002) which acts as  a platform 
for pro-caspase-1 recruitment and activation through CARD-CARD interactions (Srinivasula 
et al., 2002).  
Caspase-1 is the main effector enzyme in canonical inflammasomes. Upon assembly of the 
inflammasome, caspase-1 is recruited to the ASC speck through CARD-CARD interactions 
(Srinivasula et al., 2002), where it enzymatically converts pro-IL-1β and pro-IL-18 to their 
mature forms (Cerretti et al., 1992). Canonical inflammasomes also stimulate pyroptosis in a 
caspase-1 dependent manner, although the molecules responsible for this process are not 
completely understood. Gasdermin D, the main executioner of pyroptosis upon activation of 
the non-canonical caspase-11 inflammasome, is also cleaved by caspase-1 leading to cell 
death. However, gasdermin D is not the sole pyroptosis executioner upon canonical 
inflammasome activation (Kayagaki et al., 2015). It is possible that other members of the 
gasdermin family could be involved in pyroptosis. Although no evidence was found for 
caspase-1 cleavage of gasdermin A, B, C (Shi et al., 2015), and  deafness autosomal 
dominant 5 (DFNA5, also known as gasdermin E) (Rogers et al., 2017), it is possible that 
these proteins are involved in cell death in specific contexts, as there is precedent for other 
members of the gasdermin family to be used as a caspase substrate. For example, It was 
demonstrated that during apoptosis caspase-3 can cleave DFNA5 causing secondary 
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necroptosis/pyroptosis, although the physiological relevance of this finding is still unclear 
(Rogers et al., 2017; Wang et al., 2017). 
 
1.4.2. Caspase-2  
The presence of functional redundancy amongst caspases is further illustrated by caspase-
2; despite being one of the most conserved caspases across species (Lamkanfi et al., 2002), 
caspase-2 knockout mice are only mildly impaired in regulating apoptosis (Bergeron et al., 
1998). It is, therefore, challenging to study the precise role of this enzyme in the 
development of innate immune responses. 
Despite this limitation, in vitro studies have shown that upon stimulation with a variety of 
apoptosis-inducing agents, caspase-2 is recruited and activated in a macromolecular 
complex termed the PIDDosome, containing (RIP)-associated ICH-1/CED-3 homologous 
protein with a death domain (RAIDD) and the p53-inducible protein with death domain 
(PIDD) (Berube et al., 2005; Tinel, 2004). The PIDDosome then acts as an initiator in the 
intrinsic apoptotic pathway by activating BH3 interacting-domain death agonist (Bid) which 
permeabilizes the mitochondria allowing cytochrome c to be released to the cytosol (Paroni 
et al., 2002; Robertson et al., 2002). Cytochrome c then binds to ICE protease-activating 
factor-1 (IPAF-1) forming the apoptosome (Zou et al., 1999) which cleaves pro-caspase-9 to 
its mature form. Caspase-9 continues the amplifying cascade by cleaving and activating the 
apoptosis executioner caspases -3, -6 and -7 (Li et al., 1997). Some of the key events of the 





Figure 1.12: Intrinsic and extrinsic apoptotic pathways. Extracellular apoptotic signals 
engage the extrinsic apoptotic pathway, resulting in the formation of the protein complex 
DISC and caspase-8-dependent activation of the executioner caspases -3, -6 and -7. 
Intracellular apoptotic signals trigger activation of caspase-2 via the PIDDosome, resulting in 






Links between this caspase and proinflammatory forms of cell death, including pyroptosis, 
have also been also described. Brucella suis is capable of inducing a caspase-1-
independent and caspase-2-dependent proinflammatory cell death in macrophages, 
featuring some characteristics of pyroptosis such as IL-1β release (Chen et al., 2011). 
Another report linked NLRP3 activation to the mitochondria-destabilizing role of caspase-2 
(Bronner et al., 2015). Induction of mitochondrial ROS production in response to 
endoplasmic reticulum stress signals the recruitment of NLRP3 to the mitochondria, 
independently of ASC, and triggers the cleavage and activation of caspase-2 and the pro-
apoptotic protein Bid. Activation of caspase-2 and Bid subsequently induces 
permeabilization of the mitochondria which allows mitochondrial DAMPs to be released to 
the cytosol and activate the canonical NLRP3 inflammasome. 
 
1.4.3. Caspase-8 
Caspase-8 is classically regarded as an apoptosis initiator in the extrinsic apoptotic pathway. 
In this pathway, a membrane death receptor such as the tumor necrosis factor receptor 
(TNFR) interacts with a pro-apoptotic stimulus, an event that stimulates the receptor to 
homodimerize and triggers a conformational change in its cytoplasmic portion (Scott et al., 
2009; L. Wang et al., 2010). This conformational change allows for homotypic death domain 
interactions between the receptor and Fas-associated protein with Death Domain (FADD) 
(Chinnaiyan et al., 1995; Kischkel et al., 1995). Following its recruitment, FADD’s Death 
Effector Domain (DED) recruits pro-caspase-8 (Kischkel et al., 1995; Muzio et al., 1996) 
forming a protein complex known as Death Inducing Signalling Complex (DISC). In this 
complex, pro-caspase-8 is then dimerised and cleaved resulting in the release of the p18 
fragment which represents the active form of the enzyme. (Medema et al., 1997; Muzio, 
1998), events required for the activation of this protease (Oberst et al., 2010; van Raam and 
Salvesen, 2012). 
Upon caspase-8 activation, apoptosis may occur via the intrinsic or extrinsic pathways: In 
the extrinsic pathway, caspase-8 directly activates the executioner caspase-3 (Enari et al., 
1996; Scaffidi et al., 1998), which, in turn, cleaves and activates numerous targets such as 
Poly-(ADP-Ribose) polymerase (PARP) (Nicholson et al., 1995). In the intrinsic pathway, 
activated caspase-8 cleaves Bid which translocates to the mitochondria and stimulates the 
release of cytochrome c (Cosulich et al., 1997; Li et al., 1998). Figure 1.12 summarises the 
signalling events leading to apoptosis. 
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Caspase-8 deletion in mice was found to be lethal in utero (Varfolomeev et al., 1998), and 
this embryonic lethality is rescued by co-deletion of caspase-8 and RIPK3, suggesting that 
caspase-8 is required to prevent RIPK3-induced cell death (Kaiser et al., 2011; Oberst et al., 
2011). Upon stimulation of receptors such as TNF receptor 1 (TNFR1), FADD and tumor 
necrosis factor receptor type 1-associated death domain protein (TRADD) are recruited in 
the cytoplasmic region of the receptor through DD homotypic interactions (Boldin et al., 
1995; Hsu et al., 1996b). This complex is then capable of recruiting RIPK1 and, when 
caspase-8 is absent or inactivated, RIPK1 recruits RIPK3 to what is now termed the 
necroptosome (Cho et al., 2009; Hsu et al., 1996a; Stanger et al., 1995). This complex is 
then capable of phosphorylating MLKL leading to necroptotic cell death (Zhao et al., 2012). 
In this pathway, caspase-8 acts by cleaving RIPK1 and RIPK3 to their inactive forms thus 
preventing the oligomerization of the full-length RIPK1/3 and, therefore, blocking necroptosis 
(Li et al., 2012). Figure 1.13 summarises RIPK3-dependent necroptosis. 
 
 
Figure 1.13: RIPK3-dependent necroptosis. In situations where caspase-8 is absent or 
inactivated, the multiprotein complex known as the necroptosome can be formed. This 
complex is responsible for the RIPK3-dependent phosphorylation of MLKL leading to 
necroptotic cell death. 
 
Caspase-8 was also implicated in pro-IL-1β processing using HEK293T system 
overexpressing this enzyme (Maelfait et al., 2008).  The first evidence for such a role in a 
more physiological setting came from studies of the dectin-1 pathway (Gringhuis et al., 
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2012). During fungal infections, the C-type receptor dectin-1 recognizes polysaccharides 
such as curdlan (Yoshitomi et al., 2005)  and triggers the activation of spleen tyrosine kinase 
(SYK). This enzyme then phosphorylates various targets such as protein kinase C- (PKC-) 
and induces the production of ROS (Rogers et al., 2005; Strasser et al., 2012; Underhill et 
al., 2005). Active PKC- phosphorylates the adaptor CARD9, which mediates the formation 
of a complex with BCL10 and mucosa-associated lymphoid tissue lymphoma translocation 
protein 1 (MALT1), resulting in activation of NF-B and thus modulating the production of 
proinflammatory cytokines such as IL-6, pro-IL-1β, TNF-α and IL-23 in dendritic cells (Gross 
et al., 2006; LeibundGut-Landmann et al., 2007; Strasser et al., 2012). Dectin-1 activation by 
curdlan derived from Candida albicans is able to stimulate IL-1β production in BMDCs by the 
formation of a non-canonical inflammasome, without caspase-1 recruitment (Gringhuis et al., 
2012). In this case, the activation of dectin-1 stimulates SYK and allows the adaptor CARD9 
to interact with BCL10 and MALT1 as described above. This interaction can stimulate NF-B 
and upregulate the expression of pro-IL-1β. Caspase-8 and ASC are then recruited to the 
CARD9-BCL10-MALT1 complex, allowing pro-IL-1β to be processed (Gringhuis et al., 2012). 




Figure 1.14: The dectin-1 pathway. The C-type lectin receptor dectin-1 recognises fungal 
PAMPs and activates NF-kB and noncanonical caspase-8 inflammasome formation via SYK 
and CARD9. 
 
Caspase-8 is also involved in the formation of canonical inflammasomes. FADD and 
caspase-8 can modulate the expression of inflammasome-related genes such as Nlrp3 and 
il1b, thus affecting the priming step of the NLRP3 inflammasome activation (Gurung et al., 
2014). Pro-caspase-8 is recruited to the inflammasome during both NLRC4 and NLRP3 
activation (Man et al., 2014), where it is processed to mature caspase-8 in an ASC-
dependent fashion. Mature caspase-8 then cleaves pro-IL-1β to IL-1β but it is not involved 
35 
 
either in pyroptosis or in IL-18 processing during Salmonella infection (Man et al., 2013). The 
observation that caspase-8 is not involved in pyroptosis was made in cells expressing 
caspase-1/11, known to be the major players in this response (Mariathasan et al., 2004). In 
the absence of caspase-1/11, caspase-8 triggers cell death in the context of NAIP/NLRC4 
activation, further illustrating the extensive redundancy found in this protein family (Lee et al., 
2018; Mascarenhas et al., 2017; Schneider et al., 2017). 
 
1.4.4. Caspase-11 (Human caspase-4 and -5) 
Analogous to human caspase-4 and -5, caspase-11 was originally described as an enzyme 
capable of activating caspase-1 (Wang et al., 1998). Its expression is induced by LPS via the 
production of interferon β (Broz et al., 2012; Wang et al., 1998). In 2011, researchers 
demonstrated that the caspase-1-/- mouse strain widely used in the field of innate immunity 
was in fact a caspase-1 and caspase-11 double knockout, since their proximity in the 
chromosome made it difficult for these genes to be segregated by recombination (Kayagaki 
et al., 2011).  
We now know that, upon infection with pathogens such as E. coli and C. rodentium, 
caspase-11 can form a non-canonical inflammasome responsible for IL-1β maturation 
(Kayagaki et al., 2011). There is also evidence to suggest that this enzyme is involved in the 
TLR4-independent response to LPS from bacteria that escape the cytoplasmic vacuole, 
raising the possibility of developing new therapeutic strategies in conjunction with TLR4 
antagonists (Aachoui et al., 2013; Case et al., 2013; Hagar et al., 2013; Kayagaki et al., 
2013). One of the hypotheses regarding this response is that caspase-11 itself could act as 
an intracellular PRR that can recognise LPS and trigger the assembly of the non-canonical 
inflammasome (Shi et al., 2014). As a result, caspase-11 oligomerizes and cleaves the full 
length gasdermin D to a N-terminal p30 fragment which creates pores in the membrane 
leading to cell death (Aglietti et al., 2016; Kayagaki et al., 2015; Liu et al., 2016; Shi et al., 
2015). In addition to its role in non-canonical pyroptosis, gasdermin D may also link 
caspase-11 to the NLRP3 inflammasome. This is because caspase-11-dependent cleavage 
of gasdermin D can activate the NLRP3 inflammasome. Although the details of this 
activation are still unknown, it is likely that this mechanism is responsible for the caspase-11-




Figure 1.15: Non-canonical caspase-11 inflammasome. Cytosolic LPS is the PAMP 
responsible for caspase-11 oligomerization resulting in the formation of the noncanonical 
caspase-11 inflammasome. This inflammasome then triggers pyroptosis and canonical 
NLRP3 activation via gasdermin D. 
 
1.4.5. Caspase-12 
Caspase-12 was originally described as an inflammatory caspase due its high amino acid 
sequence identity with caspase-1 and -11 (-1, -4 and -5 in humans). Caspase-12 mRNA is 
transcribed in most tissues, especially in the lungs and skeletal muscle (Van De Craen et al., 
1997). The full length caspase-12 protein is 48 kDa and consists of three domains: a N-
terminal prodomain containing a CARD, a large catalytic subunit and a C-terminal small 
catalytic subunit (Lamkanfi et al., 2004). 
In animal models, initial studies using caspase-12 knockout mice reported an inhibitory effect 
of this caspase in the production of pro-inflammatory cytokines IL-1βand IL-18, rendering 
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caspase-12-/- mice resistant to LPS-induced sepsis, possibly due a physical interaction 
between caspase-12 and caspase-1 (Saleh et al., 2006). The same group later reported an 
additional caspase-12 anti-inflammatory role by blocking the NOD2 pathway (LeBlanc et al., 
2008). 
In contrast, caspase-12 can also exhibit inflammatory properties in the context of viral 
infections. As discussed previously, upon recognition of RNA viruses in the cytoplasm, RIG-I 
undergoes ubiquitination, leading to interaction with MAVS and subsequent type I interferon 
responses. Notably, caspase-12 was found to stimulate tripartite motif containing protein 25 
(TRIM25)-mediated RIG-I ubiquitination, positively regulating this antiviral pathway (P. Wang 
et al., 2010). However, it was recently discovered that the caspase-12-/- mice used by most 
experimenters so far were in fact deficient in both caspase-12 and caspase-11. The use of 
caspase-12 single knockout mice failed to reproduce the anti-inflammatory phenotype 
previously described, although the inflammatory response to RNA virus infection was not re-
evaluated (Vande Walle et al., 2015).  
 
1.5. Salmonella Typhimurium 
Salmonella enterica, subspecies enterica, is a flagellated, facultative anaerobic, gram 
negative bacillus. It is of great significance in terms of public health because it can infect 
humans and animals and cause diseases of varying clinical manifestations. Amongst these, 
typhoid fever affects an estimated 21.7 million people while paratyphoid fever affects around 
5.4 million people worldwide. In both cases, the highest percentage of people affected live in 
low-income countries (Crump and Mintz, 2010).  
S. enterica is divided into more than 50 serogroups (based on the O antigen) and more than 
2400 serological variants (based on flagellar H antigen) (Grimont and Weill, 2007). Some 
serovars are of particular interest in human and animal health for causing invasive forms of 
the disease, such as the serovars Typhi (Salmonella Typhi) and Typhimurium (Salmonella 
Typhimurium). S. Typhi is only capable of infecting humans and it is the main pathological 
agent of typhoid fever, a disease endemic in areas with poor sanitary conditions and whose 
symptoms include fever, malaise, anorexia, nausea, abdominal discomfort and myalgia, 
(Parry et al., 2002). S. Typhimurium, on the other hand, is capable of infecting humans and 
several other species, causing different syndromes in different hosts. In humans, S. 
Typhimurium causes an enteric disease whose symptoms are enteritis and diarrhoea, 
whereas in mice it is responsible for a disease similar to human typhoid fever (Bryan Coburn 
et al., 2007; Santos, 2014). 
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Due to host specificity difficulties in establishing an animal model to study S. Typhi, most 
studies investigating the host’s immune responses against S. enterica are conducted in mice 
infected with S. Typhimurium. The development of animal models to study S. Typhi is 
however necessary and some progress has been made in recent years. For instance, the 
receptor TLR11 is absent in humans but present in mice, and S. Typhi can successfully 
colonise Tlr11-/- mice and cause a disease very similar to human typhoid fever (Mathur et al., 
2012). Despite that, the use of S. Typhimurium is still preferred for safety reasons and the 
fact that for every gene of interest the experimenters would need to generate the knockout 
strain in Tlr11-/- animals, which is a laborious and time-consuming process. 
S. Typhimurium infection in mice usually occurs by ingestion of contaminated food or water. 
The bacteria first colonise the intestinal lumen and after adhering to the epithelium, they can 
invade enterocytes and dendritic cells of the intestinal epithelium and macrophages of the 
submucosa. From there, they access the systemic circulation and subsequently spread to 
the whole body. Upon entering the host cell, the pathogen modifies the surface of the 
vacuole that contains it to form the Salmonella containing vacuole (SCV) in which it can 
evade several host cell defence mechanisms. From inside the SCV, the bacteria can inject 
into the cytoplasm an ample array of effector molecules that can modulate several cellular 
processes. A plethora of virulence factors are involved in the invasion process described 
above, such as flagella and fimbria involved in cell adhesion and invasion; T3SS, important 
for the modification of the SCV and secretion of a variety of molecules; and finally different 
effector molecules secreted into the cytosol that can affect a variety of cell signaling events. 
(de Jong et al., 2012). Many of these virulence factors are encoded by genes in specific 
regions of the Salmonella spp. chromosome known as Salmonella pathogenicity islands 
(SPI). These SPI vary in quantity and composition between different Salmonella serovars 
(Marcus et al., 2000). SPI-1 and SPI-2 are amongst the most well-studied SPIs. SPI-1 codes 
for a T3SS that translocate bacterial proteins across  the host plasma membrane and is 
required for cellular invasion (Que et al., 2013). The expression of SPI-1 proteins are 
required for host NLRC4 activation (Lara-Tejero et al., 2006). SPI-2 codes for a distinct 
T3SS responsible for injecting effector molecules in the host cytosol across the SCV, 
modulating hosts cellular responses and increasing bacterial proliferation (Jennings et al., 
2017). 
 
1.5.1. S. Typhimurium and innate immunity 
TLR4 appears to be of particular importance against infection with S. Typhimurium. Both in 
vivo and in vitro, TLR4 signalling is key for inducing the pro-inflammatory response and 
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controlling bacterial burden (Hoshino et al., 1999; Poltorak et al., 1998; Talbot et al., 2009). 
In addition to TLR4, TLR2 also plays a complementary role in controlling S. Typhimurium 
infections. TLR2 mRNA levels are upregulated in the spleen and liver of Salmonella-infected 
mice, in a TLR4-dependent manner (Tötemeyer et al., 2005, 2003). Mice lacking TLR2 
and/or TLR4 have higher bacterial burden and decreased survival in comparison to WT 
controls, whereas deficiency in other TLRs does not appear to significantly increase 
susceptibility to infection (Arpaia et al., 2011; Jessen et al., 2014). TLR5 recognizes bacterial 
flagellin (Hayashi et al., 2001), but it is not required for controlling systemic S. Typhimurium 
infection in mice although it may be important in recognising bacteria during the enteric 
phase of an infection (Feuillet and Medjane, 2006; Vijay-Kumar et al., 2006). Flagellin also 
drives inflammasome activation through NLRC4, limiting the infection (Franchi et al., 2006; 
Lage et al., 2013; Lai et al., 2013; Miao et al., 2006). 
TLRs are not the only players in the defense against Salmonella spp. (Royle et al., 2003). 
Caspase-1 is also an important component of the innate immune response against 
Salmonella. This is because caspase-1-/- mice harbor significantly more bacteria in their 
internal organs and succumb to infection earlier than WT controls. It is likely that the 
protective effect of caspase-1 is mediated via IL-18, which confers resistance during the 
systemic phase of the infection, and IL-1β, which is involved in resistance during the 
intestinal phase of the infection (Lara-Tejero et al., 2006; Raupach et al., 2006). The 
transcription of IL-1, IL-1β and IL-18 are strongly upregulated in various organs in mice 
infected with S. Typhimurium (Sebastiani et al., 2002). Salmonella infection also drives 
caspase 1 recruitment to the inflammasome upon NLRC4 and/or NLRP3 stimulation (P. Broz 
et al., 2010; Man et al., 2014; Mariathasan et al., 2004). 
NLRC4 and NLRP3 are both activated by salmonellae. In vitro evidence links NLRP3 
inflammasome activation to S. Typhimurium infection, although, unlike NLRC4, the bacterial 
PAMPs or host DAMPs responsible for this effect is unknown (P. Broz et al., 2010; Man et 
al., 2014).  
The role of NLRs in Salmonella infection in vivo is not as well characterized as that observed 
in vitro. Inflammasome activation is involved in host defense against this pathogen, because 
caspase-1, ASC, IL-1β and IL-18 are all involved in restricting microbial growth in vivo (Lara-
Tejero et al., 2006; Raupach et al., 2006). Nlrc4-/- and WT mice had similar bacterial burden 
and survival rates in a S. Typhimurium oral infection model (Lara-Tejero et al., 2006), and 
similarly no difference was found between WT and Nlrp3-/- mice (Sutterwala et al., 2006). 
Mice deficient in both NLRs, however, exhibited a phenotype very similar to that of caspase-
1-/- mice with increased bacterial burden in the spleen, liver, and lymph nodes, as well as 
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impaired IL-18 production (P. Broz et al., 2010). Using a subclinical S. Typhimurium infection 
model, it was observed that both NLRP3 and NLRC4 are involved in controlling bacterial 
burden as both knockout strains are more susceptible to infection than the WT controls (Man 
et al., 2014). Accordingly, the same study observed that both NLRC4 and NLRP3 are 
relevant in vitro. By using super resolution microscopy to visualise  inflammasome assembly, 
the authors found that upon Salmonella infection of bone marrow derived macrophages, 
NLRC4 and NLRP3 are recruited to the same ASC speck (Man et al., 2014). Further studies 
revealed that NLRP3 is recruited to the inflammasome speck downstream to NLRC4, 
although the signalling events leading to this dual recruitment are not fully understood (Qu et 
al., 2016).  
S. Typhimurium-derived flagellin is also capable of stimulating IL-1 production in BMDM, a 
pro-inflammatory cytokine important in controlling bacteremia, that is associated with non-
canonical inflammasome formation and stimulates a novel form of cell death. This form of 
cell death has morphological features similar to apoptosis and autophagy and involves the 
release of cathepsin B and D into the cytosol (Lage et al., 2013). It is unknown at the 
moment how important this form of cell death is during S. Typhimurium infections, but it 
could occur in response to bacteria that escapes the SCV. Similarly, the induction of the 
non-canonical caspase-11 inflammasome could also play a role in inducing cell death upon 
LPS release from the SCV into the cytosol (Kayagaki et al., 2011). At the moment it is 
unclear how important these events are in the course of salmonellosis in physiological 
conditions, but it could complement the NLRC4 response (Broz et al., 2012).  
Various lines of evidence suggest a role for NOD2 during S. Typhimurium infection. NOD1 
and NOD2 are also potentially involved in NF-B signalling in response to bacterial T3SS 
protein SipA in vitro. In vivo however, Nod1-/-Nod2-/- mice produce less Ifng and Tnfa upon S. 
Typhimurium oral infection, but no statistically significant difference was observed between 
WT and SipA S. Typhimurium. An independent study found a similar pattern, where NOD1 
and NOD2 absence dampened in vivo production of pro-inflammatory cytokines, an effect 
that was dependent of the T3SS, although the identity of the effector molecule remained 
unknown (Geddes et al., 2010; Keestra et al., 2011). It was later demonstrated that SipA is 
not required for NOD2 activation during Salmonella infections, as bacterial MDP can escape 
the SCV and reach the cytosol via the transporters SLC15A3 and SLC15A4, leading to 
NOD2-dependent activation of the NF-B pathway (Nakamura et al., 2014). 





Figure 1.16: Innate immune pathways activated in response to S. Typhimurium 
infection. Amongst others, TLR2/4, NOD2, NLRC4 and NLRP3 are activated upon S. 
Typhimurium infection. 
 
Bacterial molecules that are capable of modulating inflammasome activity to benefit the 
pathogen have been described in several genera such as Yersinia, Pseudomonas, 
Mycobacterium and Francisella (Taxman et al., 2010). S. Typhimurium is also capable of 
avoiding detection by either regulating inflammasome activation or directly inhibiting it. For 
example, upon infection, S. Typhimurium downregulates its flagellin expression thus 
avoiding recognition by the NLRC4 inflammasome (Cummings et al., 2006, 2005). The 
protein Salmonella outer protein B (SopB) is a virulence factor encoded by SPI-1, and can 
inhibit NLRC4 inflammasome activation, although the mechanism is largely unknown (Hu et 
al., 2017). In B-cells, S. Typhimurium downregulates the host NLRC4 expression, thus 
inhibiting pyroptosis. This inhibition involves a protein encoded in the bacterial SPI-1, 
although its identity is still unknown (Perez-Lopez et al., 2013). 
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It has been shown that the regulatory NLRs NAIP12 and NLRP6 can dampen immune 
responses against Salmonella. First, mice deficient for these NLRs are more resistant than 
WT to Salmonella infection. Second, LPS-primed macrophages from such mice have higher 
NF-B and ERK activation in response to the Salmonella infection (Anand et al., 2012; Zaki 
et al., 2014). It is possible that S. Typhimurium stimulates these NLRs in order to avoid 




Despite their importance in modulating innate immune responses, very little is known about 
the signalling events leading to inflammasome formation and the regulatory mechanisms 
that finely tune their activation. Novel canonical and non-canonical inflammasomes are still 
being discovered as illustrated by the recently described NLRP9 inflammasome in the 
context of viral infections (Zhu et al., 2017). It is possible that other, not well characterised 
NLRs can form inflammasomes and/or act as regulators of the already known 
inflammasomes, such as NLRP3 and NLRC4.  
Once the inflammasome is formed, little is known about its components, their exact role and 
their interactions. For example, work done in our lab and by others identified caspase-8 as a 
molecule recruited to the inflammasome, contributing to IL-1βproduction (Gurung et al., 
2014; Man et al., 2014, 2013). The functional redundancy of caspases suggests it is possible 
that other caspases are also recruited to the inflammasome. Other proteins that contain 
CARD or pyrin domains could also be recruited to the inflammasome. 
The importance of inflammasome activation in the host response against S. Typhimurium, 
(Petr Broz et al., 2010a; Lara-Tejero et al., 2006; Man et al., 2014) make this pathogen a 
good model for studying the signalling events involved in the activation and regulation of the 
NLRC4 and NLRP3 inflammasomes. 
The aims my thesis were to: 
1. Determine whether NLRs, caspases and CARD domain containing proteins not known to 
be important in inflammasome formation might be important regulators of its activation.  To 
do this I used in vitro S. Typhimurium infection assays of bone marrow derived macrophages 




2. Determine how proteins identified in Aim 1 would modify inflammasome formation in 









Material and methods 
 
2.1. Mice 
WT C57BL/6 mice were obtained from Charles River, UK. Caspase-1-/--11-/-, Nlrc4-/-, Nlrp3-/- 
and Pycard-/- mice on a C57BL/6 background were produced by Millenium Pharmaceuticals 
and obtained from Kate Fitzgerald (University of Massachusetts). Card9-/- mice on a 
C57BL/6 background, originally produced by Xin Lin (University of Texas) (Hsu et al., 2007), 
were provided by David Underhill (Cedars-Sinai Medical Center). Nod2-/- mice were provided 
by Peter Murray (St. Jude Children’s Research Hospital). Nlrc3-/-, Nlrc5-/-, GasderminD-/-, 
GasderminD-/-Dfna5-/-, Nlrp6-/-, Nlrx1-/-, Pidd-/-, Nlrp1a-c-/-, Caspase-2-/-, Caspase-11-/- and 
Caspase-12-/- were produced by Genentech. Caspase-1-/--11-/-Nlrc4-/- were generated in 
house by crossing Caspase-1-/--11-/- and Nlrc4-/- animals. Mice were backcrossed on a 
C57BL/6 background for at least 8 generations.  
All animals were housed under specific pathogen-free conditions and all work involving live 
animals complied with the University of Cambridge Ethics Committee regulations under 
Home Office Project License number 80/2572.  
 
2.2. Cell isolation and culture 
Mice were killed by cervical dislocation, they were then sprayed with ethanol 70% for 
sterilization and their hind legs without the skin were aseptically removed and placed in 
Dulbecco’s modified Eagle’s medium (DMEM) on ice. In a laminar flow cabinet, muscle and 
connective tissue surrounding the bones were removed, the tibia and femur were separated 
at the knee joint with the proximal and distal epiphysis removed. For bone marrow derived 
macrophages (BMDM) culture, bone marrow was flushed out using BMDM growth media 
(DMEM supplemented with 10% HyClone® (Thermo Fisher Scientific), 20% L929 
conditioned media and 5 mM L-Glutamine (Sigma)) with the help of a 2 mL syringe and a 
size 25G needle. Collected cells were centrifuged at 300 x G for 10 minutes at 15 oC and 
resuspended in BMDM growth media. For bone marrow derived dendritic cells (BMDC), the 
bone marrow was flushed out using BMDC growth media (RPMI 1640 supplemented with 
10% FCS, 50 µM 2-Mercaptoethanol and 1000 U/mL GM-CSF (PeproTech). BMDMs and 
BMDCs were then cultured at 37 oC under 5% CO2 atmospheric conditions, in Petri dishes 
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(9cm diameter, 10 mL per dish) with the addition of equal volume of the appropriate media 
after 2 days in culture and completely replenishing the media after 4 days in culture. 
After 6 to 8 days in culture, the petri dishes containing BMDCs or BMDMs were washed 
three times in plain media, the cells were then carefully scraped and resuspended in 
complete media. Next, the cells were counted with a hemocytometer, diluted in complete 
media to a concentration of 106 cells/mL and specific number of cells were plated, as 
described in each individual experiment. In all cases, the plates were incubated overnight at 
37 oC under 5% CO2. Every experiment was conducted using cells cultured for 7 to 9 days. 
L929 conditioned media was prepared by growing L929 cells to confluence for 2 weeks, in 
RPMI 1640 (Sigma) supplemented with 10% Hyclone® and 5 mM L-Glutamine. The culture 
supernatant was collected and sterilized by filtration through 0.22 µm filters (Milipore). 
WT and Card9-/- immortalized bone marrow derived macrophages were obtained from 
Katherine A. Fitzgerald (University of Massachusetts) and cultured in DMEM containing 10% 
fetal bovine serum (Sigma) and 5 mM L-Glutamine. 
 
2.3. In vivo infections 
The attenuated S. Typhimurium strain M525P was grown statically for 18 hours at 37 oC in 
LB Broth (Sigma), then washed and resuspended in D-PBS (Sigma). 1.90 to 2.04 x104 
CFU/mouse were administered systemically via the lateral tail vein to both male and female 
mice with ages ranging from 8 to 16 weeks, while control mice were inoculated with PBS 
only. At days 1, 3 and 7 post-infection, the animals were euthanized, and their spleens and 
livers were aseptically removed.  
Livers were homogenized in 10 mL sterile water using a Colworth stomacher. To obtain 
single cell suspensions from the spleen, the whole organ was disrupted through a 70 µm cell 
strainer (BD Biosciences) using the inner part of a 2 mL syringe. Cell suspensions were then 
centrifuged at 300 x G for 10 minutes, the supernatant was collected for quantification of 
cytokines and bacterial burden, and the pellet was resuspended in 1 mL of Red Blood Cell 
lysis buffer (Sigma) and incubated for 10 minutes at room temperature. To stop the reaction, 
suspensions were toped up to 15 mL with RPMI and then centrifuged at 300 x G for 10 
minutes. Supernatant was discarded and the cell pellet was washed once more with 15 mL 
of RPMI. The purified splenocytes were then lysed for 10 minutes in ice using buffer 
containing 10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-100, 10 mM NaF, 1 
mM NaVO4, 20 mM PMSF, Phosphatase inhibitor cocktail 3 (1 in 100 dilution, Sigma) and 
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Protease inhibitor cocktail (1 in 100 dilution, P8340, Sigma). The proteins were probed by 
immunoblotting as described below. 
Bacterial burden was quantified by serially diluting (10-fold) the organ homogenates in PBS, 
plating the appropriate dilutions on LB agar plates followed by overnight incubation at 37 °C. 
The in vivo infections were conducted by Dr. Panagiotis Tourlomousis. 
 
2.4. Cell stimulation and infection 
Salmonella Typhimurium strain SL1344, Escherichia coli strain P19A, and Listeria 
monocytogenes strain EGD-e were cultured to log phase. This was done by pre-culturing the 
bacteria for 17.5 hours in 5 mL LB broth (Sigma) at 37 oC and 200 rpm, followed by a 1 in 10 
dilution of the pre-culture in LB broth and further culture for 2 hours (S. Typhimurium and E. 
coli) or 3 hours (L. monocytogenes). The bacteria were then centrifuged for 10 min at 4,300 
x G and resuspended in BMDM or BMDC growth media. Next, the bacteria solutions were 
diluted to the adequate concentrations in BMDM or BMDC growth media and used for 
infections. 
For gentamicin protection assays (GPA), the bacteria solutions were added to 200,000 
BMDM or BMDC cells, adhered to 3 different 96 wells plates at the indicated multiplicity of 
infection (MOI). Infections using S. Typhimurium SL1344 ΔfliCΔfljBΔprgJ included a 
centrifugation step (5 min at 1,000 x G) to allow the non-motile bacteria to infect the cells. 
The infection was carried out for an hour at 37 oC and 5% CO2. Next, the supernatant was 
collected and replaced with complete media containing 50 µg/mL gentamicin, followed by 1 
hour incubation at 37 oC and 5% CO2. Gentamicin is an antibiotic that is unable to cross the 
eukaryotic plasma membrane, thus killing off the extracellular bacteria. This allows for 
quantification of intracellular bacteria later in the assay.  
After the 50 µg/mL gentamicin incubation, the first plate (2 hours total infection time) had its 
supernatant collected, and intracellular bacteria counts and cell viability assays were carried 
out as described below. The remaining 2 plates had their supernatants collected and 
replaced with complete media containing 10 µg/mL gentamicin. This concentration of the 
antibiotic has bacteriostatic effects on the bacteria released to the supernatant during the 
infection, whilst not toxic to eukaryotic cells in the incubation times used in this assay. The 
second plate was incubated at 37 oC for another 4 hours (6 hours total infection time) and 
the third plate was incubated at 37 oC for another 22 hours (24 hours total infection time). 
After incubations, both plates had their supernatants collected and intracellular bacteria 
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counts and cell viability assays were carried out as described below. Culture supernatants 
were collected and either stored at -80 oC or used immediately for cytokine quantification. 
Selected experiments required the use of BMDMs or BMDCs primed with LPS. This was 
performed by incubating the cells in growth media containing 200 ng/mL ultrapure LPS from 
Escherichia coli O111:B4 (InvivoGen) for 3 hours at 37 oC and 5% CO2, followed by washing 
in LPS-free media. For stimulation experiments, the LPS-primed cells were incubated with 
Nigericin 10 µM (Sigma), ATP 5 mM (Sigma), Poly(dA:dT)/LyoVec 2 µg/mL (Invivogen), 
MDP 10 µg/mL (Sigma) or 60 ng ultrapure flagellin from Salmonella Typhimurium 
(Invivogen). Before applying it to the cells, 1.5 µg of flagellin was mixed with 2.5 µL Profect-
P1 reagent (Target Systems) in a final volume of 500 µL in plain media, and incubated at 
room temperature for 20 minutes for formation of a lipid-protein complex that allows flagellin 
to be delivered into the cytosol. Zymosan A from Saccharomyces cerevisae (Sigma) and 
NaClO-oxidized zymosan were used at a concentration of 100 µM. NaClO-oxidized zymosan 
was prepared by incubating 0.05 g of Zymosan in 0.1 M NaOH with 0.5% NaClO at 4 oC for 
24 hours with gentle agitation, followed by centrifugation at 3000 x G for 5 minutes and re-
suspension of the sediment in PBS. Table 2.1 summarises the treatments used in this 
thesis. 
 
Table 2.1: Treatments commonly used in this project. 
Treatment Concentration time (minutes) 
Muramyl Dipeptide 
(MDP) 
10 µg/mL 60 
ATP 5 mM 30 
Nigericin 10 µM 60 
Flagellin 
60 ng per 200.000 
cells 
60 
Poly(dA:dT)/LyoVec 2 µg/mL 240 
Zymosan 100 µM 60 
Oxidized-Zymosan 100 µM 60 
 
For inhibition experiments, a pre-incubation step was carried out before the cells were 
stimulated or infected, according to each specific inhibitor (Table 2.2). For dectin-1 blocking 
experiments, LPS-primed cells were incubated for one hour at 37 oC with BMDM growth 
media containing anti-dectin-1 2A11 (Abd Serotec) diluted 1 in 10 (100 µg/mL final 
concentration). Equal volume of S. Typhimurium at appropriate MOI was added without 
removing the media and the infection carried out as detailed above. 
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Table 2.2: Concentrations and pre-incubation times of the inhibitors used in this 
project.  







2.5 mM Sigma 15 Autophagy 
Anti-Dectin-1 2A11 100 µg/mL Abd Serotec 60 
Dectin-1 
Receptor 
Epoxomicin 1 µM Sigma 60 Proteasome 
Glibenclamide 200 µM Sigma 15 NLRP3 
MCC950 10 µM Cayman 15 NLRP3 
R406 1 µM Cayman 60 SYK 
SB203580 10 µM Tocris 30 p38 
SP600125 10 µM Tocris 30 JNK 
SR11302 10 µM Tocris 30 AP1 






2.5. Cellular viability assays and intracellular bacteria counts 
BMDM and BMDC cytotoxicity was measure using the CytoTox 96 Non-Radioactive 
Cytotoxicity Assay (Promega). Briefly, adherent cells were first washed three times in pre-
warmed non-supplemented DMEM and then incubated with 40 µL per well of Triton X-100 
0.5% for 15 minutes at 4 oC. Cells were then scraped off the bottom of each well using a 
multichannel mechanical pipette. From this, 10 µL were used for intracellular bacteria counts 
and another 10 µL for cellular viability. 
For intracellular bacteria counts, 10 µL of the scraped-cell solution were serially 10 fold 
diluted in PBS. The dilutions ranging from 10-2 to 10-4 were plated in LB agar and incubated 
overnight at 37 oC. The CFUs were then manually counted. 
Another 10 µL of the scraped-cell solution were transferred to a new plate already containing 
105 µL Triton X-100 1.2% and incubated at 37 oC for 1 h. Next, 25 µL were transferred to a 
new plate already containing 25 µL PBS, and 50 µL of CytoTox reagent was added and 
gently mixed. After 30 minutes of incubation at room temperature, 50 µL of stop solution was 
added and absorbance at 492 nm was quantified using a plate reader. Cellular viability was 
then calculated in relation to a standard curve containing 100% viability (200,000 uninfected 
cells) serially 2-fold diluted to 6.25% viability (12,500 uninfected cells).  
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2.6. Cytokine quantification 
Secreted cytokines in the cell culture supernatants after appropriate dilution in growth media 
were quantified by enzyme linked immunosorbent assay (ELISA). All cytokines were 
measured according to the manufacter’s instructions. Mouse IL-1β was measured by the 
OptEIA Mouse IL-1β Set (BD Biosciences) or mouse IL-1 Tissue culture kit (Meso Scale 
Discovery). Mouse IL-18 was measured by the mouse IL-18 ELISA kit (MBL International), 
while for mouse TNF-α the TNF-α DuoSet ELISA kit (R&D Systems) was used. 
 
2.7. Immunofluorescence 
For immunofluorescence assays, BMDMs were prepared as described above and 100,000 
cells were plated overnight into 8-chambers glass slides (Thermo Fisher Scientific). 
After stimulations, BMDMs were washed three times in PBS and fixed in -20 oC methanol for 
5 minutes or 4% paraformaldehyde for 15 minutes at room temperature. Cells were washed 
three times in pre-warmed PBS and then blocked in PBS (Sigma) containing 10% normal 
goat serum (Dako) and 0.1% saponin (Sigma) for 1 h at 37 oC. After blocking for non-specific 
protein binding, cells were stained with the primary antibody solution (1:500 dilution in PBS 
containing 10% goat serum), anti-ASC produced in rabbit (Enzo) for 50 minutes at 37 oC. 
Cells were then washed three times in pre-warmed PBS and stained with the secondary 
antibody solution (1:1000 dilution in PBS containing 10% goat serum, anti-rabbit Alexa-fluor 
568 produced in goat (Invitrogen)) for 40 minutes at 37 oC. After three more washes with 
pre-warmed PBS, cells were counterstained in DAPI mounting medium (Vecta Labs). 
For CARD9 and ASC co-colocalization experiments, after incubation with anti-ASC primary 
and Alexa-fluor 568 secondary antibody, cells were washed three times in PBS and blocked 
once again in PBS containing 1% BSA and 0.1% saponin. Staining was then carried out as 
before, using anti-CARD9 (Santa Cruz, 1:300 dilution) and anti-Rabbit-Alexa 430 (1:1000 
dilution in PBS containing 1% BSA, Invitrogen). Counterstaining with DAPI was performed 
as described above. Table 2.3 summarises the antibodies used in this thesis. 
To stain for active caspase-8 and caspase-1, LPS-primed BMDMs were stimulated with 
nigericin, the cell supernatant was then replaced by media containing 0.5X FLICA caspase-8 
or caspase-1 reagent (ImmunoChemistry Technologies) and incubated for one hour at 37 
oC. After carefully washing three times with PBS, immunofluorescence staining was 




2.8. Immunoprecipitation, protein precipitation and immunoblot 
Proteins from cell culture supernatants and spleen homogenates were precipitated using 
methanol and chloroform. Briefly, one volume of the sample was vortexed for 20 seconds 
with one volume of methanol at -20 oC and 0.25 volume of chloroform, followed by 
centrifugation (4 oC, 16000 x G for 12 minutes). The intermediate phase containing the 
precipitated proteins was collected, washed twice in -20 oC methanol, left in the fume hood 
for roughly 10 minutes until dry and resuspended in 2x concentrated PierceTM Lane Marker 
Reducing Sample Buffer (Life Technologies).  
Cells were lysed for 10 minutes in ice using buffer containing 10 mM Tris pH 7.4, 150 mM 
NaCl, 5 mM EDTA, 1% Triton X-100, 10 mM NaF, 1 mM NaVO4, 20 mM PMSF, 
Phosphatase inhibitor cocktail 3 (1 in 100 dilution, Sigma) and Protease inhibitor cocktail (1 
in 100 dilution, P8340, Sigma). Protein levels were quantified using PierceTM BCA Protein 
Assay Kit (Life Technologies) and adjusted to 600 µg/mL for immunoprecipitation or within 
the range of 250 to 2500 µg/mL for immunoblotting. The samples were then used for co-
immunoprecipitation assays (described below) or incubated for 5 minutes at 100 oC with 
PierceTM Lane Marker Reducing Sample Buffer (Life Technologies) for immunoblotting. Gels 
were loaded with 20 µL of the sample per lane, with a final protein mass ranging from 5 to 50 
µg. 
For co-immunoprecipitation assays, 10,000,000 BMDMs adhered to Petri dishes were 
primed with LPS and stimulated with nigericin or infected with S. Typhimurium as described 
above. After treatments, cells were washed three times with PBS at 4 oC. The cells were 
then reversibly cross-linked with 5 mM DTBP (Fisher Scientific) for 30 minutes at 4 oC then 
lysed as described above. Protein concentration was adjusted to 600 µg/mL and 800 µL was 
incubated overnight with 2 µL antibody (goat anti-ASC, (sc-33958, Santa Cruz); rabbit anti-
CARD9 (mouse preferred) (12283, Cell Signaling); mouse anti-SYK (MA1-19332, Thermo 
Fisher Scientific)) and 20 µL of Protein A/G PLUS-agarose beads (Santa Cruz). The 
remainder of the protein sample was stored for use as protein input controls for the 
immunoblotting. After incubation, the beads were washed four times in lysis buffer, re-
suspended in PierceTM Lane Marker Reducing Sample Buffer (Life Technologies), incubated 
for 5 minutes at 100 oC, centrifuged for 1 minute at 5000 x G and the supernatant used for 
immunoblotting. 
Immunoblots were probed using the following primary antibodies: caspase-1 p10 (mouse) 
(sc-514, Santa Cruz) 1 in 500; cleaved caspase-8 (rabbit) (8592, Cell Signaling) 1 in 500; 
caspase-8 (rabbit) (IG12, Enzo) 1 in 500; IL-1β (goat) (AF-401, R&D Systems) 1 in 1000; 
SYK (mouse) (MA1-19332, Thermo Fisher Scientific) 1 in 1000; p-SYK (rabbit) (2711, Cell 
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Signaling) 1 in 1000; ASC (rabbit) (AL177, Enzo) 1 in 2000; -Actin (mouse) (AB3280, 
ABCAM) 1 in 2500; CARD9, mouse preferred (rabbit) 1 in 1000 (12283, Cell Signaling). The 
secondary antibodies used were: anti-goat IgG-HRP (sc-2922, Santa Cruz) 1 in 5000; anti-
mouse IgG-HRP (7076, Cell Signaling) 1 in 6000; anti-rabbit IgG-HRP (A24537, Thermo 
Fisher Scientific) 1 in 6000 as appropriate. Table 2.3 summarises the different antibodies 
and how they were used in this work. 
 
2.9. Reactive oxygen species (ROS) assay 
BMDMs were seeded in 96-well white opaque plates (OptiPlate-96, PerkinElmer) at a 
density of 2x105 cells per well and left overnight at 37 oC and 5% CO2 in BMDM growth 
media without phenol red. BMDMs were then washed three times with DPBS+ solution 
(Dulbecco PBS supplemented with 100 mg/L Ca2+, 100 mg/L Mg2+, 1 g/L glucose and 4 mM 
sodium bicarbonate). Next, 80 µL of DPBS+ was added to each well, incubated at 37 oC for 3 
minutes, followed by addition of 100 µL DBPS+ containing 320µM luminol and 37.5U/mL 
HRP and immediately afterwards 20 µL of DBPS+ (control), zymosan in DPBS+ (final 
concentration 100 µg/mL), S. Typhimurium or L. monocytogenes (both in DPBS+, MOI 50) 
were added and chemioluminescence at 425 nm was recorded every 2 minutes for 120 
minutes. 
 
2.10. Quantitative PCR (qPCR) 
Primers were selected based on previous work done by others and uploaded to the primer 
bank database (http://pga.mgh.harvard.edu/primerbank/index.html) (Spandidos et al., 2009). 
Table 2.4 summarizes the primers employed. The reverse transcriptase and PCR reaction 
were carried out in a single step according to manufacturer instructions (SensiFAST™ One-























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The infection was carried out for 1 hour using 6-well plates with 1.6x106 BMDMs per well, at 
an MOI of 5, followed by another hour of incubation in media containing 50 µg/mL 
gentamicin. The supernatant was collected to confirm IL-1 production, and after 2 washes 
with PBS, cells were detached from the wells by scrapping in the presence of 1 mL RNA 
protect cell reagent (QIAGEN). The cell lysis and RNA isolation were performed as 
described by the manufacturer (RNAEasy, QIAGEN), followed by enzymatic DNA cleavage 
as described by the manufacturer (Ambion®, Life Technologies). 
Gene transcription analyses was carried out using GAPDH and β-actin as reference genes, 
employing Pfaffl method correcting for reaction efficiency (Pfaffl, 2001), according to 
equation 1: 
 
(1)   Fold increase =  Efficiency (Target)CT(target,untreated)−CT(target,treated)Efficiency (Reference)CT(ref,untreated)−CT(ref,treated)  
 
2.11. Schematic diagrams 
The individual graphical elements used in the schematic diagrams in this thesis were hand 
drawn by Caroline R. Paié, and later assembled into the final figures using Adobe Photoshop 
CC 2014 (Adobe Systems Incorporated). 
 
2.12. Statistical analysis 
Statistical analysis was performed using the software Prism 6.0 (GraphPad Software) as 
indicated for each individual experiment. In summary, and depending on the number of 
experimental groups, the data type and the number of qualitative variables, statistical 
difference was determined using either unpaired t-test, one-way analysis of variance 
(ANOVA) with Tukey’s post-test, or two-way ANOVA with Bonferroni post-test. In this work, a 













Caspase-1, ASC, IL-1 and IL-18 are all important in the host response against S. 
Typhimurium in vivo (Lara-Tejero et al., 2006; Raupach et al., 2006). In particular, S. 
Typhimurium activates both the NLRC4 and NLRP3 inflammasomes (Broz et al., 2010a; 
Man et al., 2014). In myeloid cells in vitro, S. Typhimurium stimulates NLRC4 early during 
infection, triggering rapid pyroptosis, IL-1 and IL-18 release, whilst NLRP3 is recruited on a 
later stage contributing to optimal cytokine production (Man et al., 2014). In this context, 
NLRC4 activation not only induces pyroptosis in an ASC-independent fashion (Broz et al., 
2010b), but also signals the recruitment of NLRP3 to the ASC speck (Man et al., 2014; Qu et 
al., 2016). Caspase-1 and caspase-8 are both recruited to the ASC-speck in response to 
Salmonella infection showing somewhat redundant activities: caspase-1 is involved in IL-
1/IL-18 production and pyroptosis, whereas caspase-8 is involved in IL-1 production (Man 
et al., 2013). The role of other caspases during Salmonella infection is not very well 
characterised. 
Activation of the NLRC4 inflammasome is achieved upon recognition of several Salmonella 
PAMPs by NAIPs, such as flagellin recognized by NAIP5, PrgJ by NAIP2, PrgI and SsaG by 
NAIP1 (hNAIP in humans) (Miao et al., 2010; Yang et al., 2013; Zhao et al., 2016, 2011). 
Less clear, however, is how S. Typhimurium activates the NLRP3 inflammasome. It is 
possible that bacterial mRNA triggers NLRP3 inflammasome assembly, although the 
physiological relevance for this remains unclear (Sander et al., 2011). Another hypothesis 
involves NLRP3 activation by cellular stress signals such as high citrate concentration 
(Wynosky-Dolfi et al., 2014) or low intracellular potassium concentration  (Franchi et al., 
2007). 
Although it is well established that inflammasomes play an important role in controlling 
bacterial infections, very little is known about molecules that finely tune this response. For 
instance, SYK is involved in phosphorylating ASC at tyrosine 144, leading to an increase in 
inflammasome activity (Gross et al., 2009; Hara et al., 2013; Lin et al., 2015) and, similarly, 
NLRC4 is activated by phosphorylation at serine 533 by a mechanism involving PKC- (Qu 
et al., 2012). Other molecules including SHP and A20 are capable of inhibiting 
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inflammasome activity, the first acts by physically interacting with the inflammasome whilst 
the second inhibits transcription events important for inflammasome activity (Walle et al., 
2014; Yang et al., 2015). 
Since there are still gaps in our understanding on how inflammasomes operate in the context 
of Salmonella infection, this chapter will focus on better characterising the events leading to 
NLRC4 and NLRP3 inflammasome activation and assembly. It will also investigate whether 
other molecules such as NLRs and caspases could be involved in the immune response 
against Salmonella infection. To achieve this, BMDMs from wild-type and various knockout 
strains were infected in vitro with S. Typhimurium and the effects on cell viability, intracellular 
microbial load and levels of cytokines such as IL-1 were assessed.   
 
3.2. Results 
The assay used in this body of work is the gentamicin protection assay (GPA). During this 
assay, BMDMs are infected with Salmonella at different MOIs for one hour, after which cell 
culture supernatant is replaced by fresh medium containing 50 μg/mL gentamicin. At this 
high concentration, gentamicin will kill all extracellular bacteria. However, and at least for 
short exposure times, this antibiotic cannot cross the plasma membrane to access the 
cytosol of the cell and, for this reason, intracellular bacteria are not affected and can be 
enumerated as a means to assess microbial invasiveness. After 1 h incubation in the 
presence of 50 μg/mL gentamicin, cell culture supernatant is replaced by fresh medium 
containing 10 μg/mL gentamicin. At this low concentration, gentamicin has a bacteriostatic 
rather than a bactericidal effect on extracellular bacteria and it is less likely to gain access 
the cell cytosol. In this way, intracellular bacteria will not be killed by the antibiotic and can 
still be enumerated at later time points, such 6 h and 24 h after infection. Apart from 
enumeration of intracellular bacteria, this assay also allows for cell viability to be assessed 
indirectly via measurement of LDH and levels of cytokines present in the supernatant to be 
determined by ELISA. 
LDH is an enzyme responsible for converting lactate to pyruvate and is constitutively 
expressed in most cells, including mammalian cells and bacteria. A possible pitfall in the 
GPA is that bacterial LDH could interfere with the quantification of eukaryotic cellular 
viability. This is unlikely, as the cells are lysed at 37 oC using 1.2% Triton X-100, a non-ionic 
detergent. This condition is not enough to lysis bacteria, and harsher treatments including 
boiling would be required (Sung et al., 2003). To confirm that the lysis method used in the 
GPA is incapable of lysing the bacteria, I have compared LDH activity from BMDMs treated 
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with Triton X-100 (200,000 to 12,500 cells) to that of bacteria treated in the same conditions 
(1,000,000 to 1,000 bacteria). In BMDMs, the resulting LDH activity was proportional to the 
number of cells lysed, whereas no LDH activity was observed when bacteria are treated with 
Triton X-100, regardless the number of bacteria treated. This suggests that despite the 
presence of live bacteria inside the cells during the GPA, bacterial LDH does not contribute 
to the total amount of LDH quantified. This is either due the fact that the Triton X-100 
incubation is not enough to cause bacterial lysis or that bacterial cells express much less 
LDH compared to eukaryotic cells, so the bacterial contribution in this assay is negligible 
(Figure 3.1). In either case, the LDH activity measured in the GPA correlates primarily to 
eukaryotic cellular viability. 
 
 
Figure 3.1: S. Typhimurium microbial cells does not contribute to the amount of LDH 
released during the GPA. LDH activity measured after one hour incubation with Triton X-
100 1.23% at 37 oC, as described in material and methods under “Cell stimulation and 
infection”. Data represent the mean from three independent experiments while error bars 
show the standard error of the mean (s.e.m.). 
 
3.2.1. NLRC4, Caspase-1 and Caspase-11 
The NLRC4 inflammasome is quickly assembled in BMDMs in response to Salmonella 
infection to drive pyroptosis and IL-1 production (Man et al., 2014). It has been shown that 
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this NLRC4-dependent rapid pyroptotic cell death does not depend on ASC (Broz et al., 
2010b). Less clear however is the role of caspase-1/11 in ASC-independent and NLRC4-
mediated cell death and if other enzymes, including other caspases, are involved in this 
process. To answer this question, cell viability of WT, Caspase-1-/-Caspase-11-/-, Nlrc4-/- and 
Nlrc4-/-Caspase-1-/-Caspase-11-/- BMDMs was assessed in response to infection with 
Salmonella. 
As expected, Caspase-1-/-Caspase-11-/- BMDMs at 2 and 6 hours after infection were more 
resilient to cell death in comparison to WT controls. This occurs because caspase-1 is the 
pyroptosis executioner caspase in the NLRC4 inflammasome (Poyet et al., 2001). Nlrc4-/- 
cells exhibited increased survival in comparison to Caspase-1-/-Caspase-11-/- at 2 and 6 
hours after infection. This suggests that upon Salmonella infection, NLRC4 triggers cell 
death independent of caspase-1/11, as previously observed (Broz et al., 2010b). 
Interestingly, Nlrc4-/-Caspase-1-/-Caspase-11-/- cells were even more resilient to cell death 
than Nlrc4-/- cells but only moderately and only at 2 hours after infection, suggesting that 
early in the infection NLRC4 can trigger cell death via different pathways, one of which 
involves Caspase-1/11 (Figure 3.2). Interestingly, however, is that at 24 hours post-infection 
at MOI 10 and 50, substantial cell death occurs in all knockout strains. Thus, it is possible 
that other proteins such as NLRs and caspases could be involved in driving cell death in S. 
Typhimurium infections. In the context of the NLRC4 and NLRP3 inflammasomes, caspase-
8 is not involved in pyroptosis when caspase-1 is present (Man et al., 2013). Possible roles 
for caspase-2 and caspase-12, as well as other NLRs, are going to be investigated later in 
this chapter. 
Intracellular bacteria count followed a similar pattern to that observed in cell viability. Overall, 
Nlrc4-/- and Nlrc4-/-Caspase-1-/-Caspase-11-/- BMDMs showed increased bacteria burden in 
comparison to WT controls, possibly a consequence of the increased number of viable cells. 
Caspase-1-/-Caspase-11-/- also showed increased intracellular bacteria counts, but not as 
much as the other knockout strains (Figure 3.2). 
No consistent differences in Il-1 production was observed between Nlrc4-/-, Caspase-1-/-
Caspase-11-/- and Nlrc4-/-Caspase-1-/-Caspase-11-/- (Figure 3.3), suggestive that Caspase-
1/11 activation downstream NLRC4 is necessary for IL-1β production upon Salmonella 
infection. Thus, the data suggests that the NLRC4-dependent and caspase-1/11-
independent death pathway does not contribute significantly to IL-1β production. It is likely 
that at 6 and 24 hours post infection, NLRP3 and caspase-8 are involved in IL-1β production 




Figure 3.2: NLRC4 and Caspase-1/Caspase-11 are involved in cell death and 
intracellular bacteria counts in BMDMs infected with S. Typhimurium SL1344. (a), (c) 
and (e) Cellular viability (as measured by LDH release) and (b), (d) and (f) intracellular 
bacteria counts of WT, Nlrc4-/-, Caspase-1-/-Caspase-11-/- and  Nlrc4-/-/Caspase-1-/-Caspase-
11-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a-b), 6 (c-d) and 
24 (e-f) hours. * p<0.05 (one-way ANOVA with Tukey’s multiple comparisons test). Data 




Figure 3.3: NLRC4 and Caspase-1/Caspase-11 are essential for IL-1β production in 
BMDMs infected with S. Typhimurium SL1344. IL-1β secretion (as measured by ELISA) 
of WT, Nlrc4-/-, Caspase-1-/-Caspase-11-/- and Nlrc4-/-/Caspase-1-/-Caspase-11-/- BMDMs 
after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) hours. * 
p<0.05 (one-way ANOVA with Tukey’s multiple comparisons test). Data represent the mean 
from three independent experiments while error bars show the s.e.m. 
 
3.2.2. Caspase-11 
Caspase-11 was first described as an accessory caspase capable of activating caspase-1 
(Wang et al., 1998). The role of this enzyme in inflammasome biology was revisited when it 
was discovered that the very popular caspase-1-/- mice were actually deficient in both 
caspase-1 and caspase-11 due the proximity of these genes in the chromosome (Kayagaki 
et al., 2011). Generation of caspase-1 and caspase-11 single knockouts led to the discovery 
that caspase-11 can form a non-canonical inflammasome and may act as an intracellular 
PRR sensing cytosolic LPS (Hagar et al., 2013; Kayagaki et al., 2013, 2011; Shi et al., 
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2014). How relevant these responses are in the context of Salmonella infection in vitro have 
not been so far investigated. 
Infection of caspase-11-/- BMDMs revealed no differences in intracellular bacteria, cellular 
viability or IL-1 production in comparison to WT controls (Figure 3.4-5). This however does 
not rule out an effect of caspase-11, because the rapid and robust NLRC4-driven response 
could be masking a potentially delayed caspase-11-dependent effect. To check this 
hypothesis, two different experimental approaches could be employed. The first one makes 
use of macrophages derived from Nlrc4-/-Caspase-11-/- mice. The second one relies on the 
use of a bacterial strain that cannot activate NLRC4. Our laboratory does not possess Nlrc4-
/-Caspase-11-/- mice. For this reason, I infected wild-type and Caspase-11-/- cells with 
SL1344 S. Typhimurium ΔfliCΔfljBΔprgJ. This triple knockout microbial strain lacks flagella 
and PrgJ, a type III secretion system inner rod protein, thus it fails to activate NLRC4 (Man 
et al., 2014).  
In the absence of NLRC4 activation, little to no cell death is observed at 2 and 6 hours post 
infection (Figure 3.6), whilst IL-1β production only starts to be reliably detected at 6 hours 
post infection (Figure 3.7). Caspase-11-/- BMDMs infected with S. Typhimurium 
ΔfliCΔfljBΔprgJ showed impaired cell death and increased intracellular bacteria counts at 24 
hours post infection (Figure 3.6). Additionally, caspase-11-/- had deficient IL-1β production at 
6 and 24 hours post infection (Figure 3.7). Taken together, the data suggests that caspase-
11 is involved in the innate response against Salmonella in vitro. A possible explanation for 
these effects involves the formation of the non-canonical caspase-11 inflammasome due the 
release of LPS into the cytosol (Kayagaki et al., 2011). Another hypothesis is that caspase-
11 could potentially be involved with the canonical NLRP3 inflammasome, which is activated 




Figure 3.4: Caspase-11 has no effect on cellular viability and intracellular bacteria 
counts in BMDMs infected with S. Typhimurium SL1344. (a), (c) and (e) Cellular viability 
(as measured by LDH release) and (b), (d) and (f) intracellular bacteria counts of WT and 
Caspase-11-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a-b), 6 
(c-d) and 24 (e-f) hours. p>0.05 unpaired t-test. Data represent the mean from two 




Figure 3.5: Caspase-11 has no effect on IL-1β production in BMDMs infected with S. 
Typhimurium SL1344. IL-1β secretion (as measured by ELISA) of WT and Caspase-11-/- 
BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) 
hours. p>0.05 unpaired t-test. Data represent the mean from two independent experiments 




Figure 3.6: Caspase-11 is involved in cell death and intracellular bacteria counts at 
later time points in BMDMs infected with S. Typhimurium fliCfljBprgJ, deficient in 
NLRC4 activation. (a), (c) and (e) Cellular viability (as measured by LDH release) and (b), 
(d) and (f) intracellular bacteria counts of WT and Caspase-11-/- BMDMs after infection with 
S. Typhimurium ΔfliCΔfljBΔprgJ at MOIs 1, 10 and 50 for 2 (a-b), 6 (c-d) and 24 (e-f) hours. * 
p<0.05 unpaired t-test. Data represent the mean from two independent experiments while 




Figure 3.7: Caspase-11 is involved in IL-1β production in BMDMs infected with S. 
TyphimuriumfliCfljBprgJ, deficient in NLRC4 activation. IL-1β secretion (as 
measured by ELISA) of WT and Caspase-11-/- BMDMs after infection with S. Typhimurium 
ΔfliCΔfljBΔprgJ at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) hours. * p<0.05 unpaired t-
test. Data represent the mean from two independent experiments while error bars show the 
s.e.m. 
 
3.2.3. NLRC3 and NLRC5 
NLRC3 and NLRC5 are CARD-containing NLRs which act as inhibitors of innate immune 
pathways, with NLRC3 inhibiting NF-B and cGAS/STING and NLRC5 inhibiting NF-B and 
RIG-I (Cui et al., 2010; Schneider et al., 2012; Tong et al., 2012; Zhang et al., 2014). These 
studies however focused on specific TLR ligands or viruses, and their role in bacterial 
infections, including S. Typhimurium, remains unknown. 
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Cellular viability of Nlrc3-/- and Nlrc5-/- BMDMs infected with Salmonella was similar to that of 
WT cells at MOIs 10 and 50 in all time points. At MOI 1, however, Nlrc3-/- and Nlrc5-/- cells 
exhibited a decrease in cellular viability at all time points which reached statistical 
significance (p<0.05 one-way ANOVA) at 24 hours only (Figure 3.8). This suggests that both 
NLRC3 and NLRC5 are negative modulators of Salmonella-induced cell death at later time-
points. The lack of significant differences at MOIs 10 and 50 are possibly due the extensive 
cell death observed at these MOIs, making it difficult to detect effects that result in increased 
cell death. 
The increased cell death was accompanied by a decrease in IL-1 production in both Nlrc3-/- 
and Nlrc5-/- BMDMs. At MOIs 1 at 2 and 6 hours, WT BMDMs produced twice as much IL-1β 
as the knockout strains. At MOI 10, the IL-1β produced by both Nlrc3-/- and Nlrc5-/- are only 
slightly above the detection limit (16 pg/mL), whilst WT controls produced around 50 pg/mL 
at 2 hours and 100 pg/mL at 6 hours (Figure 3.9). No differences were observed at 24 hours 
and in all time points infected with MOI 50 (Figure 3.9). The impaired IL-1β production in 
Salmonela-infected Nlrc3-/- and Nlrc5-/- BMDMs could potentially be a consequence of 
decreased cellular viability. Quantification of IL-18, however, made this hypothesis unlikely. If 
the increased cell death was responsible for the observed decrease in IL-1β production, a 
similar trend would be expected for IL-18. Upon S. Typhimurium infection, WT, Nlrc3-/- and 
Nlrc5-/- produced the same amount of IL-18 at all time points and MOIs investigated (Figure 
3.10). Whilst the cell viability data supports a role for NLRC3 and NLRC5 as NF-κB 
inhibitors, the IL-1β data suggests that it is possible that NLRC3 and NLRC5 are involved in 
activating NF-κB signalling during S. Typhimurium infection. Further experimentation is 




Figure 3.8: NLRC3 and NLRC5 are involved in cell death at later time points in BMDMs 
infected with S. Typhimurium SL1344, without affecting intracellular bacteria counts. 
(a), (c) and (e) Cellular viability (as measured by LDH release) and (b), (d) and (f) 
intracellular bacteria counts of WT, Nlrc3-/- and Nlrc5-/- BMDMs after infection with S. 
Typhimurium at MOIs 1, 10 and 50 for 2 (a-b), 6 (c-d) and 24 (e-f) hours. * p<0.05 one-way 
ANOVA with Tukey’s multiple comparisons test. Data represent the mean from three 




Figure 3.9: NLRC3 and NLRC5 are involved in IL-1β production in BMDMs infected 
with S. Typhimurium SL1344. IL-1β secretion (as measured by LuminexTM) of WT, Nlrc3-/- 
and Nlrc5-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a), 6 (b) 
and 24 (c) hours. * p<0.05 one-way ANOVA with Tukey’s multiple comparisons test. Data 





Figure 3.10: NLRC3 and NLRC5 are not involved in IL-18 production in BMDMs 
infected with S. Typhimurium SL1344. IL-18 secretion (as measured by ELISA) of WT, 
Nlrc3-/- and Nlrc5-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 
(a), 6 (b) and 24 (c) hours. p>0.05 one-way ANOVA. Data represent the mean from three 
independent experiments while error bars show the s.e.m. 
 
3.2.4. Gasdermin D and DFNA5 
As previously discussed, pyroptosis is a form of cell death characterised by membrane 
rupture and release of intracellular contents including inflammatory cytokines and DAMPs 
into the extracellular space. Upon activation of the caspase-11 non-canonical 
inflammasome, gasdermin D is the main executioner of pyroptosis: it is cleaved by caspase-
11, allowing its N-terminal fragment to create pores in the plasma membrane leading to cell 
lysis (Aglietti et al., 2016; Kayagaki et al., 2015; Liu et al., 2016; Shi et al., 2015). Upon 
activation of canonical inflammasomes, however, it is not clear if gasdermin D is the sole 
mediator of cell lysis (Kayagaki et al., 2015).  
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Upon infection with S. Typhimurium, GasderminD-/- BMDMs were more resilient than WT to 
cell death only at MOI 10 and only at 2 post infection. However, a substantial number of 
GasderminD-/- cells were still lysed at MOI 10, while they did not survive the infection with 
MOI 50 any better than WT BMDMs. This suggests that gasdermin D is not the only 
executioner of pyroptosis during Salmonella infection (Figure 3.11). 
DFNA5, also known as gasdermin E, could be playing a role in mediating pyroptosis during 
canonical inflammasome activation. This protein belongs to the gasdermin family and was 
recently described as a caspase-3 target during apoptosis, causing secondary cell lysis 
(Rogers et al., 2017; Wang et al., 2017). This protein could, therefore, be involved in 
Salmonella-induced pyroptosis. Infection of both GasderminD-/- and GasderminD-/-/Dfna5-/- 
BMDMs, however, revealed no difference in cellular viability between them (Figure 3.11). 
Gasdermin D is also involved in IL-1β release. This is shown by the impaired production of 
this cytokine in comparison to WT controls at all time points and MOIs analysed (Figure 
3.12). Pore formation is one of the proposed mechanisms for IL-1β secretion (Fink and 
Cookson, 2006), so it is feasible that the decrease in membrane integrity due gasdermin D 
activity accounts for the IL-1β released to the supernatant. This effect is, however, specific to 
IL-1β, as IL-18 production was similar between WT and GasderminD-/- BMDMs (Figure 
3.19). No differences in IL-18 nor IL-1production were detected between GasderminD-/- 
and GasderminD-/-/Dfna5-/- (Figure 3.11-13), suggesting that DFNA5 plays no role in these 
processes. 
Differences in intracellular bacteria counts in Salmonella-infected GasderminD-/- and 
GasderminD-/-/Dfna5-/- BMDMs in comparison to WT controls were inconsistent and no 




Figure 3.11: Neither Gasdermin D or DFNA5 has an effect on cellular viability and 
intracellular bacteria counts in BMDMs infected with S. Typhimurium SL1344. (a), (c) 
and (e) Cellular viability (as measured by LDH release) and (b), (d) and (f) intracellular 
bacteria counts of WT, GasderminD-/- and GasderminD-/-/Dfna5-/- BMDMs after infection with 
S. Typhimurium at MOIs 1, 10 and 50 for 2 (a-b), 6 (c-d) and 24 (e-f) hours. Data represent 




Figure 3.12: Gasdermin D, but not DFNA5, suppresses IL-1β production in BMDMs 
infected with S. Typhimurium SL1344. IL-1β secretion (as measured by LuminexTM) of 
WT, GasderminD-/- and GasderminD-/-/Dfna5-/- BMDMs after infection with S. Typhimurium at 
MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) hours. * p<0.05 one-way ANOVA with Tukey’s 
multiple comparisons test). Data represent the mean from four independent experiments 





Figure 3.13: Neither Gasdermin D or DFNA5 have any effect on IL-18 production in 
BMDMs infected with S. Typhimurium SL1344. IL-18 secretion (as measured by ELISA) 
of WT, GasderminD-/- and GasderminD-/-/Dfna5-/- BMDMs after infection with S. Typhimurium 
at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) hours. p>0.05 one-way ANOVA. Data 
represent the mean from four independent experiments while error bars show the s.e.m. 
 
Because NLRC4 is the single most potent inducer or early pyroptosis in BMDMs infected 
with Salmonella, its dramatic effect could mask more subtle contributions from other players, 
such as DFNA5. To address this, WT, GasderminD-/- and GasderminD-/-/Dfna5-/- 
macrophages were infected with S. Typhimurium ΔfliCΔfljBΔprgJ, a microbial mutant that 
cannot activate NLRC4 (Man et al., 2014).  Cellular viability was found to be similar between 
all three genotypes for all MOIs and time points tested (Figure 3.14). In this setting, no cell 
death is observed at 2 hours (as illustrated in Figure 3.6). Taken together, the data suggests 
that DFNA5 is not involved in inflammasome biology in the context of Salmonella infection, 




Figure 3.14: Neither Gasdermin D or DFNA5 have any effect on cellular viability in 
BMDMs infected with S. Typhimurium fliCfljBprgJ, deficient in NLRC4 activation. 
Cellular viability (as measured by LDH release) of WT, GasderminD-/- and GasderminD-/-
/Dfna5-/- BMDMs after infection with S. Typhimurium ΔfliCΔfljBΔprgJ at MOIs 10, 25 and 50 
for 6 (a) and 24 (b) hours. No cell death is observed at 2 hours. p>0.05 one-way ANOVA. 
Data represent the mean from two independent experiments while error bars show the 
s.e.m. 
 
3.2.5. NLRP6 and Caspase-12 
Overexpression of NLRP6 results in the formation of inflammasome-like structures that 
contain ASC and activated caspase-1 (Grenier et al., 2002). This finding, however, could not 
be confirmed under more physiological conditions (Anand et al., 2012). The same two 
studies also reported conflicting results regarding the role of this NLR in NF-κB signalling. 
This controversy makes NLRP6 an interesting protein to study in the context of Salmonella 
infection. 
Like caspase-11, caspase-12 was originally described to play a role in sepsis. In particular, 
caspase-12 knockout mice were found to be more resilient to sepsis and have lower levels 
of IL-18 and IL-1 when compared to WT controls (Saleh et al., 2006). It was recently 
discovered, however, that the caspase-12 knockout mice used in the original studies were in 
fact deficient for both caspase-11 and caspase-12 (Vande Walle et al., 2015). It is, therefore, 
necessary to re-evaluate the role(s) of caspase-12 in microbial infection. 
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Infection of caspase-12-/- and Nlrp6-/- BMDMs with S. Typhimurium revealed no differences 
in cellular viability (Figure 3.15) and IL-1secretion (Figure 3.16) when compared to WT 
cells at all MOIs and time-points investigated. 
The lack of involvement of caspase-12 and NLRP6 in inflammasome dependent host 
responses to Salmonella meant no further work was done with cells from these mice. 
 
 
Figure 3.15: NLRP6 and Caspase-12 have no effect on cellular viability in BMDMs 
infected with S. Typhimurium SL1344. Cellular viability (as measured by LDH release) of 
WT, Nlrp6-/- and Caspase-12-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10, 
and 50 for 2 (a), 6 (b) and 24 (c) hours. p>0.05 unpaired t-test. Data represent the mean 





Figure 3.16: NLRP6 and Caspase-12 have no effect on IL-1β production in BMDMs 
infected with S. Typhimurium SL1344. IL-1β secretion (as measured by LuminexTM) of 
WT, Nlrp6-/- and Caspase-12-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 
50 for 2 (a), 6 (b) and 24 (c) hours. p>0.05 unpaired t-test. Data represent the mean from 
two independent experiments while error bars show the s.e.m. 
 
3.2.6. NLRX1 and PIDD 
NLRX1 is a mitochondrial outer membrane protein that acts as a negative regulator in the 
responses against viruses. This NLR acts by inhibiting the interaction between RIG-I and 
MAVS in the context of viral ssRNA infections, resulting in decreased IRF3 and NF-κB 
responses (Moore et al., 2008).  This NLR can also inhibit NF-κB signalling via interaction 
with TRAF3 and TRAF6 (Allen et al., 2011). NF-κB signalling is important in the host 
response against Salmonella infections, so it is possible that NLRX1 could be relevant in the 
innate immune response against bacteria. The role of this protein in the context of 
pathogens such as Salmonella remains unknown. 
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In the intrinsic apoptotic pathway, the PIDDosome is a macromolecular complex composed 
of PIDD and RAIDD. It activates caspase-2, which results in cytochrome c release from the 
mitochondria into the cytoplasm (Paroni et al., 2002; Robertson et al., 2002). So far, no links 
between PIDD and Salmonella infection have been described, although it is possible that its 
effect on caspase-2 activation and, as a result, on apoptosis could have an impact on the 
infection outcome (Jesenberger et al., 2000). 
GPAs using S. Typhimurium revealed no statistically significant differences in cellular 
viability between WT and Nrlx1-/- or Pidd-/- cells (Figure 3.17). However, Pidd-/- BMDMs 
showed an increase in IL-1 production at the MOI 50 when measured at 6 and 24 hours 
post infection (Figure 3.18). The reasons for the difference in IL-1β production between WT 
and Pidd-/- BMDMs are yet unknown, but it is possible that it involves caspase-2. The role of 
caspase-2 in the context of Salmonella infection is going to be explored later. 
 
Figure 3.17: NLRX1 and PIDD have no effect on cellular viability in BMDMs infected 
with S. Typhimurium SL1344. Cellular viability (as measured by LDH release) of WT, 
Nlrx1-/- and Pidd-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10, and 50 for 2 
(a), 6 (b) and 24 (c) hours. p>0.05 unpaired t-test. Data represent the mean from two 




Figure 3.18: NLRX1 has no effect on IL-1β production in BMDMs infected with S. 
Typhimurium SL1344, whilst PIDD absence enhances IL-1β production in specific 
conditions. IL-1β secretion (as measured by LuminexTM) of WT, Nlrx1-/- and Pidd-/- BMDMs 
after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) hours. * 
p<0.05 unpaired t-test. Data represent the mean from two independent experiments while 
error bars show the s.e.m. 
 
3.2.7. NLRP1a-c 
Although NLRP1 was the first inflammasome to be described (Martinon et al., 2002), very 
few studies have examined its role in inflammasome activation triggered by Salmonella. 
Previously, researchers compared the mechanisms of caspase-1 activation in cells 
challenged with either S. Typhimurium or Bacilus anthracis Lethal Toxin (LeTx). They 
concluded that although caspase-1-mediated cell death occurred in both cases, it was very 
likely that LeTx and S. Typhimurium stimulated different mechanisms of caspase-1 activation 
with the first using NLRP1 and the latter NLRC4 as the primary NLR (Fink et al., 2008). This 
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study however did not directly investigate the possibility that different NLRP1 paralogues 
could be activated during S. Typhimurium infection. To investigate this, I conducted GPAs in 
BMDMs from mice lacking the NLRP1 paralogues a, b and c. 
Nlrp1a-c-/- BMDMs infected with Salmonella showed no differences in cellular viability or IL-
1production when compared with WT cells (Figures 3.19-3.20). It is therefore unlikely that 
this NLR is involved in inflammasome activation during S. Typhimurium infection, so no 
further work was carried out in cells from these mice. 
 
 
Figure 3.19: NLRP1a-c has no effect on cellular viability in BMDMs infected with S. 
Typhimurium SL1344. Cellular viability (as measured by LDH release) of WT and Nlrp1a-c-
/- BMDMs after infection with S. Typhimurium at MOIs 1, 10, and 50 for 2 (a), 6 (b) and 24 (c) 
hours. p>0.05 unpaired t-test. Data represent the mean from two independent experiments 





Figure 3.20: NLRP1a-c has no effect on IL-1β production in BMDMs infected with S. 
Typhimurium SL1344. IL-1β secretion (as measured by LuminexTM) of WT, Nlrp1a-c-/- 
BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) 
hours. p>0.05 unpaired t-test. Data represent the mean from two independent experiments 
while error bars show the s.e.m. 
 
3.2.8. Caspase-2 
Caspase-2 is an enzyme involved in apoptosis triggered by several stimuli (Bergeron et al., 
1998). Briefly, upon stimulation this enzyme is recruited and activated in the PIDDosome, a 
molecular complex containing PIDD and RAIDD. This leads to mitochondria permeabilization 
and release of cytochrome c initiating the intrinsic apoptotic pathway. 
Little is known, however, about the role of caspase-2 in inflammasome activation by 
Salmonella. A study using an infection model with S. Typhimurium transitioning from the 
stationary to logarithmic phase described a marginal, albeit statistically significant, 
contribution of caspase-2 to what it was then termed “apoptosis”  (Jesenberger et al., 2000). 
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This study, however, was published before inflammasomes were described, and it is 
possible that the form of programmed cell death triggered by Salmonella and described by 
the authors as “apoptosis” was in fact pyroptosis, at least in part of the cell population. The 
occurrence of extensive functional redundancy between caspases, as illustrated by caspase-
8 in the inflammasome (Man et al., 2013) together with published data supporting a role for 
caspase-2 in Salmonella infections (Jesenberger et al., 2000) prompted me to investigate 
whether caspase-2 is involved in Salmonella-induced inflammasome formation. Importantly, 
the GPA conducted in this work used log-phase bacteria, which stimulate NLRC4 
inflammasome assembly due to the expression of SPI-I genes (Lara-Tejero et al., 2006). 
S. Typhimurium infection of caspase-2-/- and WT BMDMs showed similar cellular viability 
and intracellular bacterial numbers in all MOIs and time points tested (Figure 3.21). IL-1 
production, however, was decreased in caspase-2-/- BMDMs in comparison to WT controls in 
most conditions, particularly at MOIs 10 and 50 at 6 hours post-infection (Figure 3.22). On 
the contrary, there was no statistically significant difference in IL-18 production between WT 
and caspase-2-/- macrophages (Figure 3.23). This pattern involving decreased IL-1β 
production without relevant differences in IL-18 production and cell viability is strikingly 
similar to that observed in caspase-8-/-/Ripk3-/- BMDMs infected with S. Typhimurium (Man et 
al., 2013). There, the authors reported that caspase-8 is recruited to the inflammasome, 
where it acts only on IL-1β production, whilst caspase-1 acts on the production of IL-1β, IL-
18 and in pyroptosis.  It is possible, therefore, that caspase-2 assumes a similar role to 





Figure 3.21: Caspase-2 has no effect on cellular viability and intracellular bacteria 
counts in BMDMs infected with S. Typhimurium SL1344. (a), (c) and (e) Cellular viability 
(as measured by LDH release) and (b), (d) and (f) intracellular bacteria counts of WT and 
Caspase-2-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a-b), 6 
(c-d) and 24 (e-f) hours. p>0.05 unpaired t-test. Data represent the mean from three 





Figure 3.22: Caspase-2 is involved in IL-1β production in BMDMs infected with S. 
Typhimurium SL1344. IL-1β secretion (as measured by LuminexTM) of WT and Caspase-2-/- 
BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) 
hours. * p<0.05 unpaired t-test. Data represent the mean from three independent 





Figure 3.23: Caspase-2 has no effect on IL-18 production in BMDMs infected with S. 
Typhimurium SL1344. IL-1β secretion (as measured by ELISA) of WT and Caspase-2-/- 
BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) 
hours. p>0.05 unpaired t-test. Data represent the mean from three independent experiments 
while error bars show the s.e.m. 
 
3.2.9. CARD9 
CARD9 is an adaptor protein originally described in the context of NF-κB signalling in 
HEK293T cells, where it forms a signalling platform with BCL10 and MALT1 (Bertin et al., 
2000). Later, the formation of CARD9 complexes was described in other contexts. For 
instance, in the dectin-1 pathway in dendritic cells, the receptor dectin-1 recognizes PAMPs 
from the fungal wall and signals the activation of SYK and subsequent CARD9 
phosphorylation, leading to NF-B translocation via the formation of the 
CARD9/MALT1/BCL10 signalling complex (Gross et al., 2006). Similarly, the formation of the 
CARD9/MALT1/BCL10 complex was observed downstream fragment crystallisable receptor 
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(FcR)-activation (Hara et al., 2007). In the context of viral infections, RIG-I recognises viral 
nucleic acids and activates MAVS, which in turn signals the formation of a CARD9/BCL10 
complex responsible for NF-κB activation (Poeck et al., 2010).  
In bacterial infections, CARD9 was described as an adaptor in the NOD2 pathway, linking 
this NLR to MAPKs activation without affecting NF-κB (Hsu et al., 2007). CARD9 is also a 
positive regulator of ROS production by the NADPH complex in response to intracellular 
bacterial infections (Wu et al., 2009). No work has thus linked CARD9 to canonical 
inflammasomes. 
In comparison to WT controls, infection of Card9-/- BMDMs with S. Typhimurium revealed 
only a marginal increase in cellular viability and intracellular bacterial numbers only at MOI 
10 and only at 2 hours post-infection (Figure 3.24). Nlrc4-/- cells, in contrast, showed a 
marked increase in viability and intracellular bacterial numbers, illustrating the importance of 
this NLR in the context of Salmonella infection (Figure 3.24). The production of IL-1 was, 
however, significantly increased in Card9-/- macrophages (Figure 3.25). For example, Card9-
/- cells produced up to four times more IL-1 than WT cells at 24 hours post-infection at MOI 
10.  Nlrc4-/- cells, as expected, were critically impaired in IL-1 production (Figure 3.25).  
To rule out the possibility that this increase in cytokine production is a consequence of the 
marginally higher cellular viability in Card9-/- BMDMs, the cytokine TNF- was also 
quantified. TNF- levels were increased in the Nlrc4-/- compared to WT cell cultures (Figure 
3.26), presumably as a consequence of their increased survival rates (Figure 3.24). In 
accordance with the viability data, Card9-/- cells secreted more TNF- only at MOI 10 and 
only at 2 hours post-infection (Figure 3.26). The increase in the amount of IL-1 produced by 
Card9-/- macrophages, therefore, cannot be explained by an increase in cellular viability 
alone. The rapid effect that CARD9 has on IL-1β production suggests that this protein may 
inhibit NLRC4-mediated cytokine production, since early IL-1β produced is largely 
dependent on this NLR (Man et al., 2014). How exactly CARD9 inhibits the inflammasome, 




Figure 3.24: CARD9 has a mild effect on cellular viability and intracellular bacteria 
counts in BMDMs infected with S. Typhimurium SL1344. (a), (c) and (e) Cellular viability 
(as measured by LDH release) and (b), (d) and (f) intracellular bacteria counts of WT, Nlrc4-/- 
and Card9-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a-b), 6 
(c-d) and 24 (e-f) hours. * p<0.05 one-way ANOVA with Tukey’s multiple comparisons test. 





Figure 3.25: CARD9 loss promotes IL-1β production in BMDMs infected with S. 
Typhimurium SL1344. IL-1β secretion (as measured by ELISA) of WT, Nlrc4-/- and Card9-/- 
BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) 
hours. * p<0.05 one-way ANOVA with Tukey’s multiple comparisons test. Data represent the 





Figure 3.26: CARD9 has no effect on TNF- production in BMDMs infected with S. 
Typhimurium SL1344 in most conditions. TNF- secretion (as measured by ELISA) of 
WT, Nlrc4-/- and Card9-/- BMDMs after infection with S. Typhimurium at MOIs 1, 10 and 50 
for 2 (a), 6 (b) and 24 (c) hours. * p<0.05 one-way ANOVA with Tukey’s multiple 
comparisons test. Data represent the mean from five independent experiments while error 
bars show the s.e.m. 
 
3.3. Discussion 
The signalling events leading to NLRC4 and NLRP3 activation upon S. Typhimurium 
infection are not well understood. This is why, in this chapter, I investigated the effect of 
several NLRs, caspases and related proteins in the activation of the inflammasome induced 
by Salmonella. To achieve this, I performed GPA on BMDMs obtained from 15 genetically 
altered strains of mice. Table 3.1 qualitatively summarises the data on cellular viability, 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Amongst these 15 mouse strains, Caspase-12-/-, Nlrp1a-c-/-, Nlrp6-/- and Nlrx1-/- BMDMs 
showed no differences in cellular viability, intracellular counts and IL-1 production when 
compared to WT macrophages. These results do not completely rule out potential 
contributions for these proteins during Salmonella infection for two reasons. First, the GPA 
employed throughout this chapter used macrophages derived from bone marrow, which is a 
very specific subset of immune cells. The use of other cell types such as bone marrow-
derived dendritic cells, neutrophils, or even peritoneal macrophages could have potentially 
yielded different results. Second, and perhaps more importantly, in vitro infection with S. 
Typhimurium strongly engages the NLRC4 pathway, causing rapid cell death and cytokine 
release and potentially masking subtle contributions of other players not involved in this 
pathway. This problem can be circumvented if cells are infected with a S. Typhimurium strain 
that is deficient in activating the NLRC4 inflammasome. Indeed, this approach was used in 
this chapter to investigate the effect of caspase-11 and DFNA5 in the activation of the 
inflammasome induced by the S. Typhimurium mutant ΔfliCΔfljBΔprgJ, as it will be 
discussed in more detail below. 
Caspase-1/11 is known to significantly contribute to pyroptotic cell death, IL-1β production 
and infection clearance (Brennan and Cookson, 2000; Hersh et al., 1999; Monack et al., 
2001), a result that was reproduced in this work in BMDMs in vitro (Figure 3.2-3.3). NLRC4, 
however, appears to have an even more prominent role in regulating cell death upon 
Salmonella infection. The reason for this is that NLRC4 triggers cell death independent of 
caspase-1/11 (Broz et al., 2010b). The cumulative effect, however, of these 3 proteins had 
not been so far evaluated. BMDMs lacking NLRC4, caspase-1 and caspase-11 were more 
resilient to cell death than BMDMs lacking NLRC4 or Caspase-1/11 alone, confirming that 
NLRC4 drives multiple cell death pathways upon Salmonella infection, one involving ASC 
and caspase-1/11 (Mariathasan et al., 2004), and others independent of these proteins (Broz 
et al., 2010b). Interestingly, cell death still occurred later in the infection even in the absence 
of NLRC4, Caspase-1 and Caspase-11 (Figure 3.2). It is possible that in the absence of 
these proteins, other NLRs and caspases could be involved in driving cell death. It has been 
already shown that recruitment of caspase-8 to the inflammasome is not important for 
pyroptosis in response to S. Typhimurium infection (Man et al., 2013). The same applies for 
caspases -2 and -12, since BMDMs from caspase-2-/- and caspase-12-/- mice were infected 
with Salmonella and showed no differences in cellular viability in comparison to WT controls 
(Figure 3.15, 3.21). The data on caspases -8, -2 and -12, however, were generated in the 
context of NLRC4 activation. So, it is possible that in the absence of NLRC4 these caspases 
could drive cell death in response to Salmonella infection. 
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The caspase-1-deficient mice widely used in innate immunity studies were in fact deficient 
for both caspase-1 and caspase-11. This means that the role of these caspases must be re-
evaluated in a variety of settings, including S. Typhimurium infection. Infection of caspase-
11-/- BMDMs with log-phase Salmonella (figure 3.3 and 3.4) showed no significant difference 
regarding cell death and IL-1β production when compared to WT cells. To make sure that 
the dominant effect of NLRC4 does not mask any potential contribution of caspase-11, I 
infected macrophages with the S. Typhimurium mutant ΔfliCΔfljBΔprgJ, which cannot 
activate NLRC4. In this case, caspase-11 appears to contribute to Salmonella-induced cell 
death at later time points (figure 3.5). Similar conclusions were reported previously using an 
in vitro infection model with stationary phase S. Typhimurium. There, the authors found that 
caspase-11 is involved in NLRC4-independent cell death after 17 hours infections (Broz et 
al., 2012).  The role of caspase-11 in vivo is, however, less clear, as caspase-11-/- and WT 
mice showed similar susceptibility to the infection whilst caspase-1 appeared to play a 
fundamental role in clearing the infection (Broz et al., 2012).  
In the absence of NLRC4 activation, caspase-11 also had a very clear effect on IL-1β 
production. Cells lacking caspase-11 were impaired at secreting this cytokine, and once 
again the result was more pronounced after 24 hours of infection (figure 4.6). Similarly, 17-
hours infection with stationary-phase S. Typhimurium ΔfliG also showed a role for caspase-
11 in IL-1β production (Broz et al., 2012). It is interesting to note that similar findings were 
reported using LPS-primed macrophages during infection with Legionella pneumophila: 
Caspase-11-/- BMDMs infected with mutants incapable of activating the NLRC4 
inflammasome exhibited an increase in cell survival and a substantial decrease in IL-1β 
production when compared to WT macrophages (Case et al., 2013).  
It is unclear how exactly caspase-11 controls IL-1 production and cell death in the absence 
of NLRC4 stimulation. One explanation is that caspase-11 was originally described as an 
activator of caspase-1;  its absence could therefore block caspase-1 activation which drives 
IL-1β maturation and cell death (Wang et al., 1998). Caspase-11 is also a key component of 
a non-canonical inflammasome responsible for the maturation of IL-18 and IL-1, although 
the physiological relevance of this inflammasome in the context of Salmonella infection in 
macrophages is still unknown (Kayagaki et al., 2011; Knodler et al., 2014; Shi et al., 2014). 
Another hypothesis is that caspase-11 is required for canonical NLRP3 inflammasome 
activation via gasdermin D, and caspase-11 deficiency could lead to deficient NLRP3 
activation in my experimental setting (Kayagaki et al., 2015). In summary, caspase-11 is not 
required for optimal inflammasome activation in response to infection with S. Typhimurium. It 
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does, however, appear to contribute to inflammasome activation only when NLRC4, is not 
activated. 
The noncanonical caspase-11 inflammasome is known to trigger the cleavage and activation 
of gasdermin D, a protein responsible for creating pores in the plasma membrane, thus 
mediating pyroptosis (Kayagaki et al., 2015; Shi et al., 2015). Its role as the executioner of 
pyroptosis appears to be complemented by a yet unknown molecule during canonical 
NLRP3 inflammasome activation (Kayagaki et al., 2015). The data I generated from infecting 
GasderminD-/- BMDMs with S. Typhimurium corroborated this; although cellular viability in 
GasderminD-/- BMDMs was higher than that of WT controls, a significant amount of cell 
death was still observed (Figure 3.11). Two conclusions can be extracted from this. First, 
gasdermin D is indeed involved in NLRC4-mediated cell death. This complements a 
previous report using flagellin from P. aeruginosa that suggested that gasdermin D has an 
early effect on cell death mediated by NLRC4 (Kayagaki et al., 2015). Similarly, I observed 
that early in the Salmonella infection, gasdermin D is involved in cell death, whereas this 
effect is not observed at later time points (Figure 3.11). Second, since early cell death is still 
observed in the absence of Gasdermin D, other pyroptosis executioners are likely to exist. 
The identity of this pyroptosis executioner is still unknown. I hypothesised that the 
gasdermin-related protein DFNA5 could play this role, but the data did not support a role for 
DFNA5 in Salmonella-dependent pyroptosis as GasderminD-/-/Dfna5-/- and GasderminD-/- 
BMDMs showed similar cell death upon Salmonella infection. It is, however, possible that 
DFNA5 executes pyroptosis in a caspase-3-dependent fashion in other contexts (Rogers et 
al., 2017; Wang et al., 2017).  
Interestingly, the production of IL-1 was greatly impaired, but not completely blocked, in 
both GasderminD-/- and GasderminD-/-/Dfna5-/- BMDMs when compared to WT controls 
(Figure 3.12). It is unclear how gasdermin D controls IL-1 production. It is conceivable that 
the lower IL-1 detected in the supernatant is secondary to a decrease in membrane pore 
formation, a process that involves gasdermin D (Aglietti et al., 2016). IL-1β lacks a secretion 
signal sequence (Auron et al., 1984), and pore-formation is one of the proposed 
mechanisms for IL-1β release (Fink and Cookson, 2006). Thus, lower cell death would 
cause a decrease in IL-1β detected in the supernatant. This hypothesis is contradicted by 
the IL-18 data, where both gasdermin D and DFNA5 had no effect on IL-18 production in all 
time points and MOIs (Figure 3.13). Since IL-18 also lacks a secretion signal sequence 
(Kohka et al., 1998), the discrepancy between IL-1β and IL-18 detected in the supernatant 




The literature on NLRC3 and NLRC5 suggests that these NLRs act as inhibitors of innate 
immune pathways, with NLRC3 inhibiting NF-κB and cGAS/STING (Schneider et al., 2012; 
Zhang et al., 2014) and NLRC5 inhibiting NF-κB and RIG-I signalling (Cui et al., 2010; Tong 
et al., 2012). Analysis of cellular viability during Salmonella infection appear to support a role 
for NLRC3 and NLRC5 as NF-κB inhibitors. Generally, upregulation of NF-κB signalling 
results in increased cell death due to upregulation of genes such as Nlrp3 and Tnfa 
(Bauernfeind et al., 2009; Shakhov et al., 1990). Upon Salmonella infection, NLRC3 and 
NLRC5 inhibited cell death (Figure 3.8), an effect that could be attributed to their potential 
role as NF-κB negative regulators. Analysis of cytokine production, however, suggests the 
opposite. Upon Salmonella infection, NLRC3 and NLRC5 stimulates IL-1β production 
without affecting IL-18 (Figure 3.9-10), an effect that could be attributed to a positive effect 
on NF-B signalling, as Il1b is a NF-B-inducible gene whereas Il18 is constitutively 
expressed (Hiscott et al., 1993; Puren et al., 1999).  
It is important to notice that previous work done in LPS-primed macrophages derived from 
Nlrc5-/- mice infected with S. Typhimurium showed no difference in IL-1 production in 
relation to WT controls (Kumar et al., 2011). This could be explained by the fact that the 
priming was done using high LPS concentration for a long period of time (500 ng/mL for 24 
hours), potentially masking subtle effects NLRC5 could have in the NF-B pathway. 
Additionally, Kumar and collaborators employed S. Typhimurium at MOI 50, an experimental 
condition not ideal for studying small effects, since this MOI kills BMDMs very early in the 
infection. In line with this, I was unable to detect statistically significant differences in cellular 
viability, intracellular counts, IL-1 and IL-18 production in Nlrc3 and Nlrc5 knockout 
macrophages at MOI 50, regardless of the time point analysed. Further experimentation is 
now required to confirm that NLRC3 and NLRC5 are involved in cell death upon S. 
Typhimurium infection at later time points. Analysis of gene transcription by qPCR and 
stimulation of Nlrc3-/- and Nlrc5-/- BMDMs by canonical NLRP3 ligands, such as ATP and 
nigericin, could possibly improve our understanding on how these NLRs affect cellular 
viability during infection. 
Functional redundancy between caspases is of relevance to inflammasome biology. This is 
illustrated by caspase-1 and caspase-11, both involved in triggering pyroptosis in a number 
of settings and by the fact that caspase-8 and caspase-1 are both involved in processing 
pro-IL-1 to its mature form (Kayagaki et al., 2011; Man et al., 2013). Less clear, however, is 
how other caspases affect this process. Infection of caspase-2-/- BMDMs revealed no 
difference in cellular viability in comparison to WT controls (Figure 3.21). This observation 
contradicts data generated in a previous study, according to which infection of caspase-2-/-
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BMDMs with S. Typhimurium showed a small albeit statistically significant impairment in cell 
death (Jesenberger et al., 2000). This difference could be explained by the fact that the 
authors used bacteria transitioning from stationary to logarithmic phase. Stationary phase 
bacteria is known to sub optimally stimulate the NLRC4 pathway due to lower expression of 
SPI-I proteins (Lara-Tejero et al., 2006). The activity of the NLRC4 inflammasome could, 
therefore, be masking a potential role for caspase-2 in cellular viability in my experimental 
setting. Of note however is the observation that IL-1 production is slightly impaired in 
caspase-2-/- BMDMs whereas IL-18 production remained unaltered (Figures 3.21-3.22). This 
follows a very similar pattern to that observed in caspase-8-/-/Ripk3-/- cells when compared to 
Ripk3-/- and WT BMDMs; IL-1 production was impaired but IL-18 production and the degree 
of cellular viability were the same (Man et al., 2013). These observations imply a 
complementary role for caspase-2 during inflammasome activation.  
Interestingly, this role is probably unrelated to the well-established effect of caspase-2 in 
apoptosis. This is because I found that PIDD, which is located upstream of caspase-2 in the 
intrinsic apoptotic pathway, did not affect cellular viability and intracellular bacteria counts. 
IL-1 production is, however, increased at MOI 50 upon 6 and 24 hours of infection where 
PIDD appeared to significantly inhibit IL-1 production (Figures 3.17-3.18). Assuming that 
caspase-2 indeed possess a role in inflammasome-regulated IL-1 processing, it is possible 
that the inhibitory effect of PIDD on IL-1 production occurs due to competition; in the 
presence of PIDD, caspase-2 can either interact with the PIDDosome or with the 
inflammasome and once PIDD is removed from the system (as in Pidd-/- BMDMs), a higher 
amount of caspase-2 is available to interact with the inflammasome, thus increasing IL-1β 
production. At the moment, this hypothesis is speculative, and more work is needed to 
establish if caspase-2 is actively involved in the activation of the Salmonella-induced 
inflammasome and whether PIDD plays a role in this process. 
Despite evidence that the dectin-1 pathway could recognise bacterial PAMPs (Jackson et 
al., 2014), little is known about this receptor and its downstream adaptors in the context of 
inflammasome formation in response to Salmonella. For this reason, I examined the role of 
CARD9 in this process and I found that it had a profound inhibitory effect on IL-1β 
production. According to the well-established paradigm of inflammasome activation, one 
could expect that CARD9 would also have an inhibitory effect on pyroptotic cell death, since 
IL-1β production and pyroptosis are usually coupled processes.  This, however, was clearly 
not the case. On the contrary, CARD9 was found to marginally promote cell death upon S. 
Typhimurium infection. This unexpected inhibitory activity of CARD9 in IL-1β production also 
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contradicts its roles as a positive regulator of inflammatory pathways such as NF-B and 
MAPK (Bertin et al., 2000; Hsu et al., 2007; Poeck et al., 2010).  
In the dectin-1 pathway, in addition to its involvement in NF-κB activation, CARD9 mediates 
the assembly of a noncanonical inflammasome containing caspase-8, responsible for IL-1β 
processing (Gringhuis et al., 2012). Little is known about the link between CARD9 and 
canonical inflammasomes. Previous work found no evidence of CARD9 involvement in IL-18 
production mediated by AIM2 and NLRP3 (Hara et al., 2013). CARD9 is also not involved in 
NLRP3 activation in LPS-primed primary dendritic cells (Gross et al., 2009). Due to the 
unexpected impact of CARD9 on IL-1β production which is uncoupled from cell death, I 
decided to further investigate the role of CARD9 in regulating inflammasome activation upon 









CARD9 regulation of canonical inflammasome activation 
 
4.1. Introduction 
CARD9 is a 62 kDa protein containing a N-terminal CARD followed by a coiled coil domain 
and expressed in several different tissues including the spleen (Bertin et al., 2000). Its role in 
innate immunity was first described in the context of NF-B signalling, in which the authors 
used HEK293T overexpression systems to study the physical interaction between CARD9 
and BCL10. This interaction activates NF-B signalling via the IKK complex (Bertin et al., 
2000). Later it was demonstrated that the CARD9/BCL10 interaction is physiologically 
relevant in the context of fungal infections in dendritic cells. Fungal pathogens such as 
Candida albicans contain the PAMP -glucan that is recognised by dectin-1, a plasma 
membrane receptor containing a immunoreceptor tyrosine-based activation motif (ITAM). 
Upon recognition of its ligand, dectin-1 is phosphorylated and recruits spleen tyrosine kinase 
(SYK) (Gross et al., 2006). SYK is then activated and stimulates protein kinase C- (PKC-), 
responsible for phosphorylating CARD9 at threonine 231. This phosphorylation event allows 
CARD9 to interact with BCL10 and MALT1 forming a complex that stimulates the 
phosphorylation and activation of TAK1, responsible for activating NF-B signalling via IKK 
phosphorylation. Interestingly CARD9 appears to modulate specific aspects of the dectin-
1/SYK signalling pathway, as phagocytosis of zymosan particles is dependent on dectin-1 
and SYK but independent of CARD9 (Gross et al., 2006; Strasser et al., 2012). The role of 
CARD9 in the NF-B pathway is highly context-dependent, as illustrated by the fact that in 
macrophages CARD9/MALT1/BCL10 plays no role in NF-B translocation despite the 
reasonably high expression of these proteins (Goodridge et al., 2009).  
Studies in T-cells suggests that dectin-1 is a PRR that recognises bacterial β-(1,3)-glucan. In 
those cells, dectin-1 recognises the purified antigen, resulting in the production of IL-2 and 
facilitating antigen presentation (Jackson et al., 2014). It is unclear if this response is 
relevant in vivo, and if other cell types such as macrophages are able to recognise bacterial 
PAMPs via dectin receptors. 
In addition to its role in the regulation of gene transcription via NF-κB, CARD9 is also 
involved in the assembly of a non-canonical inflammasome upon dectin-1 stimulation in 
dendritic cells. There, fungal pathogens such as C. albicans are recognised by the C-type 
lectin dectin-1, triggering the upregulation in the transcription of genes such as Il1b via 
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assembly of the CARD9/MALT1/BCL10 complex. This complex then recruits ASC and 
caspase-8 and results in the production of pro-inflammatory cytokines such as IL-1 
(Gringhuis et al., 2012). 
Other ITAM proteins employ CARD9 as an adaptor whilst transducing extracellular signals. 
In myeloid cells such as dendritic cells and macrophages, the ITAM-containing adaptors 
fragment crystallisable receptor (FcR)- and DNAX activating protein of 12 kDa (DAP12) are 
recruited by a number of receptors, allowing CARD9 to be activated via SYK, as described 
above. This phenotype is only observed in myeloid cells, as lymphocytes and natural killer 
(NK) cells employ the adaptor CARD11 instead and CARD9 deficiency has no impairment in 
the activation of FcR- and DAP12-associated ITAM receptors (Hara et al., 2007; Hara and 
Saito, 2009). 
Upon viral infection, CARD9 acts as an adaptor in the RIG-I and Rad50 pathways. RIG-I 
interacts with viral dsRNA, leading to its activation by K63 ubiquitination and subsequent 
activation of MAVS forming the CARD9/BCL-10 complex responsible for activating NF-B 
signalling (Poeck et al., 2010; Seth et al., 2005). In response to foreign dsDNA such as 
poly(dA:dT), the cytoplasmic protein Rad50 acts as a PRR in dendritic cells and triggers the 
formation of the CARD9/BCL10 complex that upregulates pro-IL-1 expression. CARD9 in 
the context of viral infections thus acts by controlling the transcription of pro-inflammatory 
cytokines (Roth et al., 2014). Interestingly, the CARD9 antiviral response appears to be 
specific to the RIG-I pathway, as CARD9 does not modulate AIM2 inflammasome activity nor 
is it involved in the cGAS/STING pathway (Roth et al., 2014). 
Termination of CARD9/MALT1/BCL10 signalling is achieved by the RUN domain Beclin-1-
interacting cysteine-rich-containing (Rubicon). Upon dectin-1 or RIG-I activation the 
CARD9/MALT1/BCL10 signalling complex is formed, whilst in parallel Rubicon is 
unphosphorylated and changes its binding partner from 14-3-3 to CARD9. The 
Rubicon/CARD9 interaction results in the disruption of the interactions between 
CARD9/MALT1/BCL10 and termination of signalling (Yang et al., 2012). 
Genome-wide association studies link CARD9 mutations to the development of inflammatory 
diseases such as colitis and Crohn’s disease (Balzola et al., 2012; Beaudoin et al., 2013; 
Hong et al., 2015; Zhernakova et al., 2008). As discussed previously, NOD2 mutations are 
also strongly linked to those conditions (Hugot et al., 2001; Uniken Venema et al., 2017). 
Mechanistically, CARD9 is an adaptor in the NOD2 signalling pathway. Upon NOD2 
stimulation, CARD9 interacts with the NACHT domain of NOD2 leading to activation of the 
MAPKs p38 and JNK, but it is not involved in NF-B signalling in the context of NOD2 
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signalling (Hsu et al., 2007; Parkhouse et al., 2014). The activation of MAPKs further 
illustrate the context-dependent activity of CARD9, as in lymphocytes this adaptor is not 
involved in MAPK signalling (Hara et al., 2007). Figure 4.1 illustrates some of the roles of 
CARD9 in dendritic cells. 
 
Figure 4.1: CARD9 as an adaptor in innate immunity. CARD9 involvement in the RIG-I 
pathway, non-canonical inflammasome formation, and NOD2 signalling in the response 
against ssRNA viruses, C. albicans and MDP respectively. CARD9 role in non-canonical 
inflammasome formation was only studied in dendritic cells. 
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CARD9 is also involved in the clearance of invasive bacterial pathogens by stimulating the 
production of ROS. This production is, in large part, controlled by the NADPH oxidase 
complex which is activated by the Rho-family GTPase Rac1. Upon infection, Rac1 is 
activated by GTP and is recruited to the membrane together with various NADPH complex 
proteins, forming a complex responsible for ROS production. This process is inhibited by the 
protein Ly GDP-dissociation inhibitor (LyGPI). In this context, CARD9 disrupts LyGDI 
inhibition of the ROS-producing complex and plays a key role in ROS production in 
macrophages in response to E. coli, L. monocytogenes and S. Typhimurium, but is not 
involved in ROS production in response to zymosan nor C. albicans (Figure 4.2) (Gross et 
al., 2009; Wu et al., 2009).  
 
 
Figure 4.2: CARD9 and ROS production. CARD9 stimulates the production of ROS in 





With respect to Mycobacteria infection, CARD9 appears to adopt an anti-inflammatory role. 
In a model of aerosol Mycobacterium tuberculosis infection, Card9-/- mice succumbed earlier 
to the disease and demonstrated a higher quantity of pro-inflammatory cytokines in the 
serum and lungs. These findings were linked by the authors to a deficiency in IL-10 
production by the CARD9 knockout animals (Dorhoi et al., 2010). 
The various roles that CARD9 plays during infection suggests that when it comes to innate 
immunity, all roads lead to CARD9 (Colonna, 2007). Evidence linking CARD9 to canonical 
inflammasomes, however, is missing, although some evidence in the literature from SYK 
studies suggest a possible role for CARD9. Upon C. albicans infection of BMDCs, CARD9 is 
involved in regulating pro-IL-1 expression via formation of a complex with BCL10 and 
MALT1 and activation of NF-B (Gross et al., 2006). When BMDCs are initially primed with 
LPS, however, causing them to express great quantities of pro-IL-1β, CARD9 has no effect 
on NLRP3-mediated IL-1 production (Gross et al., 2009). In BMDMs, stimulation of the 
NLRP3 inflammasome by nigericin and stimulation of the AIM2 inflammasome by 
poly(dA:dT) in Card9-/- revealed similar IL-18 production in comparison to WT controls, albeit 
the production of IL-1 was not investigated (Hara et al., 2013). 
In the previous chapter, I showed during S. Typhimurium infection of Card9-/- BMDMs there 
was a substantial increase in IL-1 production relative to their WT counterparts. This was not 
coupled to TNF- production, suggesting a specific effect on IL-1 production, and was 
unlikely to be a consequence of the marginal increase in cellular viability (Figure 3.24-26). 
This was a surprising finding since the CARD9 functions thus far described suggests that 
this protein predominantly plays a key pro-inflammatory role in cell signalling, although 
whether it plays a role in canonical inflammasome activation in macrophages is unknown.  
This chapter will focus on the elucidation of which inflammasomes CARD9 is capable of fine-
tuning during Salmonella infection to explain the elevated IL-1β production seen in Chapter 




The enhanced IL-1 production from BMDMs after S. Typhimurium infection suggests a 
previously unknown role for CARD9 in the innate immune response to bacteria.  
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NLRC4 and NLRP3 are the main NLRs activated in response to Salmonella infection  (Man 
et al., 2014), both capable of forming inflammasomes and converting pro-IL-1β to IL-1β. One 
of the differences between these two NLRs in vitro is the timing at which they are activated. 
In unprimed WT BMDMs, NLRC4-mediates IL-1β production as early as two hours post-
infection. This contrasts with the NLRP3 inflammasome, that induces IL-1β production at 
later time points (Man et al., 2014).  In primed macrophages both NLRC4 and NLRP3 can be 
activated at the same time (Man et al 2014). In the infection assays presented in the 
previous chapter (Figure 3.26-28), unprimed Card9-/- BMDMs produced more IL-1β than the 
WT controls throughout the course of the experiment. Since a significant difference in 
cytokine production is observed as early as 2 hours post-infection, I hypothesized that 
CARD9 acts as an inhibitor of the NLRC4 inflammasome. 
To test whether CARD9 inhibits NLRC4 activation, WT, Card9-/-, Nlrc4-/- and Nlrp3-/- BMDMs 
were primed with LPS (200 ng/mL for 3 hours) prior to transfection with ultrapure flagellin 
from S. Typhimurium, a NLRC4 ligand, for one hour. Next, I quantified cellular viability and 
the levels of IL-1β production. Flagellin transfection had no effect on BMDM cell viability 
(Figure 4.3 a), while marked IL-1β production was observed in all mouse lines except the 
NLRC4 knockout negative controls. Interestingly, WT, NLRP3 and CARD9 knockouts 
secreted similar IL-1β quantities into the supernatant (Figure 4.3 b). Taken together these 
results do not support a link between flagellin-activated NLRC4 and CARD9. 
 
Figure 4.3: CARD9 does not influence flagellin activated NLRC4-mediated IL-1 
production and cellular viability in LPS-primed BMDMs. WT, Nlrc4-/-, Nlrp3-/- and Card9-/- 
LPS-primed BMDMs (200 ng/mL for 3 hours) were transfected with 60 ng ultrapure flagellin 
for one hour followed by analysis of cellular viability (as measure by LDH release) (a) and IL-
1 production (as measured by ELISA) (b). * p<0.05 one-way ANOVA with Tukey’s multiple 
comparisons test. Data represent the mean from three independent experiments while error 
bars show the s.e.m.  
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Salmonella also activates NLRC4 through its SPI protein PrgJ as well as via flagellin.  To 
further investigate a possible link between NLRC4 and CARD9, GPAs were conducted using 
S. Typhimurium SL1344 ΔfliCΔfljBΔprgJ. This non-motile Salmonella mutant is deficient in 
NLRC4 activation (Man et al., 2014). If CARD9 acts by negatively regulating NLRC4 activity, 
then infection with the ΔfliCΔfljBΔprgJ mutant would stimulate similar IL-1β production in WT 
and Card9-/- BMDMs, presumably via NLRP3. 
In this set of GPAs, WT and CARD9 knockout unprimed BMDMs were infected with S. 
Typhimurium ΔfliCΔfljBΔprgJ or with the parental S. Typhimurium SL1344 strain, at an of 
MOI 10. The plates were then centrifuged to allow for both the motile and amotile bacteria to 
contact the cell surface at the same time and allowed to infect the cells for up to 24 hours. 
Cellular viability and IL-1β production were determined at 2, 6 and 24 hours post-infection. 
WT and Card9-/- BMDMs showed similar patterns of cell viability post infection, regardless of 
the bacterial strain used and at all time-points studied (Figure 4.4 a-c). Although the original 
infection assays revealed a slight increase in cell viability in Card9-/- macrophages (Figure 
3.24), this difference was absent in this set of experiments possibly due the fact that a 
centrifugation step was carried out to allow the S. Typhimurium ΔfliCΔfljBΔprgJ infection to 
occur, and thereby potentially increasing the infectivity of the WT bacteria as well. This 
observation, however, does not affect the conclusions drawn from this set of experiments.  
The levels of IL-1β, however, remained increased in Card9-/- BMDMs regardless of the 
bacteria strain used. Infection with S. Typhimurium SL1344 increased IL-1β production in 
CARD9 knockout macrophages compared to WT controls, by 2 hours post infection. 
Similarly, in cells infected with the triple mutant S. Typhimurium ΔfliCΔfljBΔprgJ, IL-1β 
production was enhanced in Card9-/- BMDMs, most notably at 6 and 24 hours post-infection. 
Interestingly, infection with this bacterial strain caused no detectable IL-1β production at 2 
hours in WT BMDMs, but at this time point the level of cytokine produced by Card9-/- BMDMs 
exceeded the detection limit (150 pg/mL detected, with a detection limit around 16 pg/mL). 
At 6 and 24 hours, Card9-/- macrophages produced 2.5 times more IL-1 than the WT 
controls for both bacterial strains (Figure 4.4 d-f). The ratio of IL-1β produced by Card9-/-/WT 
BMDMs was similar regardless of the bacteria strain used. Since ΔfliCΔfljBΔprgJ does not 
activate the NLRC4 inflammasome, the data suggests that the enhanced IL-1β production 
observed in Card9-/- BMDMs in the context of Salmonella infection does not require NLRC4. 
This is consistent with the flagellin transfection data (Figure 4.3) and therefore the 




Figure 4.4: Cellular viability and IL-1 production in WT and Card9-/- BMDMs infected 
with S. Typhimurium SL1344 WT and fliCfljBprgJ further suggest that NLRC4-
mediated IL-1 production is unlikely to be controlled by CARD9. Cellular viability (a-c) 
and IL-1β production (d-f) from unprimed BMDMs after infection with S. Typhimurium WT or 
the NLRC4 activation deficient mutant ΔfliCΔfljBΔprgJ at MOI 10 for 2 (a,d), 6 (b,e) and 24 
(c,f) hours. * p<0.05 in comparison to WT (one-way ANOVA with Tukey’s multiple 
comparisons test). Data represent the mean from three independent experiments while error 
bars show the s.e.m.  
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In the dectin-1 pathway, CARD9 links SYK to NF-B signalling and to the noncanonical 
caspase-8 inflammasome (Gringhuis et al., 2012). Although there is some evidence that 
dectin-1 can function as a Salmonella PRR in T cells (Jackson et al., 2014), this link was not 
established, to my knowledge, in macrophages. I hypothesized that CARD9 could potentially 
modulate the IL-1 production in macrophages through the dectin-1 pathway.  
To test this hypothesis, I infected macrophages in presence of a dectin-1 blocking antibody. 
First, to verify if the antibody was suitable for functional assays, I have performed dectin 
stimulation assays in LPS-primed BMDMs using the dectin ligand zymosan. Oxidised 
zymosan was also included in this experiment, as primary macrophages are known to be 
better stimulated by the oxidised form of this molecule (Saijo et al., 2007). Next, cellular 
viability, IL-1β and TNF-α production were quantified. In this experiment, no difference in 
cellular viability was detected, whilst TNF- production decreased in WT BMDMs incubated 
with ox-zymosan in presence of the blocking antibody. CARD9 knockout macrophages 
produced substantially less TNF- and were not influenced by the presence of the blocking 
antibody, indicative that CARD9 is important in the response against ox-zymosan (Figure 
4.5). No IL-1 was detected in any of the zymosan or ox-zymosan treatments. This suggests 
that the anti-dectin-1 antibody is suitable for functional assays. 
 
 
Figure 4.5: Anti-Dectin-1 antibody blocks TNF- induced by oxidised-zymosan in WT 
BMDMs. Cellular viability (a) and TNF- production (b) from LPS-primed (200 ng/mL for 3 
hours) WT and Card9-/- BMDMs after one-hour stimulation with 100 µg/mL zymosan or 
oxidized zymosan. No IL-1 was detected in any of the treatments. * p<0.05 in comparison 
to WT (one-way ANOVA with Tukey’s multiple comparisons test). Data represent the mean 
from three independent experiments while error bars show the s.e.m.  
108 
 
Next, LPS-primed WT and Card9-/- BMDMs were infected with S. Typhimurium for one hour 
in presence or absence of dectin blocking antibody, followed by cellular viability 
measurement and culture supernatants collection for cytokine (IL-1β and TNF-α) 
quantification. The use of LPS-priming allows for quicker inflammasome activation during 
Salmonella infection, which is ideal for experiments using inhibitors or neutralizing antibodies 
where long exposure to these molecules could have adverse effects on the cells. Upon 
infection, Card9-/- BMDMs produced more IL-1 than the WT cells, but the presence or 
absence of anti-dectin failed to elicit any difference in cellular viability or levels of IL-1 and 
TNF- (Figure 4.6). Possible interpretations of these results would be that dectin-1 is not a 
PRR during S. Typhimurium infections in macrophages, or at least its activity does not result 
in IL-1β or TNF-α production therefore it is unlikely this receptor is a candidate for the 
CARD9-mediated IL-1β inhibition. 
 
Figure 4.6: Dectin-1 neutralisation does not affect IL-1 production in BMDMs infected 
with S. Typhimurium. Cellular viability (a), IL-1 (b) and TNF- production (c) from LPS-
primed (200 ng/mL for 3 hours) WT and Card9-/- BMDMs after one hour infection with S. 
Typhimurium at MOI 10. * p<0.05 in comparison to WT (one-way ANOVA with Tukey’s 
multiple comparisons test). Data represent the mean from three independent experiments 
while error bars show the s.e.m.  
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Upon infection, bacterial DNA is thought to act as a PAMP triggering IL-1 production via the 
AIM2 inflammasome. This pathway however appears to be of little relevance during S. 
Typhimurium infections (Rathinam et al., 2010; Warren et al., 2010). Researchers also failed 
to link the adaptor CARD9 to AIM2 inflammasomes in dendritic cells (Roth et al., 2014). 
Although it is unlikely that AIM2 is involved in CARD9 regulation of IL-1β production I tested 
whether AIM2 ligands could induce greater IL-1 production in CARD9 knockout BMDMs 
compared to WT controls. WT and Card9-/- BMDMs were primed with LPS (3 hours, 200 
ng/mL) then transfected the AIM2 ligand poly(dA:dT) and the cellular viability and IL-1β 
production quantified. AIM2 stimulation led to no differences in cellular viability nor IL-1 
production between WT and Card9-/- cells (Figure 4.7). This result is in agreement with 
previous reports that AIM2 is not involved in the response against Salmonella and that 
CARD9 is not involved in AIM2 signalling (Roth et al., 2014).  
 
 
Figure 4.7: WT and CARD9 knockout LPS-primed BMDMs have similar cellular 
viability and IL-1 production after AIM2 stimulation with poly(dA:dT). Cellular viability 
(a) and IL-1 production (b) from LPS-primed (200 ng/mL for 3 hours) WT and Card9-/- 
BMDMs after four hours stimulation with 2 µg/mL poly(dA:dT). * p>0.05 (unpaired t-test). 
Data represent the mean from three independent experiments while error bars show the 
s.e.m.  
 
During the infection process, S. Typhimurium engages both the NLRC4 and the NLRP3 
inflammasome (Broz et al., 2010; Man et al., 2014). NLRC4 stimulation and infection assays 
using a Salmonella mutant deficient in NLRC4 activation failed to demonstrate a link 
between CARD9 and IL-1β produced by this inflammasome (Figure 4.3-4). I therefore 
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determined whether NLRP3 was important in the inhibitory effect that CARD9 exerts on IL-
1 production during Salmonella infection.  
Unprimed WT and CARD9 knockout macrophages were infected with S. Typhimurium at 
MOI 10 for 2 and 6 hours in presence or absence of the drug glibenclamide. This drug is a 
sulfonylurea commonly used in human medicine for the treatment of type 2 diabetes, but it 
also has an inhibitory effect on the NLRP3 inflammasome (Lamkanfi et al., 2009). After 
infection, cellular viability and IL-1β production in the supernatant was quantified. Upon 
infection, glibenclamide had no discernible effect on the cellular viability in both WT and 
Card9-/- BMDMs. Similarly, the drug had no effect on IL-1β released by Salmonella-infected 
WT BMDMs, confirming that in WT BMDMs infected with Salmonella, NLRP3 is not involved 
in IL-1β production early in the infection (Man et al., 2014). In contrast, glibenclamide 
inhibited IL-1 production at 2 and 6 hours in CARD9 knockout BMDMs, thus upon NLRP3 
inhibition the resulting IL-1 secretion was similar between WT and Card9-/- (Figure 4.8). 
This suggested that CARD9 inhibits NLRP3 and that in the absence of the former, NLRP3 
activation in vitro occurs as early as 2 hours post Salmonella infection, a time point that 





Figure 4.8: NLRP3 inhibition with glibenclamide decreases IL-1 production in Card9-/- 
but not in WT BMDMs. Cellular viability (a-b) and IL-1β production (c-d) from unprimed 
BMDMs after infection with S. Typhimurium at MOI 10 for 2 (a,c) and 6 (b,d) hours in the 
presence of 200 µM glibenclamide. * p<0.05 in comparison to WT (one-way ANOVA with 
Tukey’s multiple comparisons test). Data represent the mean from three independent 
experiments while error bars show the s.e.m.  
 
 
More recently researchers have reported the development of MCC950, a potentially specific 
NLRP3 inhibitor (Coll et al., 2015). To further confirm the link between NLRP3 and CARD9, I 
performed a NLRP3 inhibition assay using MCC950. Using the same experimental design as 
for the glibenclamide experiment (Figure 4.8) similar data was obtained with IL-1 production 
unaffected in WT cells treated with MCC950, whilst Card9-/- BMDMs produce less IL-1β at 2 
and 6 hours upon MCC950 inhibition. The resulting IL-1 production when the inhibitor is 
present is similar between WT and Card9-/- macrophages (Figure 4.9). This corroborates the 





Figure 4.9: NLRP3 inhibition with MCC950 decreases IL-1 production in Card9-/- but 
not in WT BMDMs. Cellular viability (a-b) and IL-1β production (c-d) from unprimed BMDMs 
after infection with S. Typhimurium at MOI 10 for 2 (a,c) and 6 (b,d) hours in presence of 10 
µM MCC950. * p<0.05 in comparison to WT (one-way ANOVA with Tukey’s multiple 
comparisons test). Data represent the mean from three independent experiments while error 
bars show the s.e.m.  
 
To provide further evidence that CARD9 inhibits IL-1 production via the NLRP3 
inflammasome, I investigated whether the IL-1β production in WT and Card9-/- BMDMs was 
similar after stimulation with canonical NLRP3 activators such as the ionophore nigericin 
(Mariathasan et al., 2006). WT, Card9-/-, Nlrp3-/- and Nlrc4-/- BMDMs were primed with LPS 
(200 ng/mL for 3 hours), and then stimulated for one hour with nigericin. After stimulation, 
cellular viability and IL-1β present in the supernatants were quantified. Similar cell viability 
was observed in WT, Card9-/- and Nlrc4-/- macrophages, whilst Nlrp3-/- BMDMs were 
protected from cell death, as expected, because pyroptotic cell death is impaired in this 
knockout mouse line post nigericin stimulation (Figure 4.10 a). Similarly, IL-1production is 
greatly impaired in Nlrp3-/- cells following nigericin treatment. WT and Nlrc4-/- BMDMs 
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produced two times less IL-1β than Card9-/- macrophages (Figure 4.10 b). This once again 
suggests that the IL-1β production mediated by NLRP3 is inhibited by CARD9, whilst 
pyroptosis remains unnaffected. 
 
 
Figure 4.10: CARD9 influences NLRP3-mediated IL-1 production but not cellular 
viability in response to nigericin stimulation of LPS-primed BMDMs. WT, Nlrc4-/-, Nlrp3-
/- and Card9-/- LPS-primed BMDMs (200 ng/mL for 3 hours) were incubated with 10 µM 
nigericin for one hour followed by analysis of cellular viability (as measure by LDH release) 
(a) and IL-1 production (as measured by ELISA) (b). * p<0.05 in comparison to WT (one-
way ANOVA with Tukey’s multiple comparisons test). Data represent the mean from three 
independent experiments while error bars show the s.e.m.  
 
Finally, to further substantiate the CARD9/NLRP3 link, I have conducted another NLRP3 
stimulation assay using a different stimulus. In LPS-primed macrophages, ATP is a DAMP 
that triggers the assembly of the canonical NLRP3 inflammasome via the purinergic receptor 
P2X7R and production of ROS by NADPH oxidase (Cruz et al., 2007; Hewinson et al., 2008; 
Mariathasan et al., 2006). Here, WT, Nlrp3-/- and Card9-/- BMDMs were primed with LPS 
(200 ng/mL for 3 hours), stimulated with 5 mM ATP for 30 minutes, and then cellular viability 
and IL-1β production were quantified. At this concentration and incubation time, ATP did not 
cause any loss in cellular viability in all mouse lines analysed. In comparison to WT controls 
the levels of IL-1 production were decreased in Nlrp3-/- macrophages and enhanced in 
Card9-/- (Figure 4.11). The increased level of IL-1β production in Card9-/- macrophages upon 





Figure 4.11: CARD9 influences NLRP3-mediated IL-1 production but not cellular 
viability in response to ATP stimulation of LPS-primed BMDMs. WT, Nlrp3-/- and Card9-/- 
LPS-primed BMDMs (200 ng/mL for 3 hours) were incubated with 5 mM ATP for 30 minutes 
followed by analysis of cellular viability (as measure by LDH release) (a) and IL-1 
production (as measured by ELISA) (b). * p<0.05 in comparison to WT (one-way ANOVA 
with Tukey’s multiple comparisons test). Data represent the mean from three independent 
experiments while error bars show the s.e.m.  
 
The data above (Figures 4.8-11) supports the hypothesis that CARD9 negatively regulates 
the activity of the NLRP3 inflammasome both during S. Typhimurium infection of unprimed 
macrophages and after direct stimulation by canonical NLRP3 ligands in LPS-primed 
macrophages. To further consolidate this finding and to investigate whether CARD9 is 
relevant in other infection models known to activate the NLRP3 inflammasome, I infected 
cells with the enteropathogenic E. coli strain P19A. E. coli activates the NLRP3 
inflammasome (Brereton et al., 2011), but little work was done to characterize the 
enteropathogenic P19A strain.  
To confirm that this strain activates the NLRP3 inflammasome, I have conducted GPAs in 
unprimed WT, Nlrp3-/-, Nlrc4-/- and Caspase-1-/-/11-/- BMDMs using E. coli P19A at MOI 10. 
Upon 2 and 6 hours of infection, cellular viability and IL-1β production were assayed. The 
P19A strain caused cell death as early as 2 hours post-infection in WT and Nlrc4-/- 
macrophages, whilst Nlrp3-/- and Caspase-1-/-/11-/- macrophages were protected (Figure 4.12 
a). At 6 hours, Nlrp3-/- macrophages remained with near 100% cell viability (Figure 4.12 c). 
At 2 hours, E. coli P19A induced IL-1β production in both WT and NLRC4 knockout BMDMs, 
whilst this production was below detection limit in Nlrp3-/- and Caspase-1-/-/11-/- macrophages 
(Figure 4.12 b). No IL-1β was detected in Nlrp3-/- cells at 6 hours (Figure 4.12 d). Taken 
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together, this GPA confirms that E. coli P19A activates the NLRP3 inflammasome in vitro as 
early as 2 hours post infection. This bacterial strain is, therefore, suitable to study any links 
between CARD9 and NLRP3. 
 
Figure 4.12: NLRP3 and Caspase-1/11, but not NLRC4, are important in triggering cell 
death and IL-1 release during E. coli strain P19A infection. (a,c) Cellular viability (as 
measured by LDH release) and (b,d) IL-1 release in WT, Nlrp3-/-, Nlrc4-/- and Caspase-1-/-
Caspase-11-/- BMDMs after infection with E. coli P19A at MOI 10 for 2 (a-b), and 6 (c-d) 
hours. * p<0.05 in comparison to WT (one-way ANOVA with Tukey’s multiple comparisons 




WT and Card9-/- BMDMs were infected with E. coli P19A (MOIs 1, 10 and 50 for 2 and 6 
hours) and analysed for cell viability, intracellular bacteria and cytokine production (IL-1β 
and TNF-α). At both 2 and 6 hours post-infection, E. coli P19A caused similar levels of cell 
death in WT and CARD9 knockout macrophages, whilst no differences in intracellular 
bacteria counts was observed (Figure 4.13). ELISA of the cell culture supernatants showed 
a significant increase in IL-1 production in CARD9 knockout BMDMs in comparison to WT 
controls, whilst TNF- production in both macrophage strains remained similar (Figure 4.14). 
CARD9 therefore inhibits the production of IL-1β without affecting pyroptosis or the 
production of pro-inflammatory cytokines such as TNF-α in response to both E. coli and S 
Typhimurium. Since E. coli activates the NLRP3 inflammasome, it is likely that CARD9 
inhibits this inflammasome. 
 
Figure 4.13: CARD9 has no effect on cellular viability and intracellular bacteria counts 
in BMDMs infected with E. coli P19A. (a,b) Cellular viability (as measured by LDH release) 
and (c,d) intracellular bacteria counts of WT, and Card9-/- BMDMs after infection with E. coli 
P19A at MOIs 1, 10 and 50 for 2 (a-c) and 6 (b-d) hours. * p<0.05 in comparison to WT (one-
way ANOVA with Tukey’s multiple comparisons test). Data represent the mean from two 




Figure 4.14: CARD9 affects IL-1β but not TNF- production in BMDMs infected with E. 
coli P19A. IL-1β secretion (as measured by ELISA) (a,b) and TNF- secretion (as 
measured by ELISA) (c,d) of WT, and Card9-/- BMDMs after infection with E. coli P19A at 
MOIs 1, 10 and 50 for 2 (a-c) and 6 (b-d) hours. * p<0.05 in comparison to WT (one-way 
ANOVA with Tukey’s multiple comparisons test). Data represent the mean from two 
independent experiments while error bars show the s.e.m.  
 
Having established a link between NLRP3 and CARD9, I sought to investigate the 
mechanistic basis for how CARD9 negatively regulates this inflammasome. A possible 
mechanism for controlling NLRP3 activity is by CARD9 physically interacting with this 
inflammasome or some of its components. In practical terms, if a protein interacts with the 
assembled inflammasome, then this protein might be expected to co-localise with the ASC 
speck at the microscopic level. I therefore used immunofluorescence localisation of CARD9 
and ASC as a first approach to investigate the mechanism(s) involved in NLRP3 inhibition by 
CARD9. WT, Pycard-/- (ASC negative) and Card9-/- BMDMs were primed with LPS (200 
ng/mL for 3 hours). Next, the NLRP3 inflammasome was stimulated with nigericin (5 µM for 
30 minutes), the cells fixed in methanol and immunostained for ASC and CARD9. DAPI was 
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used for nuclei counterstaining and the preparations were then visualised under an 
epifluorescence microscope. 
As expected, WT and Card9-/- BMDMs formed ASC specks after stimulation with nigericin, 
while Pycard-/- BMDMs do not (Figure 4.15, red arrows). CARD9 was present as aggregates 
in the cytosol of both unstimulated WT and ASC knockout BMDMs but not in Card9-/- cells. 
These aggregates continued to be observed after nigericin stimulation and appear to be 
unrelated to the ASC specks. The lack of ASC/CARD9 colocalization suggests that CARD9 
is not recruited to the ASC speck (Figure 4.15, green arrows). 
The CARD9 antibody showed non-specific background staining in Card9-/- BMDMs. This 
staining, however, is much fainter than that observed in WT and Pycard-/- cells. Additionally, 
no CARD9 aggregates were observed in Card9-/- macrophages (Figure 4.15). To further 
verify the specificity of the CARD9 antibody, I performed an immunoblot assay using protein 
lysate from WT and Card9-/- cells probed with the same anti-CARD9 antibody used in the 
immunofluorescence assay. The immunoblot revealed one major protein band with an 
apparent molecular weight under 75 kDa, presumably CARD9 which is not present in the 
CARD9 knockout strain (Figure 4.16).  
Immunofluorescence and immunoblotting are fundamentally different techniques. 
Immunoblot, in most conditions, disrupts the protein structure thus altering the capability of 
the antibody to bind the protein. But Figure 4.16, taken together with the fainter signal and 
lack of aggregates observed in Card9-/- in Figure 4.15, suggests that the anti-CARD9 
antibody employed is specific enough for the purposes of this investigation and supporting 














































































































































































































Figure 4.16: Specificity of the anti-CARD9 antibody. Immunoblot of protein samples 
extracted from WT and Card9-/- BMDMs and probed with anti-Card9 and anti--Actin. The 
image is representative of two independent experiments. 
 
 
Whilst ASC and CARD9 do not co-localise at the ASC speck, it is possible that both proteins 
interact either upstream or downstream of ASC speck formation. To test whether there is 
cross talk upstream of ASC speck formation co-immunoprecipitation assays were conducted 
using anti-ASC, anti-CARD9 and anti-SYK antibodies as bait. In this set of experiments, SYK 
was chosen due its reported relevance in both NLRP3 inflammasomes and CARD9 
signalling (Gross et al., 2009; Hara et al., 2013).  
WT BMDMs were primed with LPS (200 ng/mL for 3 hours) and infected with S. 
Typhimurium (MOI 10, 30 minutes) or stimulated with nigericin (10 µM, 30 minutes), and 
after successive washes in cold PBS, the cells were fixed in 5 mM DTBP for 30 minutes to 
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preserve labile protein-protein interactions. After fixation, the cells were lysed, and the 
protein lysate was incubated with protein A/G agarose beads with one of the “bait” 
antibodies, anti-SYK, anti-CARD9 or anti-ASC. After overnight incubation, the beads were 
washed, the proteins eluted and subjected to immunoblotting. The protein lysates pre-
incubated with the agarose beads were also subjected to immunoblotting, to confirm that the 
protein input was similar in all treatments. 
The co-immunoprecipitations revealed that SYK interacts (directly or indirectly) with both 
ASC and CARD9 in unstimulated cells, but no evidence of ASC and CARD9 interaction was 
observed (Figure 4.17, Appendix 1-3). After S. Typhimurium infection or nigericin treatment, 
ASC interacted preferentially with phosphorylated SYK (p-SYK) as previously described (Lin 
et al., 2015). CARD9, however, appears to interact preferably with unphosphorylated SYK 
after infection or nigericin stimulation (Figure 4.17, Appendix 1-3). These co-
immunoprecipitation patterns further suggest that CARD9 does not interact directly with 
ASC, and its inhibitory role occurs upstream ASC speck formation. One possibility is that 
CARD9 interacts with SYK. Since the CARD9/SYK/p-SYK interactions changes whether the 
inflammasome is stimulated or not, it is feasible that SYK is somehow involved in the 






Figure 4.17: Co-immunoprecipitation assays shows no evidence of association 
between ASC and CARD9, while different phosphorylation states of SYK affects its 
interaction with both proteins. Co-immunoprecipitation of ASC, CARD9 and SYK from cell 
lysates of uninfected, S. Typhimurium-infected (MOI 10, 30min) or nigericin-stimulated (10 




As an additional control for the co-immunoprecipitation assays, protein lysates extracted 
from Card9-/- and Pycard-/- BMDMs were subjected to co-immunoprecipitation using as bait 
CARD9 and ASC antibodies respectively. Briefly, CARD9 knockout BMDMs were primed 
with LPS, and then stimulated with S. Typhimurium at MOI 10 or nigericin. The cells were 
then washed, fixed with DTBP, lysed, and the protein lysate was subjected to co-
immunoprecipitation using anti-CARD9 as bait. Immunoblot of the proteins eluted from the 
agarose beads failed to detect ASC, CARD9 or SYK. This indicates that the co-
immunoprecipitations discussed on Figure 4.17 are not due to non-specific interactions with 
the antibody. Similar results were obtained using Pycard-/- BMDMs and anti-ASC as bait 




Figure 4.18: Knockout controls for the co-immunoprecipitation assays reveals no 
unspecific immunoprecipitation. Immunoprecipitation of CARD9 from Card9-/- and 
immunoprecipitation of ASC from Pycard-/- cell lysates of uninfected, S. Typhimurium-
infected (MOI 10, 30min) or nigericin-stimulated (10 mM, 30min) LPS-primed BMDMs (200 
ng/mL for 3 hours). Image representative of three independent experiments. 
 
Since CARD9 does not co-localize with the ASC speck, it is likely that its role as a negative 
regulator of inflammasome activation occurs upstream of speck formation. One possibility is 
that absence of CARD9 increases ROS-mediated activation of the NLRP3 inflammasome 
(Cruz et al., 2007). This hypothesis however is not consistent with previous reports, as 
CARD9 knockout BMDMs have lower ROS production in response to intracellular bacteria 
such as L. monocytogenes and E. coli (Wu et al., 2009). The study in question however has 
not analysed ROS production by BMDMs in response to S. Typhimurium, prompting me to 
repeat their ROS experiments and include S. Typhimurium infection.  
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WT and Card9-/- BMDMs were seeded in opaque plates, and after washes with DPBS+ 
buffer, the cells were stimulated with 100 µg/mL zymosan, L. monocytogenes at MOI 50 or 
S. Typhimurium at MOI 50. Luminescence produced by luminol oxidation was followed as a 
readout of ROS produced by the cells. The luminescence was monitored in real time for a 
period 120 minutes.  
ROS production in WT and Card9-/- BMDMs upon zymosan stimulation was similar 
throughout the experiment (Figure 4.19 a-b). Card9-/- macrophages, however, had impaired 
ROS production during L. monocytogenes infection for most of the time course (Figure 4.19 
c-d). Similar to L. monocytogenes infection, Card9-/- BMDMs showed substantial impairment 
in ROS production during S. Typhimurium infection (Figure 4.19 e-f). These results are in 
agreement with previous publication (Wu et al., 2009), and since ROS production is impaired 
in CARD9 knockout macrophages, it unlikely that ROS production is the mechanism for 
increased NLRP3-mediated IL-1 production in Card9-/-. 
CARD9 is a regulator of the NF-B pathway under specific conditions and in certain cell 
types (Bertin et al., 2000). It is possible, therefore, that the CARD9 effect observed in 
NLRP3-mediated IL-1 production is attributable to an increase in pro-IL-1 expression. To 
investigate whether Card9-/- BMDMs produce more pro-IL-1β that the WT controls, 
immunoblot analysis of uninfected cells was conducted. Briefly, protein lysates were 
prepared from WT, Card9-/- and Pycard-/- BMDMs and immunoblots were probed with 
antibodies raised against pro-IL-1β, SYK, caspase-8, CARD9 and ASC. Uninfected cells had 
similar expression levels of pro-caspase-1, pro-caspase-8 and SYK, while pro-IL-1was 
undetectable by immunoblotting in all three mouse lines. As expected, ASC is not expressed 
in Pycard-/- and is expressed at similar levels in WT and CARD9 knockouts. Similarly, 
CARD9 is not expressed in Card9-/- and expressed at similar levels in WT and Pycard-/- 
BMDMs (Figure 4.20, Appendix 5). Furthermore, the pool of pro-caspase-1 and pro-
caspase-8 are similar in all BMDMs strains, with no detectable active caspase-1 or -8. This 
suggests that CARD9 does not alter the level of pro-IL-1β protein expression in unstimulated 
cells, and whatever differences observed in IL-1β production and caspase activity upon 





Figure 4.19: CARD9 is required for ROS production in BMDMs during infection with S. 
Typhimurium SL1344, L. monocytogenes but not in BMDMs stimulated with zymosan. 
(a,c,e) ROS production and area under the curve (AUC) in relation to WT (b, d, f) in BMDMs 
stimulated with (a, b) Zymosan 100 µM or (c, d) infected with L. monocytogenes at MOI 50 
or (e, f) S. Typhimurium at MOI 50. Images (a), (c) and (e) are representative of four 
independent experiments. Data from (b), (d) and (f) represent the mean from four 





Figure 4.20: Immunoblot analysis of WT, Card9-/- and Pycard-/- BMDMs reveals similar 
expression levels in uninfected BMDMs. Uninfected BMDMs were lysed and probed for 
Pro-IL-1, SYK, Caspase-8 full length, Caspase-1 full length, CARD9, ASC and -Actin. 
Immunoblot (a) and its densitometry in relation to WT (b). Image and densitometry are 
representative of three independent experiments. 
 
To test whether CARD9 influences protein expression upon infection, immunoblotting 
analysis of WT, Card9-/- and Pycard-/- unprimed BMDMs infected with S. Typhimurium at 
MOI 5 for 2 and 6 hours was performed. This MOI was chosen to avoid excessive cell death 
as viable cells are required for subsequent protein analysis. In addition, analysis of proteins 
present in the supernatant was undertaken to one, confirm the ELISA data regarding the IL-
1β increase in Card9-/- BMDMs, and second, to study the pattern of caspase-1 and caspase-
8 activation.  
Upon Salmonella infection, an increase in IL-1 in the supernatant was observed in WT and 
Card9-/-, while Pycard-/- IL-1 production was below detection limit. CARD9 knockout 
macrophages, as expected, had higher IL-1 levels in the supernatant than the WT control 
at 2 and 6 hours post-infection. In the cell lysate fraction, a small increase in pro-IL-1 was 
observed in Card9-/- BMDMs in comparison to both WT and Pycard-/- controls. This suggests 
that increased expression is a potential mechanism for the IL-1 increase observed in 
CARD9 knockout macrophages. Interestingly, the cell lysate fraction also revealed a small 
increase in SYK and pro-caspase-8 expression, proteins known to be important both in 
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inflammasome biology and CARD9 signalling (Gringhuis et al., 2012; Gurung et al., 2014; 
Hara et al., 2013; Man et al., 2013; Underhill et al., 2005). A small increase in caspase-8 
was observed in the supernatant of Card9-/- BMDMs in comparison to WT and ASC knockout 
macrophages. Caspase-1 in the supernatant and pro-caspase-1 in the cell lysate were found 
to be expressed at similar levels in WT and Card9-/- BMDMs. This finding is in accordance 
with the cell viability data where this parameter is found to be similar in most MOIs and time 
points between the two mouse lines (Figure 4.21, Appendix 6-8). 
This set of immunoblots reveals that the differences between Salmonella-infected WT and 
Card9-/- occur in IL-1β production and possibly in pro-IL-1β expression as well. The increase 
in active caspase-8 in the supernatants of CARD9 knockout macrophages suggests 
increased activity of this enzyme, which could contribute to the enhanced IL-1β production. 
Equally, the possible differences in pro-IL-1β, SYK and caspase-8 expression suggests that 
CARD9 can act at the transcriptional level. These possible mechanisms are going to be 
further investigated in the next chapter of this thesis. 
To further characterize this response, in vivo systemic infection assays were conducted in 
WT and Card9-/- C57BL/6 mice using a sub-lethal S. Typhimurium infection model with the 
strain M525P. At days 1, 3 and 7 post-infection, the liver and spleen microbial load showed 
no statistically significant difference between the mouse lines (Figure 4.22). Failure to 
demonstrate overall differences in bacteria burden in Card9-/- in this infection model does not 
rule out that CARD9 plays a regulatory role in context of bacterial infections in vivo, so I 
decided to focus on IL-1β analysis as a readout for inflammasome activation. Unfortunately, 
ELISA analysis of serum failed to detect IL-1 in any of the animals. This is consistent with 
other published studies, where the authors were unable to detect IL-1β in the serum of 






Figure 4.21: Immunoblot analysis of WT, Card9-/- and Pycard-/- BMDMs reveals 
differential expression levels after BMDMs infection in both the cell lysates and 
culture supernatants. BMDMs from WT, Card9-/- and Pycard-/- mice were infected with S. 
Typhimurium at MOI 5 for 2 and 6 hours, lysed and probed for Pro-IL-1, SYK, Caspase-8, 
Caspase-1, CARD9, ASC and -Actin and the supernatant was precipitated and probed for 
IL-1, Caspase-1 and Caspase-8. (a) Immunoblot and (b) densitometric analysis in the 
culture supernatants (b) and cell lysates (c). Image (a) is representative of three independent 






Figure 4.22: S. Typhimurium-infected WT and Card9-/- mice have similar bacteria 
burden in spleen and liver. Bacteria burden in the spleen (a) and liver (b) after C57BL/6 
WT and Card9-/- infection with S. Typhimurium M525P strain (1.90 to 2.02 x104 CFU/mouse). 
p>0.05 unpaired t-test. Data represent the mean from two independent experiments using 
four to six mice per genotype, plus two negative controls per genotype, while error bars 
show the s.e.m.  
 
 
Due to the technical difficulty in detecting IL-1β in animal serum by ELISA, I performed 
immunoblotting analysis of splenocyte populations pooled from the different mice. On days 
1, 3 and 7 post infections, spleens were excised and the heterogenous spleen cell 
population was harvested. After extensive washes, the cells were lysed, and the protein 
sample was subjected to immunoblotting and probed for pro-IL-1β and caspase-1. At day 7 
post-infection, immunoblot analysis revealed an increase in pro-IL-1 expression in Card9-/- 
mice splenocytes, whereas no significant differences were observed with regards to 
caspase-1 full length or p10 fragment (Figure 4.23, Appendix 9). Again, no mature IL-1β was 






Figure 4.23: CARD9 is involved in Pro-IL-1 production in spleen cells derived from S. 
Typhimurium-infected mice. (a) Immunoblot analysis of pro-IL-1β, caspase-1 and β-actin 
in spleen cells isolated from infected WT and Card9-/- C57BL/6 mice after intravenous 
infection with S. Typhimurium M525P (1.90 to 2.02 x104 CFU/mouse) and pro-IL-1/-Actin 
densitometric analysis in relation to WT (b). (a) Representative immunoblot from two 
independent experiments, using cells pooled from four to six mice per genotype, plus two 
negative controls per genotype. Mice were from 8 to 16 weeks old, both male and female. 





Even though IL-1β detection by ELISA in the serum is problematic, the detection of this 
cytokine in vivo has been previously reported using organ homogenates (Yang et al., 2015). 
Encouraged by such reports, I tried to detect IL-1β by ELISA of spleen homogenates. IL-1β 
detection from spleen homogenates gave a clean data set. In spleen homogenates, IL-1β 
production was enhanced at day 3 and 7 post-infection in both WT and Card9-/- animals. At 
day 7, a visual increase in IL-1 production in Card9-/- in relation to WT was observed. This 
difference however was not statistically significant (p = 0.0519, unpaired t-test) (Figure 4.24).  
 
 
Figure 4.24: IL-1 in spleen homogenates of S. Typhimurium-infected WT and Card9-/- 
mice. IL-1 quantified by ELISA in spleen homogenates of C57BL/6 WT and Card9-/- mice 
infected with S. Typhimurium M525P (1.90 to 2.02 x104 CFU/mouse), at days 1, 3 and 7 
post-infection. p>0.05 unpaired t-test. Data represent the mean from two independent 
experiments using four to six mice per genotype, plus two negative controls per genotype, 







Upon in vitro Salmonella infection the level of IL-1 produced by Card9-/- BMDMs under 
certain conditions, is approximately four times higher than that observed in WT 
macrophages, without accompanying increase in cellular viability, intracellular bacteria or 
TNF- production (Figure 3.24-25). This role for CARD9 as a negative regulator of 
inflammasome activity was surprising, as most of the biological functions thus far reported 
for CARD9 place this protein as a key-adaptor in the positive regulation of inflammatory 
responses such as NF-B signalling, ROS production and noncanonical caspase-8 
assembly (Bertin et al., 2000; Gringhuis et al., 2012; Wu et al., 2009). In vivo, no effect of 
CARD9 was observed in bacteria burden in the liver and spleen when compared to WT 
controls, but a visual, albeit not statistically significant, increase in IL-1 is observed in 
Card9-/- spleen homogenates and a statistically significant increase in pro-IL-1 in 
splenocytes are observed, indicating that this finding could be potentially relevant at the 
organism level (Figure 4.22-24). As the work presented in this chapter was being concluded, 
researchers reported increased Il1b transcription in the gut upon colitis induction in Card9-/- 
mice in relation to WT controls. Since the microbiota plays an essential role in colitis 
pathophysiology, their findings further substantiate the notion that CARD9 is capable of 
decreasing IL-1 production in vivo (Lamas et al., 2016). 
In this chapter, my goal was to elucidate which inflammasome(s) are regulated by CARD9 
upon Salmonella infection and to investigate the mechanisms involved in this regulation. S. 
Typhimurium infection is known to primarily activate two NLRs, NLRC4 and NLRP3 (Broz et 
al., 2010; Man et al., 2014). In vitro, NLRC4 is activated by the bacteria during the early 
stages of infection (Man et al., 2014), making it the most likely target for the observed 
CARD9 negative regulation on IL-1, as this effect is observed as early as 2 hours post-
infection. Surprisingly, careful experimentation revealed that CARD9 has no effect on 
NLRC4 activation, either by flagellin transfection or by analysing the IL-1 production profile 
upon infection with S. Typhimurium SL1344 ΔfliCΔfljBΔprgJ, which is deficient in NLRC4 
activation (Figure 4.3-4). Alternatively, the CARD9 effect could occur by negative modulation 
of the dectin-1 pathway or the AIM2 inflammasome, as dectin-1 is a potential Salmonella 
PRR and AIM2 is capable of recognizing bacterial DNA (Jackson et al., 2014; Rathinam et 
al., 2010; Warren et al., 2010). Both these possibilities were unlikely, as S. Typhimurium is 
not known to engage these pathways, and upon experimentation these possibilities were 
discarded (Figure 4.5-7).  
It is possible that the effects of CARD9 on Salmonella-induced inflammasome activity may 
be indirect, for example, by regulating the autocrine production of anti-inflammatory 
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cytokines such as IL-10, which is reduced in Card9-/- neutrophils infected with M. 
tuberculosis (Dorhoi et al., 2010). An IL-10-mediated effect of CARD9 on Salmonella-
induced IL-1 production from BMDMs, however, is unlikely as elevated IL-1 production 
occurs within the first 2 hours of infection, whereas IL-10 production occurs at later time-
points in the infection (Foster et al., 2008). Nonetheless, this possibility was not formally 
addressed. 
The NLRC4-independent increase in IL-1 production in Card9-/- macrophages could 
potentially be explained by CARD9 fine-tuning the NLRP3 inflammasome activity. Infection 
of WT and CARD9 knockout primary macrophages in the presence of the NLRP3 inhibitors 
glibenclamide or MCC950 appeared to support a role for CARD9 in NLRP3 activation. Upon 
infection in the presence of these inhibitors, the level of IL-1 production is decreased in 
Card9-/- BMDMs to the level observed in WT cells. Interestingly, these inhibitors failed to 
decrease the IL-1 production in WT cells at these time-points (Figure 4.8-9), possibly 
because in WT cells infected with S. Typhimurium in vitro, the NLRP3 inflammasome is 
engaged at later time-points and as a consequence the inhibitors have no effect early in the 
infection (Man et al., 2014). This timing indicates that CARD9 absence decreases the 
NLRP3 activation-threshold possibly by influencing the “signal 1” required for NLRP3 
activation, either by controlling transcription events or by regulating non-transcriptional 
priming of the NLRP3 inflammasome.  
Although NLRP3 expression is induced upon infection (Bauernfeind et al., 2009), its basal 
expression levels in unprimed macrophages is, however, not negligible (Heng and Painter, 
2008; Hoffman et al., 2001). Thus, an early response of the NLRP3 inflammasome could not 
be ruled out based on expression levels alone. The use of an alternative pathogen capable 
of activating the NLRP3 inflammasome early in the infection further corroborates these 
findings. E. coli is a gram-negative bacteria reported to activate the NLRP3 inflammasome 
(Brereton et al., 2011) and in this chapter it was found that the pathogenic strain P19A 
triggers cell death and IL-1 production in unprimed macrophages independent of NLRC4 
and dependent of NLRP3 as early as 2 hours post-infection (Figure 4.12). Infection of WT 
and Card9-/- BMDMs using this E. coli strain further consolidates the observation that 
CARD9 negatively regulates IL-1 production via the NLRP3 inflammasome and importantly, 
this effect is not exclusive to Salmonella infections and could be a general theme in the 
innate immune response against gram-negative bacteria (Figure 4.13-14). 
Investigation of the link between CARD9 and NLRP3 in LPS-primed macrophages supports 
the overall conclusions discussed above. Stimulation of the canonical NLRP3 inflammasome 
with nigericin or ATP revealed increased IL-1 production in Card9-/- BMDMs in comparison 
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to WT or Nlrp3-/- controls (Figure 4.10-11). These experiments are important not only for 
supporting the previous CARD9/NLRP3 conclusions but also for suggesting that the 
mechanism involved occurs not only at the transcriptional “signal 1”, and CARD9 potentially 
affects “signal 2” as well. Priming with LPS in these conditions presumably stimulates pro-IL-
1 production and NLRP3 priming at similar rates in WT and Card9-/- BMDMs, thus the 
increased IL-1 secretion observed in CARD9 knockouts are due a more efficient pro-IL-1 
to IL-1 catalysis. The “signal 2” hypothesis as well as the assumption that pro-IL-1 levels 
are similar in both cell strains after LPS-priming are going to be formally addressed in the 
next chapter. 
Next, I started investigating possible mechanism(s) for the inhibitory function that CARD9 
has on IL-1 production. Previously described negative regulators of inflammasome activity 
perform their inhibitory functions by multiple mechanisms, including direct inhibition in the 
ASC speck, inhibition of transcriptional events, and by modulation of PTMs important in 
NLRP3 biology (Hernandez-Cuellar et al., 2012; Mishra et al., 2012; Walle et al., 2014; Yang 
et al., 2015). My first approach was to investigate if CARD9 can physically interact with the 
ASC speck. Upon stimulation of LPS-primed BMDMs with nigericin, immunofluorescence 
microscopy revealed that CARD9 and ASC do not co-localize in the inflammasome speck 
(Figure 4.15). Co-immunoprecipitation assays appear to confirm this finding, as no 
interaction between ASC and CARD9 was found in my experimental settings. Interestingly 
however, SYK co-immunoprecipitated with both ASC and CARD9 in untreated cells, while 
after treatment with nigericin or infection with S. Typhimurium ASC interacted preferentially 
with p-SYK, while the CARD9/SYK interaction appears to occur preferentially with 
unphosphorylated SYK (Figure 4.17). The SYK/ASC and SYK/CARD9 interactions are not 
totally unexpected, as this kinase is known to be involved in NLRP3 inflammasome biology 
and CARD9 signalling (Gross et al., 2009; Hara et al., 2013; Lin et al., 2015), but they hint to 
a possible mechanism: after infection or stimulation with nigericin, SYK is phosphorylated 
and activated, catalysing ASC phosphorylation in the context of NLRP3 inflammasome 
activation. The preferential interaction of CARD9 with SYK here suggests that CARD9 can 
act by inhibiting SYK phosphorylation and consequentially CARD9 absence can increase 
NLRP3-inflammasome activity. 
ROS production by NADPH oxidase is a mechanism involved in activation of the NLRP3 
inflammasome (Cruz et al., 2007; Dostert et al., 2008; Hewinson et al., 2008), thus increased 
ROS in Card9-/- could potentially explain the increased IL-1 production in this strain upon 
Salmonella infection. The literature, however, suggests that upon intracellular bacteria 
challenge, CARD9 plays a role in stimulating NADPH oxidase thus increasing ROS 
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production, with CARD9 knockout macrophages producing less ROS than WT controls (Wu 
et al., 2009). The study in question did not include ROS-quantification experiments using S. 
Typhimurium specifically, so the ROS/IL-1 hypothesis could not be entirely dismissed 
based on this study alone. Furthermore, WT and Card9-/- ROS quantification upon S. 
Typhimurium challenge revealed that CARD9 knockout BMDMs have deficient ROS 
production in comparison to WT, similar to what is observed in L. monocytogenes (Figure 
4.19) (Wu et al., 2009). In summary, since ROS production in CARD9 knockout BMDMs is 
deficient, it is unlikely that ROS is the mechanism involved in the increased NLRP3-
dependent IL-1 production in Card9-/-. 
How then does CARD9 inhibit the NLRP3 inflammasome? It is possible that CARD9 
knockout BMDMs have a higher pro-IL-1 expression even in unstimulated cells. This is 
unlikely to be the case, as the concentration of this pro-cytokine was below the detection 
limit in WT and Card9-/- BMDMs (Figure 4.20). Upon Salmonella infection however, CARD9 
knockout macrophages express more pro-IL-1 than the WT cells and the amount of IL-1 in 
the supernatant was also higher in Card9-/- BMDMs. This is not caused by increase in active 
caspase-1, as shown by the presence of similar levels of the caspase-1 p10 fragment in the 
supernatant of both cell types (Figure 4.21). The lack of increase in active caspase-1 is 
consistent with the in vivo immunoblots presented in figure 4.23, where no increase in 
caspase-1 FL nor p10 fragment are observed, and consistent with the cell viability data, 
where the cell death in WT and CARD9 knockout is similar in most conditions (Figure 3.24). 
The immunoblot in figure 4.21 revealed a slight increase in pro-caspase-8 in infected Card9-/- 
BMDMs, as well as increased caspase-8 in the supernatant. This finding is particularly 
intriguing, as caspase-8 was described as having a complementary role in IL-1 production 
in the NLRP3 inflammasome, without affecting pyroptosis (Gurung et al., 2014; Man et al., 
2013), making this enzyme a candidate for explaining the observed CARD9 phenotype. 
SYK, another enzyme known to be involved in NLRP3 inflammasome and CARD9 signalling 
(Gross et al., 2009; Hara et al., 2013) was also found to be marginally upregulated (Figure 
4.21). The significant of these findings are going to be further explored in the next chapter. 
In summary, the work presented in this chapter has established CARD9 as an inhibitor of 
NLRP3-mediated IL-1 production in primary macrophages (Figure 4.25). The possible 





Figure 4.25: CARD9 inhibits NLRP3-dependent IL-1 production. Production of IL-1 
triggered by nigericin, ATP and by gram-negative bacteria such as E. coli and S. 









Molecular mechanism for CARD9 regulation of the NLRP3 inflammasome 
 
5.1. Introduction 
One of the main features of the NLRP3 inflammasome is the way in which it is activated. In 
macrophages, in vitro inflammasome assembly comprises two distinct steps. First, a priming 
event “licenses” the NLRP3 inflammasome to respond to DAMPs. This step occurs via 
upregulation of protein expression of key-components such as NLRP3 itself, as well as post-
translational modifications including NLRP3 de-ubiquitination (Bauernfeind et al., 2009; 
Juliana et al., 2012). Second, a DAMP triggers the assembly of the NLRP3 inflammasome, 
leading to IL-1β and IL-18 production, as well as pyroptotic cell death (Agostini et al., 2004).  
Both steps follow complex signalling events. The licensing step requires the activation of 
another PRR, such as TLR4, which results in the upregulation of key-genes via NF-κB, as 
well as relevant post-translational modifications (Bauernfeind et al., 2009; Juliana et al., 
2012). The signalling events involved in the second step are less well understood. Little is 
known about how exactly NLRP3 is activated and the elucidation of the molecular events 
regulating its activity remains an ongoing task. Amongst the proteins described that 
modulate NLRP3 inflammasome activity is SYK. This kinase is responsible for 
phosphorylating ASC at tyrosine 144 in its CARD domain, resulting in enhanced cytokine 
production (Hara et al., 2013). SYK however is not essential for inflammasome activity, and 
other kinases such as Pyk2 and BTK were also previously described as possessing similar 
roles (Chung et al., 2016; Ito et al., 2015). 
Once activated, caspase-1 and caspase-8 are recruited to the inflammasome (Agostini et al., 
2004; Gurung et al., 2014; Man et al., 2014, 2013). Both enzymes are capable of converting 
pro-IL-1β to IL-1β, whereas only caspase-1 is involved in the production of IL-18 and 
pyroptosis (Man et al., 2013). It is not clear whether specific conditions can favour the 
recruitment of one caspase over the other although most experimental evidence points to 
caspase-1 being the predominant caspase in inflammasome formation (Martinon et al., 
2002). 
Evidence presented in the previous chapter suggests that CARD9 regulation of NLRP3-
mediated IL-1β production could occur at both steps of NLRP3 activation. Protein expression 
of Salmonella-infected BMDMs reveals an increase in pro-IL-1β expression in Card9-/- cells, 
suggestive of a CARD9 role in controlling Il1b transcription (Figure 4.23). Furthermore, 
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nigericin and ATP stimulation experiments revealed that CARD9 inhibits the NLRP3 
inflammasome even after LPS-priming (Figure 4.12-13), a situation where pro-IL-1β 
availability is unlikely to play a role. This suggests that CARD9 may fine-tune the second 
step of NLRP3 activation. 
These two possible mechanisms are not mutually exclusive, as precedent exists in the 
literature for CARD9 acting in signalling pathways both transcriptionally and non-
transcriptionally. For instance, NOD2 stimulation activates the MAPKs p38 and JNK via 
CARD9 (Hsu et al., 2007), and dectin-1 activation leads to the formation of the 
CARD9/BCL10/MAL1 complex, responsible for NF-κB activation (Gross et al., 2006). In both 
cases CARD9 regulates gene transcription. Non-transcriptional signalling events controlled 
by CARD9 include ROS-production via the NADPH complex (Wu et al., 2009) and non-
canonical IL-1β production in the dectin-1 pathway (Gringhuis et al., 2012). 
The aim of this chapter is to investigate at which stage(s) of NLRP3 activation CARD9 acts, 
and to elucidate the possible mechanisms involved in this inhibition. Part of the data 
presented in this chapter was successfully published (Pereira et al., 2016) (Appendix 18). 
 
5.2. Results 
The immunoprecipitation pattern observed in figure 4.19 suggests a possible role of SYK in 
the enhanced IL-1β production observed in Card9-/- BMDMs. In that experiment, it was 
observed that after inflammasome stimulation, CARD9 interacts with the unphosphorylated 
form of SYK, whilst p-SYK interacts with ASC, where previous studies have shown it 
functions in ASC phosphorylation and enhancing cytokine production (Hara et al., 2013; Lin 
et al., 2015). 
To test whether SYK plays a significant role in the Card9-/- phenotype, NLRP3 was 
stimulated in LPS-primed BMDMs by nigericin or infection with S. Typhimurium in the 
presence or absence of the SYK inhibitor R406. Cellular viability and IL-1β in the culture 
supernatant were quantified. SYK inhibition decreased IL-1β production in both WT and 
Card9-/- BMDMs stimulated with nigericin or infected with bacteria, without affecting cell 
viability (Figure 5.1). This inhibition was more noticeable in Card9-/- BMDMs, and upon SYK 
inhibition the resulting IL-1β output was similar in WT and CARD9 knockout macrophages. 
This suggests that the enhanced IL-1β production observed in Card9-/- macrophages indeed 




Figure 5.1: SYK is involved in the CARD9 regulation of the NLRP3 inflammasome in 
BMDMs. LPS-primed BMDMs (200 ng/mL for 3 hours) were infected with S. Typhimurium at 
MOI 10 for one hour (a,b) or stimulated with 5 µM nigericin for one hour (c,d) in presence of 
SYK inhibitor R406 (1 µM). (a,c) Cellular viability and (b,d) IL-1 production. * p<0.05, n.s. 
Not significant (one-way ANOVA with Tukey’s multiple comparisons test). Data represent the 
mean from three independent experiments while error bars show the s.e.m.  
 
An alternative explanation for this result would be that CARD9 knockout macrophages 
respond differently to priming with LPS in the conditions used in this thesis, potentially 
expressing more pro-IL-1β than their WT counterpart. A consequence for this would be 
increased IL-1β production due to the increase in substrate concentration. To address this 
possibility, WT and Card9-/- BMDMs were primed with 200 ng/mL LPS for 3 hours, then the 
cells were lysed and the proteins analysed by immunoblot. No significant differences in pro-
IL-1β expression were observed between WT and CARD9 knockout BMDMs. The proteins 
SYK, caspase-1 and caspase-8 were also expressed at similar levels between both cell 
types upon LPS treatment (Figure 5.2). Since the levels of these proteins are also similar in 
unprimed cells (Figure 4.22, Appendix 10), it is unlikely that the results obtained from 




Figure 5.2: Expression levels of CARD9 and inflammasome constituents in LPS-
primed WT and Card9-/- BMDMs in the presence or absence of SYK or Caspase-8 
inhibitors. (a) Immunoblot analysis of pro-IL-1β, SYK, caspase-8, caspase-1, CARD9 and 
β-actin in LPS-primed WT and Card9-/- BMDMs (200 ng/mL for 3 hours) with an additional 
hour of incubation with SYK inhibitor R406 (1 µM) or caspase-8 inhibitor Z-IETD-FMK (10 
µM) and (b) its densitometry in relation to WT. Figure and densitometry are representative of 
three independent experiments. 
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SYK activity is involved in NLRP3 inflammasome activation in macrophages but not in 
dendritic cells (Hara et al., 2013). If SYK is indeed involved in CARD9 inhibition of the 
NLRP3 inflammasome, it is possible that this phenotype is different in dendritic cells. To test 
this hypothesis, bone marrow derived dendritic cells (BMDC) were prepared from WT and 
Card9-/- mice and infected with S. Typhimurium at MOI 10 for 2, 6 and 24 hours. The 
supernatants were then collected for IL-1β quantification and cell viability assays. Similar to 
my observations in macrophages, infection of WT and Card9-/- BMDCs with Salmonella 
revealed no statistically significant difference in cellular viability at 6 and 24 hours, whilst 
Card9-/- BMDCs have slightly increased cell viability at 2 hours. IL-1β production by WT and 
Card9-/-, however, had no significant difference, a phenotype not observed in macrophages 
(Figure 5.3).  
 
 
Figure 5.3: CARD9 has no effect on IL-1 production in BMDCs infected with S. 
Typhimurium. (a) Cellular viability (as measured by LDH release) and (b) IL-1 release in 
WT, and Card9-/- BMDCs after infection with S. Typhimurium at MOI 10 for 2, 6 and 24 
hours. * p<0.05 one-way ANOVA with Tukey’s multiple comparisons test. Data represent the 
mean from three independent experiments while error bars show the s.e.m.  
 
It is possible that any potential differences between the activation of the NLRP3 
inflammasome of WT and Card9-/-  dendritic cells could be masked by the effects of activating 
the NLRC4 inflammasome, the main NLR responsible for early IL-1β produced in vitro during 
Salmonella infections (Man et al., 2014). To better address the potential of a cell-specific role 
for CARD9 in fine-tuning the NLRP3 inflammasome LPS-primed WT and CARD9 knockout 
BMDCs were stimulated with nigericin. These experiments showed no difference in cellular 
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viability nor IL-1β production (Figure 5.4). Addition of the SYK inhibitor R406 had no effect in 
either cell type (Figure 5.4). These data are in agreement with a cell type specificity for 
CARD9 regulation of inflammasome activity possibly due the different role that SYK 
undertakes in macrophages and dendritic cells. 
 
 
Figure 5.4: SYK is not involved in the regulation of the NLRP3 inflammasome in 
BMDCs. LPS-primed BMDCs (200 ng/mL for 3 hours) were stimulated with 5 µM nigericin 
for one hour in presence of SYK inhibitor R406 (1 µM). (a) Cellular viability and (b) IL-1 
production. p>0.05 one-way ANOVA. Data represent the mean from three independent 
experiments while error bars show the s.e.m.  
 
The co-immunoprecipitation pattern observed in figure 4.17 suggests that upon NLRP3 
stimulation, CARD9 interacts preferentially with unphosphorylated SYK. It is possible, 
therefore, that CARD9 interaction with unphosphorylated SYK can influence the 
phosphorylation state of SYK. To verify SYK phosphorylation levels, LPS-primed WT and 
CARD9 knockout BMDMs were either left unstimulated, infected with S. Typhimurium or 
treated with nigericin. Post treatment, total cellular proteins were carefully extracted in 
presence of protease and phosphatase inhibitors and immunoblot assays were performed 
using antibodies raised against total SYK or phosphorylated SYK (Y525/526). In Card9-/- 
BMDMs, the levels of Y525/526 phosphorylated SYK (p-SYK) in relation to total SYK is 
greater than that observed in WT controls, with or without inflammasome stimulation (Figure 
5.5, Appendix 11). This suggests that the enhanced SYK phosphorylation observed in 





Figure 5.5: CARD9 absence increases phosphorylated SYK (Y519/520) in relation to 
total SYK. WT and Card9-/- LPS-primed BMDMs were infected with S. Typhimurium at MOI 
10 for 2 hours or stimulated with 10 µM nigericin for 30 minutes, the cell lysate was then 
subjected to immunoblotting and the membrane probed for p-SYK (Y519/520), total SYK, 
CARD9 and -Actin.  Immunoblot (a) and its relative p-SYK/SYK densitometry (b). Data 
representative of three independent experiments. 
 
The enhanced IL-1β production in CARD9 knockout BMDMs without a proportional increase 
in cell viability suggests that there is not an increase in caspase-1 activity, as this enzyme is 
involved in triggering pyroptosis. It is possible, however, that caspase-8 activity is 
upregulated in Card9-/- macrophages, as caspase-8 can cleave pro-IL-1β to IL-1β without 
affecting cell viability in response to S. Typhimurium infection (Man et al., 2013). To test this 
hypothesis, LPS-primed WT and Card9-/- BMDMs were infected with S. Typhimurium or 
stimulated with nigericin in presence of the caspase-8 inhibitor z-ietd-fmk. Irrespective of the 
stimuli used, caspase-8 inhibition does not affect cell viability. Upon caspase-8 inhibition, the 
IL-1β production decreased in both WT and Card9-/- BMDMs, with the resulting IL-1β levels 
similar in both cell types (Figure 5.6). This suggests that the increased IL-1β production 




Figure 5.6: Caspase-8 is involved in the CARD9 regulation of the NLRP3 
inflammasome in BMDMs. LPS-primed BMDMs (200 ng/mL for 3 hours) were infected with 
S. Typhimurium at MOI 10 for one hour (a,b) or stimulated with 5 µM nigericin for one hour 
(c,d) in presence of caspase-8 inhibitor Z-IETD-FMK (10 µM). (a,c) Cellular viability and (b,d) 
IL-1 production. * p<0.05, n.s. Not significant (one-way ANOVA with Tukey’s multiple 
comparisons test). Data represent the mean from three independent experiments while error 
bars show the s.e.m.  
 
Ideally, I would have investigated the links between CARD9, SYK, Caspase-8 and IL-1β 
production by using cells with multiple simultaneous knockout mutations. Since our 
laboratory does not possess Syk-/- or Caspase-8-/-/Ripk3-/- mice strains, breeding animals 
with Card9-/- to obtain useful strains was not a viable option. Instead, I used an immortalized 
bone marrow derived macrophages (iBMDM), a system with the potential for genetic 
manipulation.  To validate this system, I attempted to replicate in WT and Card9-/- iBMDMs 
the GPA data I originally produced in primary macrophages (Figure 3.24-26). Both WT and 
CARD9 knockout iBMDMs exhibited similar cellular viability after 2 and 6 hours of infection. 
Surprisingly, the infection assays using WT and Card9-/- iBMDMs failed to replicate the IL-1β 
data observed in primary macrophages, with no statistically significant difference in the 
production of this cytokine, despite the visual difference suggesting an impairment in IL-1β 




Figure 5.7: Card9-/- iBMDMs do not behave like primary Card9-/- BMDMs during S. 
Typhimurium infection. Cellular viability (as measured by LDH release) (a,b) and IL-1 (as 
measured by ELISA) (c,d) of WT and Card9-/- iBMDMs infected with S. Typhimurium at MOIs 
1, 10 and 50 for 2 (a,c) and 6 (b,d) hours. p>0.05 unpaired t-test. Data represent the mean 
from three independent experiments while error bars show the s.e.m.  
 
One explanation for this difference lies in the expression pattern of proteins likely to be 
involved in the CARD9 inhibition of the NLRP3 inflammasome. To check for differences in 
protein expression, cell lysates derived from unstimulated WT and Card9-/- iBMDMs were 
subjected to immunoblot and probed with antibodies raised against SYK, CARD9 and ASC. 
In Card9-/- iBMDMs, SYK was found to be expressed at lower levels compared to that 
observed in WT iBMDMs, despite having similar levels of ASC (Figure 5.8, Appendix 12). 
This result further links SYK activity to IL-1β production (Hara et al., 2013). Moreover, it 
suggests that the use of immortalized cells would not be useful for my work. To circumvent 




Figure 5.8: Card9-/- immortalized bone-marrow derived macrophages have deficient 
SYK expression. WT and Card9-/- iBMDMs were cultured for 7 days, proteins were 
extracted, subjected to immunoblotting and the membrane was probed for total SYK, 
CARD9, ASC and -Actin. Immunoblot (a) and densitometry (b). Data representative of 2 
independent experiments. 
 
To further understand how SYK, caspase-8, and CARD9 are involved in controlling IL-1β 
production, I used immunofluorescence microscopy to stain for active caspase-8 and 
caspase-1 specks upon nigericin treatment of LPS-primed WT and Card9-/- BMDMs in the 
presence or absence of the SYK inhibitor R406. Both active enzymes were stained using the 
FLICA active substrate reagents relatively specific for either caspase-1 or caspase-8. This 
set of experiments assumes that the caspase specks observed under the microscope are 
the active enzymes recruited to the inflammasome foci. To support this assumption, Pycard-/- 
(ASC negative) BMDMs were included as negative controls, and as expected, the number of 
cells scored positive for caspase-1 and caspase-8 specks in Pycard-/- is very low, with any 
positive staining being most likely artefactual because specific foci were not apparent. 
(Figure 5.9).  
Upon treatment, the percentage of cells containing caspase-1 specks was similar in WT and 
Card9-/- BMDMs (around 15%) (Figure 5.9 c), whereas the percentage of cells positive for 
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caspase-8 specks was higher in Card9-/- cells (Figure 5.9 b). This result is suggestive of 
increased caspase-8 recruitment to the inflammasome in Card9-/- cells. SYK inhibition 
decreased the percentage of caspase-8 positive cells in both WT and Card9-/- BMDMs and 
caused WT and Card9-/- macrophages to behave similarly. No statistically significant 
difference was observed in the percentage of caspase-1 positive cells post SYK inhibition, 
suggesting that this kinase is relevant in signalling the recruitment of caspase-8 to the 
inflammasome, but not for not caspase-1 (Figure 5.9). The increase in caspase-8 recruited 
to the inflammasome is most likely to be involved in the enhanced IL-1β production observed 
in CARD9 knockout BMDMs, as this enzyme can process pro-IL-1β to its mature form (Man 
et al., 2013). 
The experiments described above were performed in LPS-primed cells. Under these 
conditions, the levels of pro-IL-1β are similar between WT and Card9-/- BMDMs (Figure 5.2), 
and the resulting differences in IL-1β production are unlikely to be due differential gene 
transcription and protein expression. In unprimed cells, however, a potential effect of CARD9 
on protein expression could not be ruled out. Immunoblotting of unprimed WT, Card9-/- and 
Pycard-/- (ASC negative) BMDMs showed increased pro-IL-1β expression in Card9-/- 
macrophages upon S. Typhimurium infection (Figure 4.23), suggesting that gene 
transcription could potentially contribute to the Card9-/- phenotype. To test whether this was 
the case, WT and Card9-/- primary macrophages were infected with S. Typhimurium at MOI 
5 for one hour. Total RNA was then extracted in order to quantify gene transcription by 
quantitative PCR (qPCR). The MOI chosen is lower than the one used in the initial GPAs 
(Figures 3.24 to 3.26) to avoid excessive cell death and increase the amount of RNA 
extracted. The different experimental conditions had no effect on the phenotype, as CARD9 








Figure 5.9: SYK inhibition decreases the percentage of cells containing caspase-8 
specks upon NLRP3 stimulation with nigericin. WT, Card9-/- and Pycard-/- LPS- BMDMs 
(200 ng/mL for 3 hours) were stimulated with 5 µM nigericin for 30 minutes in presence of 
caspase-1 and caspase-8 FLICA substrates and with or without 1 µM of the SYK inhibitor 
R406. (a) Arrowheads pointing to FLICA-stained caspase-1 and caspase-8 specks in 
stimulated cells. (b) Percentage of cells containing caspase-8 specks and (c) percentage of 
cells containing caspase-1 specks. (a) Image is representative of three independent 
experiments. (b,c) * p<0.05 one-way ANOVA with Tukey’s multiple comparisons test. Data 





Figure 5.10: Card9-/- BMDMs produce more IL-1 than WT cells under the conditions 
used for the qPCR experiments. 1.6x106 per well WT and Card9-/- BMDMs were plated in 
6-wells plates and infected with S. Typhimurium at MOI 5 for 2 hours. The supernatant was 
collected and IL-1 was measured by ELISA. The cells were then washed, scraped, and 
used for RNA extraction. * p<0.05 one-way ANOVA with Tukey’s multiple comparisons test. 




At the mRNA level in unstimulated WT and CARD9 knockout cells, no differences were 
observed in the transcription of genes coding for pro-IL-1β, pro-IL-18, caspase-1, caspase-8, 
NLRP3, NLRC4, ASC, Bcl-10, MALT-1, SYK, TNF-α, RANTES, FADD and NAIP5 (Figure 
5.11). This set of genes were selected because of their functional links with either CARD9 
and/or inflammasomes. Attempts to quantify additional transcripts such as those coding for 
dectin-1, IFN-β and caspase-11 failed possibly due to low transcriptional level and/or 




Figure 5.11: Card9-/- and WT BMDMs have no differences in the basal transcription of 
the genes studied in this work. Basal transcriptional levels of Pro-IL-1, Pro-IL-18, 
Caspase-1, Caspase-8, NLRP3, NLRC4, ASC, Bcl-10, MALT-1, SYK, TNF-, RANTES, 
FADD and NAIP5 in uninfected Card9-/- BMDMs in relation to uninfected WT cells. GAPDH 
and -Actin were used as reference genes. Data represent the mean from three independent 
experiments while error bars show the s.e.m.  
 
 
Upon Salmonella infection, the transcription level of genes encoding for pro-IL-1β, NLRP3, 
TNF-α, RANTES, MALT-1 and pro-IL-18 increased in both WT and Card9-/- cells (Figure 
5.12-13). However, Il1b (encoding for pro-IL-1β) increased significantly more in CARD9 
knockout BMDMs in comparison to WT controls, (i.e. a 1300-fold increase in Card9-/- 
BMDMs compared to an 800-fold increase in WT BMDMs) (Figure 5.12 a). Post infection, 
the transcription of genes encoding for SYK and caspase-8 increased marginally in Card9-/- 
BMDMs, whilst the levels of those transcripts remained unchanged in the WT counterpart 
(Figure 5.12 e-f). Fadd transcription decreased similarly in both cell types, whilst the 
remaining transcripts (ASC, BCL10, caspase-1, NAIP5 and NLRC4) exhibited no statistically 
significant changes post infection (Figure 5.12-3). These findings link CARD9 to the licensing 




Figure 5.12: CARD9 influences pro-IL-1 transcription during S. Typhimurium 
infection whilst other proinflammatory genes such as TNF- remain unaffected. qPCR 
analysis of WT and Card9-/- BMDMs infected with S. Typhimurium at MOI 5 for 2 hours. 
Transcription of genes coding for (a) Pro-IL-1, (b) NLRP3, (c) TNF-, (d) RANTES, (e) 
Caspase-8, (f) SYK, (g) Caspase-1, and (h) Pro-IL-18. GAPDH and -Actin used as 
reference genes. * p<0.05 in relation to respective uninfected control unless otherwise 
indicated (one-way ANOVA with Tukey’s multiple comparisons test). Data represent the 





Figure 5.13: Inflammatory genes not influenced by CARD9 during S. Typhimurium. 
qPCR analysis of WT and Card9-/- BMDMs infected with S. Typhimurium at MOI 5 for 2 
hours. Transcription of genes coding for (a) ASC, (b) BCL-10, (c) FADD, (d) NAIP5, (e) 
MALT-1, and (f) NLRC4. GAPDH and -Actin used as reference genes. * p<0.05 in relation 
to respective uninfected control (one-way ANOVA with Tukey’s multiple comparisons test). 





CARD9 regulates inflammatory responses downstream of PRRs such as dectin-1, NOD2 
and RIG-I, modulating gene transcription by activating NF-κB (such as in the dectin-1 and 
RIG-I pathways) and the MAPKs p38 and JNK during NOD2 signalling. The CARD9 effects 
observed on gene transcription are unlikely to be mediated via NF-κB, as TNF-α, a classic 
readout for NF-κB activity, is produced at comparable levels in WT and CARD9 knockout 
macrophages. In the NOD2 pathway however, CARD9 is used as an adaptor for activating 
MAPK but not for NF-κB (Hsu et al., 2007), making NOD2 a prime candidate for explaining 
my transcriptional data. In this context however, NOD2 would assume a role as a negative 
modulator of Il1b transcription. 
To better understand the role that NOD2 undertakes in BMDMs during Salmonella infection, 
I have conducted a GPA in WT and Nod2-/- BMDMs using S. Typhimuirum (MOI of 10) for 2, 
6 and 24 hours and measured the TNF-α and IL-1β output, as well as the cellular viability. 
Infection of WT and Nod2-/- BMDMs with S. Typhimurium demonstrated that despite 
exhibiting similar cellular viability, NOD2 knockout macrophages produce less TNF-α than 
WT cells (Figure 5.14 a-b). This suggests an impairment in NOD2-mediated NF-κB 
activation. Surprisingly, Nod2-/- macrophages produced more IL-1β than the WT controls, 
thus supporting the hypothesis that NOD2 has an inhibitory effect on the production of this 
cytokine (Figure 5.14 c), not unlike the effect observed in Card9-/- BMDMs (Figure 3.25). 
If NOD2 inhibits IL-1β production via CARD9, then co-stimulation of this NLR during S. 
Typhimurium infection should decrease pro-IL-1β expression in WT but not in Card9-/- 
BMDMs. To test this hypothesis, WT, Card9-/- and Nod2-/- BMDMs were infected with S. 
Typhimurium for one hour with or without MDP, a classic NOD2 ligand (Girardin et al., 2003). 
The cells were then lysed, and the protein expression was assessed by immunoblotting. 
After infection, pro-IL-1β is substantially expressed in all cell types, and co-stimulation with 
MDP decreases pro-IL-1β levels in WT BMDMs only, having no effect on Card9-/- and Nod2-/- 
macrophages (Figure 5.15, Appendix 13). This result, together with the Nod2-/- infection 
assay (Figure 5.14), suggests that in the context of a complex pathogen such as S. 





Figure 5.14: NOD2 differentially regulates the production of cytokines during S. 
Typhimurium infection. (a) cellular viability (as measured by LDH release), (b) TNF- and 
(c) IL-1 production (as measured by ELISA) in WT and Nod2-/- BMDMs infected with S. 
Typhimurium at MOI 10 for 2, 6 and 24 hours. *p<0.05 two-way ANOVA with Bonferroni 
post-test. Data represent the mean from two independent experiments while error bars show 
the s.e.m.  
 
 
Figure 5.15: NOD2 co-stimulation with MDP decreases pro-IL-1 expression in S. 
Typhimurium-infected WT BMDMs, but not in Card9-/- and Nod2-/- BMDMs. Pro-IL-1 
expression in WT, Card9-/- and Nod2-/- BMDMs infected with S. Typhimurium at MOI 10 for 





In the NOD2 pathway, CARD9 acts by modulating the activity of the MAPKs p38 and JNK 
(Hsu et al., 2007). These MAPKs regulate the activity of AP-1, which in turn acts on il1b 
transcription (Arthur and Ley, 2013; Roman et al., 2000). I hypothesised that AP-1, via p38 
and/or JNK in the NOD2 pathway may function as an Il1b transcriptional inhibitor. To further 
elucidate how CARD9 controls pro-IL-1β expression, WT BMDMs were infected with S. 
Typhimurium in presence of MDP to overstimulate the NOD2 pathway.  The effect of 
inhibiting p38, JNK or AP-1 were also tested. The cells were lysed, and the protein lysates 
were subjected to immunoblotting. Inhibition of AP-1 and JNK led to increased pro-IL-1β 
expression (Figure 5.16 a-b, Appendix 14). This finding provides further support for 
activation of the NOD2/CARD9 axis to inhibit pro-IL-1β expression. Blocking AP-1 or JNK in 
this context would “inhibit the inhibitor”, facilitating Il1b transcription and subsequent pro-IL-
1β expression to occur more efficiently (Figure 5.16 c). The same effect was expected by 
inhibiting p38, however no pro-IL-1β was detected. Although this is puzzling, it is possible 
that in this context p38 and JNK have opposite effects. The molecular basis for this 
difference is unknow but one possibility is that these MAPKs modulate AP-1 activity in 
different ways, one inhibiting its Il1b transcription activity whilst the other enhances it. 





Figure 5.16: Inhibition of AP-1, p38 and JNK in WT BMDMs infected with S. 
Typhimurium during NOD2 stimulation with MDP further suggests an inhibitory role of 
NOD2 in pro-IL-1 expression. WT BMDMs were infected with S. Typhimurium at MOI 10 
for one hour in presence of 10 µg/mL MDP and without or with AP-1, p38 and JNK inhibitors. 
(a) Immunoblot of the cell lysates after stimulations and (b) relative densitometry. (a) Image 
representative of three independent experiments. (b) Data represent the mean from three 
independent experiments while error bars show the s.e.m. (c) Possible interpretation of the 
results in the context of the NOD2 pathway. 
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The evidence thus far presented in this thesis suggests that CARD9 inhibits the NLRP3 
inflammasome by decreasing pro-IL-1β expression via the NOD2 pathway and in addition by 
decreasing caspase-8 recruitment to the inflammasome via inhibition of SYK. Upon infection 
however, inflammasome activation is often an outcome advantageous to the host. The 
production of pro-inflammatory cytokines by the infected cell can modulate important 
responses that allow the host to combat the infection. With this in mind, I hypothesised that 
mechanisms capable of “turning off” the CARD9 inhibitory role could potentially exist. To test 
this hypothesis, I investigated whether the CARD9 expression pattern would change over 
time upon S. Typhimurium infection of WT BMDMs. Consequently, WT macrophages were 
infected with S. Typhimurium at MOI of 5 for 0, 30, 60 and 120 minutes, then lysed and the 
protein lysates were subjected to immunoblotting and probed for CARD9. Macrophages 
infected with Salmonella showed decreased CARD9 expression in a time-dependent 
manner, with most of the protein level decreasing within the first hour of infection (Figure 
5.17, Appendix 15). This suggests that the cell overcomes the CARD9 inhibition during the 
infection by decreasing CARD9 expression levels. 
 
 
Figure 5.17: CARD9 is progressively degraded during S. Typhimurium infection in 
BMDMs. BMDMs were infected with S. Typhimurium at MOI 5, the cells were collected and 
protein extracted at 0, 30, 60 and 120 minutes post-infection. The lysates were subjected to 
immunoblot and probed for CARD9 and -Actin. Immunoblot (a) and its densitometry (b). 
Image and densitometry are representative of three independent experiments. 
 
Next, I sought to investigate whether the CARD9 expression level is related to 
inflammasome formation.  Unprimed BMDMs derived from WT, Card9-/- and Pycard-/- (ASC 
negative) mice were infected with S. Typhimurium at MOI 5 for 2 and 6 hours, followed by 
protein extraction and immunoblotting using anti-CARD9 antibody. The decrease observed 
in CARD9 expression occurs similarly in WT and Pycard-/- macrophages, suggestive of 
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CARD9 degradation independent of inflammasome formation (Figure 5.18 a, Appendix 15). 
To further study the link between CARD9 degradation and inflammasome formation, WT, 
Card9-/- and Pycard-/- BMDMs were primed with LPS (200 ng/mL for 3 hours) and then 
stimulated with either nigericin or infected with S. Typhimurium. Cells were harvested, and 
total protein was extracted and analyzed by immunoblotting using anti-CARD9 antibody as 
the probe. Similar to what was observed in unprimed macrophages, CARD9 degradation 
occurred at comparable levels in WT and ASC knockout cells infected with Salmonella. The 
use of nigericin, an activator of the canonical NLRP3 inflammasome, did not trigger CARD9 
degradation, as cells treated with this reagent had similar CARD9 expression to the 
untreated controls (Figure 5.18 b, Appendix 15). This suggests that CARD9 degradation 
occurs independently of inflammasome formation and is triggered by infection. 
The decrease in CARD9 expression observed upon Salmonella infection could potentially be 
a consequence of active protein degradation. Amongst the processes commonly used by the 
host cell to degrade endogenous proteins is proteasome degradation. The proteasome is a 
barrel-shaped protein complex that remains inaccessible to most proteins. In some cases, 
proteins are “tagged” for proteasome degradation, usually via ubiquitination, gaining access 
to the proteasome where they are enzymatically cleaved (Finley, 2009). To investigate 
whether CARD9 is degraded by proteasomes, WT BMDMs were infected with S. 
Typhimurium for 0, 60 and 120 minutes with or without the addition of epoxomicin, a 
proteasome inhibitor, and CARD9 expression was assessed by immunoblotting. The CARD9 
degradation upon Salmonella infection is, surprisingly, increased in the presence of the 
proteasome inhibitor epoxomicin (Figure 5.19, Appendix 16). This puzzling result suggests 
either the proteasome is unimportant in regulating CARD9 expression or it could be due to 






Figure 5.18: CARD9 is degraded during S. Typhimurium infection in unprimed and 
LPS-primed BMDMs independently of ASC and NLRP3 activation. (a) Unprimed WT, 
Card9-/- and Pycard-/-  BMDMs were infected with S. Typhimurium at MOI 5 for 2 and 6 hours 
and the cell lysates were subjected to immunoblot and probed for CARD9, -Actin and ASC. 
(b) LPS-primed (200 ng/mL for 3 hours) WT, Card9-/- and Pycard-/-  BMDMs were infected 
with S. Typhimurium at MOI 5 for 2 hours or stimulated with nigericin 5 µM for 30 minutes 
and the cell lysates were subjected to immunoblot and probed for CARD9, -Actin and ASC. 





Figure 5.19: Protease inhibition with epoxomicin increases CARD9 degradation in S. 
Typhimurium infected BMDMs. WT BMDMs were infected with S. Typhimurium at MOI 5 
for 60 and 120 minutes in presence or absence of 1 µM epoxomicin, the cells lysed, and the 
protein extract subjected to immunoblot probed for CARD9 and -Actin. (a) Immunoblot and 
(b) densitometry. Image and densitometry representative of two independent experiments. 
 
Under some conditions, inhibition of proteasome activity can induce autophagy (Lilienbaum, 
2013), which could explain why CARD9 degradation increases with addition of epoxomicin. 
Autophagy is a process responsible for the degradation of cellular components such as 
organelles and aggregated proteins by the lysosome (Shibutani et al., 2015). To test whether 
autophagy is the mechanism for the decrease in CARD9 degradation, WT BMDMs were 
infected with S. Typhimurium for one hour with or without the autophagy inhibitor 3-
methyladenine (3-MA). The cells were lysed, and the resulting protein lysate was subjected 
to immunoblotting. No differences in CARD9 expression was observed when using this 
inhibitor (Figure 5.20, Appendix 17). This may suggest autophagy is not the mechanism for 
CARD9 degradation, but 3-MA is a phosphoinositide 3-kinase inhibitor and, due its toxicity in 





Figure 5.20: Autophagy inhibition with 3MA has no effect on CARD9 degradation 
during S. Typhimurium infection. WT BMDMs were infected for 60 minutes with S. 
Typhimurium at MOI 5 in presence or absence of 2.5 mM 3MA, proteins were extracted and 
immunoblotted for CARD9 and -Actin. (a) Immunoblot and (b) densitometry. Image and 
densitometry representative of two independent experiments. 
 
The preliminary experiments described here sought to investigate whether CARD9 is 
actively degraded by cellular processes and components such as autophagy and 
proteasomes.  Another possibility however, is that the decrease in CARD9 expression 
occurs via decrease of card9 transcription upon infection. To test this possibility, WT BMDMs 
were infected with S. Typhimurium at MOI of 5 for one hour. The mRNA was extracted and 
Card9 transcription was quantified pre- and post-infection by qPCR. This approach revealed 
that BMDMs infected with Salmonella showed a statistically significant decrease (20%) in 
Card9 mRNA levels (Figure 5.21), suggesting that the CARD9 protein levels are 




Figure 5.21: Card9 transcription decreases in WT BMDMs upon infection with S. 
Typhimurium. WT BMDMs were infected for 2 hours with S. Typhimurium at MOI 5, the 
RNA was then extracted and subjected to qPCR using GAPDH and -Actin as reference 
genes. * p<0.05 (unpaired t-test). Data represent the mean from three independent 




Infection of CARD9 knockout macrophages with S. Typhimurium revealed that this protein is 
involved in inhibiting the production of IL-1β whilst not affecting cellular viability or TNF-α 
production. Evidence presented in Chapter 4 of this thesis suggests that CARD9 is an 
inhibitor of the canonical NLRP3 inflammasome. Due the nature of this inflammasome, two 
non-exclusive hypotheses were raised. First, the production of IL-1β is decreased due lower 
pro-IL-1β availability, meaning that CARD9 fine-tunes the “licensing step” of NLRP3 
activation by inhibiting gene transcription. Second, CARD9 inhibits the inflammasome pro-IL-
1β processing activity without affecting pyroptosis. In this chapter, my was goal to elucidate 
which stages(s) of NLRP3 inflammasome activation are inhibited by CARD9 and explore 
possible mechanisms on how this inhibition occurs. 
The first hypothesis was supported by experiments analysing mRNA levels in WT and 
Card9-/- BMDMs upon S. Typhimurium infection. This set of experiments revealed that after 
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infection, CARD9 knockout macrophages upregulate il1b transcription to a greater extent 
than the WT controls, without affecting the transcription level of genes such as Tnfa and 
Rantes (Figure 5.12). This selective effect on il1b transcription was puzzling, since TLR4 is 
the most important PRR involved in NLRP3 licensing during Salmonella infection. When 
TLR4 is activated, NF-κB activation occurs leading to transcription of genes including Il1b 
and Tnfa (Hiscott et al., 1993; Shakhov et al., 1990) and later, IRF3-dependent transcription 
of Rantes (Lin et al., 1999). Thus NF-κB is an unlikely candidate for CARD9 regulation in the 
context of Salmonella infection of BMDMs. 
The literature on CARD9 suggests an alternative mechanism.  A previous study reported 
that CARD9 functions as an adaptor in the NOD2 signalling pathway (Hsu et al., 2007). In 
this pathway, NOD2 activation leads to CARD9-independent activation of NF-κB as well as 
CARD9-dependent activation of the MAPKs p38 and JNK (Figure 1.10). Both p38 and JNK 
activate AP-1, a transcription factor involved in il1b transcription (Roman et al., 2000), 
whereas tnfa transcription is not related to these MAPKs (Baldassare et al., 1999). It is 
feasible, therefore, that CARD9 controls il1b transcription via p38 and/or JNK. 
Although NOD2 is classically regarded as an activator of inflammatory responses in 
response to “pure” ligands such as MDP (Girardin et al., 2003), co-stimulation of this NLR 
with other PRRs demonstrates that NOD2’s role is context dependent (Dahiya et al., 2011; 
Hedl and Abraham, 2012; Kim et al., 2015; Watanabe et al., 2008, 2006, 2004). For 
instance, pro-IL-1β expression is inhibited when either TLR2 or TLR4 are co-stimulated with 
NOD2 (Dahiya et al., 2011; Kim et al., 2015), and Nod2-/- splenocytes produce more IL-18 
than WT controls upon TLR2 activation (Watanabe et al., 2004). S. Typhimurium infection 
activates primarily TLR4, but NOD2 is also engaged in the response against this pathogen. It 
is possible that in the context of Salmonella infections, NOD2 negatively modulates the 
production of certain cytokines. Infection assays conducted on Nod2-/- BMDMs appear to 
support this hypothesis as these cells produce less TNF-α, but more IL-1β (Figure 5.14).  
To formally link CARD9 to NOD2 in the context of Salmonella infections and pro-IL-1β 
production, the use of primary macrophages derived from CARD9 and NOD2 double 
knockout mice would be required. Unfortunately, our laboratory does not possess this strain. 
To circumvent these problems, I have performed Salmonella infections whilst co-stimulating 
NOD2 with its ligand, MDP. The rationale behind this approach was that if NOD2 is indeed 
an inhibitor of pro-IL-1β in the context of a complex pathogen such as S. Typhimurium, then 
co-stimulation of this PRR would accentuate this inhibitory effect. Indeed, in this 
experimental setting, pro-IL-1β expression is inhibited by NOD2 overstimulation in WT cells, 
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but not in Card9-/- BMDMs (Figure 5.15) This finding provides further support for a NOD2 
inhibitory role using CARD9 as an adaptor.  
This inhibitory effect possibly involves the transcription factor AP-1, since it controls Il1b 
transcription and has its activity modulated by the MAPKs p38 and JNK (Arthur and Ley, 
2013; Roman et al., 2000). JNK and p38 are in turn controlled by CARD9 in the NOD2 
pathway (Hsu et al., 2007). An attempt to link AP-1, JNK and p38 to pro-IL-1β expression 
was made using pharmacological inhibitors in the context of S. Typhimurium infection and 
NOD2 co-stimulation. The results obtained supports an inhibitory role for AP-1 and JNK in 
pro-IL-1β expression. The data supporting this claim, however, should be interpreted with 
caution, as it relies on pharmacological inhibition of kinases and transcription factors 
involved in numerous biological responses, such that toxicity and adverse effects should be 
expected (Figure 5.16). 
Even though the evidence discussed above supports a role for CARD9 as an inhibitor of Il1b 
transcription, this alone cannot explain all of the data acquired. For instance, LPS-primed 
macrophages have similar pro-IL-1β expression levels (Figure 5.2), but upon NLRP3 
stimulation the amount of IL-1β released by primed Card9-/- macrophages is greater than 
that released by LPS-primed WT controls (Figure 4.10-11), suggesting a role for CARD9 in 
regulating the second stage of inflammasome activation. Whilst investigating CARD9 
interaction with inflammasome components, it was observed that upon inflammasome 
stimulation, CARD9 preferably interacts with the unphosphorylated form of SYK (Figure 
4.17). This finding hinted that this kinase could be involved in the described Card9-/- 
phenotype. Indeed, SYK inhibition in the context of Salmonella infection or nigericin 
stimulation inhibits IL-1β production in both WT and Card9-/- BMDMs. Upon inhibition, the IL-
1β output is similar between those two cell types. This suggests that the incremental IL-1β 
production observed in CARD9 knockout macrophages does involve SYK activity (Figure 
5.1). Immunoblot analysis of the p-SYK/SYK relation further substantiates this finding. In 
CARD9 knockout macrophages, a higher percentage of SYK is found in its active form, i.e. 
phosphorylated, likely increasing IL-1β production via the NLRP3 inflammasome (Figure 
5.5). One potential interpretation of this result is that the CARD9 interaction with 
unphosphorylated SYK “blocks” its phosphorylation, and in Card9-/- cells the p-SYK/SYK 
equilibrium is shifted towards p-SYK. Since SYK is activated by phosphorylation at tyrosine 
525/526 (Zhang et al., 2000), the higher p-SYK levels found in Card9-/- BMDMs could 
contribute to the higher IL-1β production. 
Despite their many similarities, macrophages and dendritic cells behave differently in many 
aspects, including NLRP3 (Hara et al., 2013) and CARD9 signalling (Goodridge et al., 2009; 
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Hara et al., 2008, 2007). One of the differences between the NLRP3 inflammasomes of 
macrophages and dendritic cells regards the phosphorylation of ASC by SYK. In 
macrophages, SYK activity enhances cytokine production by the NLRP3 inflammasome, 
whereas in dendritic cells SYK does not contribute to this activity (Hara et al., 2013). If the 
CARD9 phenotype indeed involves SYK, it was feasible that the phenotype would be 
different in dendritic cells. Indeed, infection of WT and CARD9 knockout BMDCs with S. 
Typhimurium revealed no statistically significant differences in relation to cell viability and IL-
1β production (Figure 5.3). Similarly, LPS-primed BMDCs from WT and Card9-/- mice 
produced comparable levels of IL-1β in response to nigericin stimulation. Both WT and 
Card9-/- cells were unaffected by SYK inhibition, as previously reported (Hara et al., 2013) 
(Figure 5.4). This observation illustrates the complexity of signalling pathways in innate 
immunity and that results obtained in a specific cell types should not be generalised. 
The enhanced IL-1β production dissociated from pyroptosis remained puzzling. Often, 
increased IL-1β production is accompanied by increased cell death via pyroptosis, a 
characteristic not observed in Card9-/- BMDMs (Figure 3.24-35). Previously, however, our 
research group described caspase-8 as a component of the inflammasome (Man et al., 
2014, 2013). In the context of inflammasome activation, caspase-8 undertakes a 
complementary role in pro-IL-1β processing but is unable to process pro-IL-18 and does not 
stimulate pyroptosis, roles attributed to caspase-1. This observation raised the hypothesis 
that in the absence of CARD9, caspase-8-mediated IL-1β production is enhanced. Recent 
evidence suggests that caspase-8 can trigger cell death downstream NLRC4 activation in 
the absence of caspase-1 (Lee et al., 2018; Mascarenhas et al., 2017; Schneider et al., 
2017). Since caspase-1 remains active in Card9-/- macrophages, it is unlikely that caspase-8 
contributes significantly to cell death. 
The caspase-8/IL-1β hypothesis was tested by stimulating the inflammasome in presence of 
the caspase-8 inhibitor z-ietd-fmk. This resulted in inhibition of IL-1β production in both WT 
and Card9-/- BMDMs, whilst cellular viability remained unchanged (Figure 5.6). Similar to 
what is observed in SYK inhibition assays (Figure 5.1), z-ietd-fmk decreased the IL-1β 
output to similar levels in WT and CARD9 knockout BMDMs, suggesting that the incremental 
IL-1β produced by Card9-/- cells involves caspase-8 (Figure 5.6). 
Interestingly, similar results and conclusions were obtained from SYK and caspase-8 
inhibition experiments. One explanation for such similar results would be that SYK and 
caspase-8 are found in the same pathway, and inhibition of either of them has comparable 
outcomes. Since caspase-8 is found downstream in the NLRP3 inflammasome signalling 
pathway, where it is responsible for IL-1β production, I hypothesized that SYK activity 
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influences caspase-8 recruitment to the NLRP3 inflammasome. Analysis of caspase-1 and 
caspase-8 speck formation upon NLRP3 stimulation supports a link between SYK and 
caspase-8, but not caspase-1. In presence of SYK inhibitor, caspase-8 specking decreases, 
whilst caspase-1 specking does not change significantly (Figure 5.9). The outcome of this 
recruitment pattern would be increased caspase-8-mediated IL-1β production whilst 
caspase-1-mediated pyroptosis would not change significantly. 
It is unclear how SYK activity enhances caspase-8 recruitment to the inflammasome. One 
possibility is that since SYK phosphorylates ASC in its CARD domain (Hara et al., 2013), it is 
plausible that this phosphorylation modulates ASC’s affinity for caspase-1 and caspase-8. 
Caspase-1 binds to ASC via CARD/CARD interactions (Srinivasula et al., 2002), a domain 
absent in Caspase-8 (Muzio et al., 1996). In this scenario, ASC phosphorylation could 
potentially decrease interaction with caspase-1 due the phosphorylated CARD, and favour 
the interaction between its PYD domain and caspase-8’s DED domain, resulting in 
enhanced caspase-8 recruitment to the inflammasome. No significant decrease in caspase-1 
recruitment, however, was observed using immunofluorescence staining. This could be due 
the low sensitivity of the technique employed, as it relies on manually enumerating cells 
positive for caspase-1 and caspase-8 specks. Counting a much greater number of events, 
either by automation of speck counting or by using techniques such as flow cytometry, could 
potentially detect differences in caspase-1 specking. Optimization of such techniques is an 
ongoing effort in our laboratory. 
This is not the first time that a functional link between SYK, CARD9 and caspase-8 is 
reported. In dendritic cells during fungal infections, the dectin-1 receptor is activated and 
stimulates SYK. This kinase in turn activates PKC- which phosphorylates CARD9 leading to 
the assembly of a non-canonical inflammasome containing CARD9, MALT1, BCL10 and 
caspase-8 (Gross et al., 2006). This is, however, the first study to link SYK, CARD9 and 
caspase-8 in the context of a canonical inflammasome. Interestingly, the well-described role 
that SYK has in the dectin-1 pathway places this kinase upstream of CARD9. This is in 
contrast with the data presented in this work, which suggests that in the canonical NLRP3 
inflammasome, SYK acts downstream of CARD9. Another key difference between the 
caspase-8 non-canonical inflammasome and the pathway suggested in this chapter is the 
role played by CARD9. Whilst in the dectin-1 pathway CARD9 has a pro-inflammatory role 
upregulating IL-1β production in response to fungal pathogens, in the canonical NLRP3 
inflammasome CARD9 decreases the production of this cytokine. 
The data presented in this thesis and studies previously published in the literature links 
CARD9 to numerous signalling pathways controlling inflammation including NOD2, Dectin-1, 
167 
 
RIG-I, ROS production and the NLRP3 inflammasome (Gross et al., 2006; Hsu et al., 2007; 
Poeck et al., 2010; Wu et al., 2009). This suggests that CARD9 is a signalling hub 
responsible for coordinating inflammatory responses, and its function must be tightly 
regulated, since both excessive inflammation and lack of inflammatory responses can be 
detrimental to the host. Not much is known, however, about the signalling events responsible 
for the modulation of CARD9 function. One example of such regulation involves PKC- In 
the context of the dectin-1 pathway, this kinase phosphorylates CARD9, allowing it to 
interact with BCL10 and MALT1 thus positively modulating gene transcription (Gross et al., 
2006). In this chapter, another potential mechanism for CARD9 regulation was described: 
downregulation of protein expression. 
CARD9 is a protein constitutively expressed in cells such as macrophages (Heng and 
Painter, 2008; Hsu et al., 2007), and upon infection, its expression decreases overtime 
(Figure 5.17). One possible cause for the observed decrease in expression is decreased 
gene transcription, as Card9 mRNA was found to be downregulated upon Salmonella 
infection (Figure 5.21). It is unclear if the observed 20% decrease in Card9 transcription is 
enough to account for the decrease in protein expression. This would be possible if CARD9 
is a protein with a high turnover rate, i.e. short half-life, but unfortunately data regarding 
CARD9’s half-life is lacking. In any case, protein degradation by processes such as 
autophagy and proteasomes cannot be ruled out. Preliminary experiments using 
pharmacological inhibitors of these processes were, however, inconclusive (Figure 5.19-20), 
but remain an avenue for further investigation. 
Many other questions regarding the decrease in CARD9 expression remain unanswered. 
Amongst those questions is what triggers its degradation. Infection experiments using S. 
Typhimurium and stimulation of the canonical NLRP3 inflammasome revealed that this 
process does not require inflammasome formation, as nigericin alone does not affect 
CARD9 expression and, equally, ASC plays no role in this phenomenon (Figure 5.18). It is 
possible that a bacterial factor causes this degradation to occur, perhaps by activating 
another PRR. If this is the case, it is unlikely to involve TLR4, as LPS-primed cells continues 
to express CARD9. Another unexplored possibility is that the bacteria itself injects effector 
protein(s) in the host cytoplasm triggering signalling events that culminates in CARD9 
decreased expression.  
In summary, data presented in this chapter suggests that CARD9 acts as an inhibitor of the 
inflammasome by fine-tuning both steps of NLRP3 activation, that is, the transcription of il1b 
via NOD2 and IL-1β production by modulating caspase-8 recruitment to the inflammasome. 
Additionally, CARD9 itself is downregulated during infection, which probably allows the cell 
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to overcome its inhibition and produce greater quantities of IL-1β over the course of the 
infection. Figure 5.22 illustrates the proposed mechanism for CARD9 regulation of the 
NLRP3 inflammasome. 
 
Figure 5.22: Simplified model for CARD9 regulation of IL-1β production in murine 
macrophages. Infection of BMDMs by S. Typhimurium triggers the assembly of the NLRP3 
inflammasome in the cytoplasm of BMDMs with subsequent processing of pro-IL-1β to 
mature IL-1β. CARD9 negatively regulates inflammasome activity at two levels: suppressing 







Inflammation is essential for combating infections. Failing to achieve inflammation resolution, 
however, can be harmful for the host (Fullerton and Gilroy, 2016). Chronic inflammation is 
often involved in pathologies such as diabetes, psoriasis, rheumatoid arthritis, ulcerative 
colitis, Chron’s disease, and others (Hotamisligil, 2017; Khor et al., 2011; Lowes et al., 
2007), while uncontrolled acute inflammation is one of the hallmarks of sepsis (Cohen, 
2002).  Inflammation must therefore be tightly regulated. 
One mechanism by which this is achieved is by regulating the activity of the inflammasome 
which triggers an immune response characterised by cell death, secretion of pro-
inflammatory cytokines and can drive an eicosanoid storm (Schroder and Tschopp, 2010; 
von Moltke et al., 2012). Impairment in inflammasome activation is thought to be involved in 
increased susceptibility to infections while gain of function mutations are involved in 
autoimmune pathologies including Muckle-Wells Syndrome, familial cold autoinflammatory 
syndrome, and other diseases featuring symptoms such as fever and cold sensitivity 
(Aganna et al., 2002; Dodé et al., 2002; Hoffman et al., 2001; Zhong et al., 2013).  
In spite of its role in health and disease, the events and molecules regulating inflammasome 
activity have only started to emerge. The aim of my PhD was, first, to identify proteins that 
may be linked to inflammasome activation in murine BMDMs infected with S. Typhimurium 
and, second, to characterise how these proteins are involved in inflammasome biology. 
A “screening” approach was employed to achieve the first aim. Our laboratory has access to 
a variety of mice carrying knockout mutations of PRR-associated genes that are related and 
unrelated to inflammasome biology. Some of these mouse strains had not been studied in 
the context of Salmonella-induced inflammasome activation. I therefore infected BMDMs 
derived from these animals with S. Typhimurium and determined intracellular bacteria 
counts, cellular viability and IL-1β release as measures of inflammasome activation. 
With this approach I found that the NLRs NLRC3 and NLRC5 are involved in inflammasome 
signalling during Salmonella infection by controlling IL-1β production and cell death. 
Previous research identified NLRC3 and NLRC5 as inhibitors of innate immune pathways 
such as NF-κB, but how these NLRs impact inflammasome activity remains unknown (Cui et 
al., 2010; Schneider et al., 2012; Tong et al., 2012; Zhang et al., 2014). Caspase-2 was 
found to have a similar role to that of caspase-8, that is production of IL-1β independently of 
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cell death, further illustrating the significant degree of functional redundancy seen amongst 
caspases (Man et al., 2013). This conflict with a previous study that found that caspase-2 is 
involved in Salmonella-dependent cell death in macrophages. These conflicting findings 
could be explained by the fact that the experimenters infected macrophages with bacteria 
transitioning from stationary to logarithmic phase whilst I infected macrophages with bacteria 
in the logarithmic growth phase, an experimental condition known to better stimulate NLRC4 
due the higher expression of SPI-I proteins (Jesenberger et al., 2000; Lara-Tejero et al., 
2006). Further studies are required to elucidate the mechanisms via which NLRC3, NLRC5 
and caspase-2 affect inflammasome activation during infection. The role of NLRC3 and 
NLRC5 will be studied in our laboratory in the near future, whilst studies on caspase-2 
activity in the context of Salmonella infection will be conducted in collaboration with 
Professor Andreas Strasser (Walter and Eliza Hall Institute of Medical Research, Australia). 
I also found evidence that gasdermin D, which is considered the executioner of pyroptosis 
(Aglietti et al., 2016; Kayagaki et al., 2015; Shi et al., 2015), is not the only player in the 
context of Salmonella infection, as macrophages derived from GasderminD-/- mice are only 
partially protected from Salmonella-induced cell death. Previously, gasdermin A, B, C and 
DFNA5, also known as gasdermin E, were shown to be insensitive to cleavage by caspase-1 
(Rogers et al., 2017; Shi et al., 2015). This however does not completely rule out these 
proteins as potential executioners of cell death in specific contexts, as illustrated by the fact 
that DFNA5 is cleaved by caspase-3 and is involved in the execution of secondary necrosis 
and pyroptosis (Rogers et al., 2017; Wang et al., 2017). I was able to show that DFNA5 is 
not the second player in executing pyroptosis in the context of inflammasome activation, 
since Dfna5-/-GasderminD-/- and GasderminD-/- macrophages had similar phenotypes. In this 
thesis I was unable to test whether other gasdermin proteins are involved in Salmonella-
pyroptosis, since mice knockout for other gasdermin family proteins were unavailable. The 
search for additional pyroptosis executioners is still ongoing. 
The most surprising finding of my initial screen, however, was that the adaptor CARD9 
inhibited Salmonella-induced IL-1β production without affecting cell death and the production 
of other Toll-like receptor-related cytokines such as TNF-α.  I therefore followed up CARD9 
for further study. CARD9 is an adaptor protein with multiple roles in cell signalling during 
innate immunity against, primarily, fungal and viral infections. This includes stimulation of the 
NF-B pathway and non-canonical caspase-8 inflammasome assembly (Bertin et al., 2000; 
Gringhuis et al., 2012; Poeck et al., 2010). My work, however, showed that CARD9 plays an 
anti-inflammatory role in the context of gram-negative infections in macrophages. Similar 
findings were independently reported using in vivo murine infection models, where increased 
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inflammation in Card9-/- mice was associated with increased Il1b transcription in the gut 
(Lamas et al., 2016). These findings suggest that, depending on the stimulus, CARD9 could 
have pro-inflammatory or anti-inflammatory properties. It could, therefore, be acting as a 
central signalling hub modulating inflammatory responses. 
The clinical relevance of this protein is illustrated by human genome-wide association 
studies often correlating CARD9 mutations to pathologies where increased inflammation is 
observed (Khor et al., 2011), such as inflammatory bowel diseases (IBD). Amongst the 
clinical relevant CARD9 mutations are non-silent single nucleotide polymorphisms (Beaudoin 
et al., 2013; Hong et al., 2015; Zhernakova et al., 2008) and splice variants (Rivas et al., 
2011) with protective effects. In other pathologies, such as nephropathy, CARD9 mutations 
are associated with increased risk in developing the disease (Kiryluk et al., 2014). It is 
unclear at the moment how most of these mutations affect the various CARD9 functions. In 
the specific case of the CARD9 splice variant CARD9Δ11, NF-κB signalling in response to 
fungal pathogens is deficient due an impairment in the interaction with the ubiquitin ligase 
TRIM62 (Cao et al., 2015). This mutation is also associated with increased protein 
expression and has protective effects on IBD (Pointon et al., 2010; Zhernakova et al., 2008). 
It is unknown whether the other clinically-relevant CARD9 mutations involve a gain or loss of 
function. 
Further analysis into the mechanisms by which CARD9 inhibits IL-1β production revealed a 
link to the canonical NLRP3 inflammasome. Upon bacterial infection, CARD9 prevents 
caspase-8 recruitment to the NLRP3 inflammasome, possibly by modulating SYK activity. In 
the inflammasome, caspase-8 is involved in processing pro-IL-1β to its mature form, whilst 
not affecting pyroptotic cell death (Man et al., 2013). Recent studies suggest that caspase-8 
can trigger cell death downstream NLRC4 activation (Lee et al., 2018; Mascarenhas et al., 
2017; Schneider et al., 2017). The caspase-8 effects on cell death were, however, only 
significant when cells lacking caspase-1 were used. Since caspase-1 remains active in 
Card9
-/- macrophages, it is unlikely that caspase-8 contributes significantly to cell death. The 
increased IL-1β production in Card9-/- cells could be explained by an increase in caspase-8 
activity or increased caspase 8 recruitment to the inflammasome. At the moment it is unclear 
how SYK controls caspase-8 recruitment to the NLRP3 inflammasome, but it is possible that 
SYK-mediated ASC Y144 phosphorylation (Hara et al., 2013) could be involved in this 
process. The use of cells that are both CARD9 knockout and ASC Y144F (tyrosine to 
phenylalanine point mutation, insensitive to phosphorylation) in future experiments could 
potentially elucidate the links between CARD9, SYK, ASC and caspase-8. 
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In addition to its inhibitory role on NLRP3-mediated IL-1β production, I have found that 
CARD9 is involved in controlling Il1b transcription, thus affecting pro-IL-1β availability. This 
effect appeared to be unrelated to other NF-κB target genes such as Tnfa and Rantes. 
Previously, in the context of bacterial infections, CARD9 was described as an adaptor in the 
NOD2 pathway, linking this NLR to gene transcription via MAPKs but not via NF-κB (Hsu et 
al., 2007). I therefore hypothesized that the CARD9 transcriptional effect occurs downstream 
the MAPK branch of the NOD2 pathway and does not require NF-κB. 
Nod2 was one of the first genes linked to Crohn’s disease in human patients (Hugot et al., 
2001), a finding that was independently confirmed in a variety of settings and experimental 
approaches, including unbiased genome-wide association studies (Uniken Venema et al., 
2017). The mechanisms mediating how NOD2 links to Crohn’s disease are, however, less 
clear. In vivo studies using Nod2-/- mice have revealed varying results, such as impairment in 
the production of -defensins (Kobayashi et al., 2005), increased production of pro-
inflammatory cytokines (Barreau et al., 2007), or no signs of intestinal pathology (Pauleau 
and Murray, 2003). In recent years however, the precise role of NOD2 is under revaluation: 
MDP stimulation of the NOD2 pathway reveals a pro-inflammatory role for this protein 
(Girardin et al., 2003), but opposite results are obtained when NOD2 is co-stimulated with 
other PRRs, such as TLR2 and TLR4 (Dahiya et al., 2011; Hedl and Abraham, 2012; Kim et 
al., 2015; Watanabe et al., 2008, 2006, 2004). This is suggestive of a context-dependent role 
for NOD2.  
CARD9 is an adaptor that acts downstream of NOD2 (Hsu et al., 2007). This potentially 
explains why both proteins are often correlated with IBD. It is also plausible that the clinical 
data supporting an anti-inflammatory role for CARD9 and NOD2 conflicts with that obtained 
from in vitro trials because in a clinical setting many PRRs are simultaneously stimulated, 
thus more similar to experiments where NOD2/TLR have been co-stimulated.  In this thesis, 
I have presented data from experiments where I stimulated NOD2 during Salmonella 
infection and found that CARD9 and NOD2 are both involved in suppressing IL-1β by 
controlling pro-IL-1β expression. This raises the question of whether CARD9 and NOD2 
mutations could result in increased IL-1β production in the gut, thus contributing to IBD 
pathogenesis. Increased IL-1β is observed in IBD patients (Ligumsky et al., 1990), but a 
definitive link between this cytokine and CARD9 in a clinical setting has yet to be 
demonstrated. A potential approach could be to use of IBD animal models. This is, however, 
not a simple task, as IBD is a broad term used to describe multiple diseases such as 
ulcerative colitis and Chron’s disease, and the numerous animal models available have their 
own limitations (Goyal et al., 2014). Assuming that CARD9 is indeed involved in IBD 
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pathogenesis by acting as an adaptor in the NOD2 pathway raises the possibility for 
pharmacological intervention to potentially treat these diseases. The physical interaction 
between these two proteins requires the NACHT domain and the linker region between 
CARD and NACHT of NOD2, but the CARD9 domains involved in this interaction are 
unknown (Parkhouse et al., 2014). To design a drug to target this interaction would require 
further biochemical studies to determine how CARD9 interacts with NOD2 and/or structural 
studies on these proteins. Targeting specific CARD9 interactions is feasible, as illustrated by 
the recent development of a pharmacological inhibitor that targets the CARD9 interaction 
with the ubiquitin ligase TRIM62. Disrupting this interaction impairs the NF-κB pathway 
during fungal innate immunity, thus having an anti-inflammatory effect without disrupting 
other pathways where CARD9 is involved (Cao et al., 2015; Leshchiner et al., 2017). 
My data suggests that the inhibitory effect that CARD9 has on IL-1β transcription and 
production is prevented by CARD9 degradation during infection. Upon BMDM infection with 
Salmonella, CARD9 expression decreases, potentially enhancing NLRP3 inflammasome 
activity. One of the open questions from my work at the moment is how exactly decreased 
CARD9 expression occurs and what are its consequences. I saw a decrease in Card9 
transcription, so this is likely to contribute to its decreased expression. Preliminary 
experiments on autophagy and proteasome degradation were inconclusive and further 
experimentation is required to establish whether CARD9 degradation also occurs. It is 
possible that a bacterial factor unrelated to inflammasome activation may trigger the 
reduction in CARD9 expression, since NLRP3 stimulation with nigericin did not alter CARD9 
expression. It is possible that the bacteria actively secrete an effector protein into the cytosol 
to decrease CARD9 expression. If expression of CARD9 is supressed by a bacterial factor, it 
is then unclear whether CARD9 expression is beneficial to the bacteria or to the host. In vivo 
infection of Card9-/- mice with S. Typhimurium showed a marginal, but not statistically 
significant, increase in bacterial burden in the spleen and liver of infected animals. Closer 
examination of the cytokine profile of Salmonella infected WT and Card9-/- mice could 
provide further clues on CARD9 relevance during infection. Unfortunately, the serum 
samples from this set of experiments were used in a failed attempt to quantify IL-1β and 
none was left to quantify other cytokines. 
In summary, Salmonella infection of cultured macrophages derived from specific knockout 
mice identified proteins likely to be involved in inflammasome biology, such as NLRC3, 
NLRC5, caspase-2 and CARD9. While work on NLRC3, NLRC5 and caspase-2 is still 
ongoing, detailed investigation into CARD9 function during Salmonella infection revealed 
that this protein finely tunes IL-1β production by modulating both pro-IL-1β availability and 
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Appendix 1: Uncropped immunoblots presented in Figure 4.17, CARD9 co-
immunoprecipitations. Membranes were probed using the indicated antibodies (-Actin, 





Appendix 2: Uncropped immunoblots presented in Figure 4.17, ASC co-
immunoprecipitations. Membranes were probed using the indicated antibodies (-Actin, 





Appendix 3: Uncropped immunoblots presented in Figure 4.17, SYK co-
immunoprecipitations. Membranes were probed using the indicated antibodies (-Actin, 





Appendix 4: Uncropped immunoblots presented in Figure 4.18, immunoprecipitations 
knockout controls. Membranes were probed using the indicated antibodies (ASC, -Actin, 





Appendix 5: Uncropped immunoblots presented in Figure 4.20, uninfected cell 
lysates. Membranes were probed using the indicated antibodies (ASC, -Actin, CARD9, 





Appendix 6: Uncropped immunoblots presented in Figure 4.21, cell culture 
supernatants after 2 and 6 hours of S. Typhimurium infection. Membranes were probed 






Appendix 7: Uncropped immunoblots presented in Figure 4.21, cell lysates after 2 
hours of S. Typhimurium infection. Membranes were probed using the indicated 





Appendix 8: Uncropped immunoblots presented in Figure 4.21, cell lysates after 6 
hours of S. Typhimurium infection. Membranes were probed using the indicated 





Appendix 9: Uncropped immunoblots presented in Figure 4.23, Pro-IL-1 production 
in spleen cells derived from S. Typhimurium-infected mice. Membranes were probed 





Appendix 10: Uncropped immunoblots presented in Figure 5.2. Membranes were 






Appendix 11: Uncropped immunoblots presented in Figure 5.5. Membranes were 





Appendix 12: Uncropped immunoblots presented in Figure 5.8. Membranes were 





Appendix 13: Uncropped immunoblots presented in Figure 5.15. Membranes were 





Appendix 14: Uncropped immunoblots presented in Figure 5.16. Membranes were 





Appendix 15: Uncropped immunoblots presented in Figure 5.17 and 5.18. Membranes 





Appendix 16: Uncropped immunoblots presented in Figure 5.19. Membranes were 





Appendix 17: Uncropped immunoblots presented in Figure 5.20. Membranes were 







Appendix 18: Published article - Pereira, M., Tourlomousis, P., Wright, J., P. Monie, T., 
Bryant, C.E., 2016. “CARD9 negatively regulates NLRP3-induced IL-1β production on 
Salmonella infection of macrophages.” Nature Communications. 7, 12874. 
doi:10.1038/ncomms12874 
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Interleukin 1 (IL-1) is a proinflammatory cytokine required for host control of bacterial infections, 
and its production must be tightly regulated to prevent excessive inflammation. Here we show that 
caspase recruitment domain-containing protein 9 (CARD9), a protein associated with induction of 
proinflammatory cytokines by fungi, has a negative role on IL-1 production during bacterial 
infection.  Specifically, in response to activation of the nucleotide oligomerization domain receptor 
pyrin-domain containing protein 3 (NLRP3) by Salmonella infection, CARD9 negatively regulates IL-1  
by fine-tuning pro-IL-1β expression, spleen tyrosine kinase (SYK)-mediated NLRP3 activation and 
repressing inflammasome-associated caspase-8 activity.  CARD9 is suppressed during Salmonella 
enterica serovar Typhimurium infection, facilitating increased IL-1β production.  CARD9 is, therefore, 
a central signalling hub that coordinates a pathogen-specific host inflammatory response. 
 
INTRODUCTION 
Interleukin 1 (IL-1) is a cytokine of critical importance in inflammatory, infectious and 
autoimmune diseases. Its powerful proinflammatory effects mean that production of this cytokine 
must be tightly regulated to prevent excessive inflammation.  Pro-IL-1 is cleaved to bioactive IL-1 
by several enzymatic complexes, the most important of which are the inflammasomes. 
Inflammasomes assemble in the cytoplasm of cells and utilize caspases, such as caspase-1 and 
caspase-8, for cytokine processing
1
. Canonical inflammasomes comprise a nucleotide 
oligomerisation domain receptor (NLR), an adaptor protein (ASC; apoptosis-associated speck-like 
protein containing a CARD (caspase recruitment domain)) and effector caspases. Non-canonical 
inflammasomes are formed in response to activation of other pattern recognition receptors (PRRs), 
such as the complex formed by dectin-1, spleen tyrosine kinase (SYK) and caspase-8 in response to 
fungal infection
2,3,4
.    
Formation of the macromolecular inflammasome structure requires protein-protein interactions, 
often between CARD domain containing proteins, for example between ASC and caspase-1, NLR 
family CARD domain-containing protein 4 (NLRC4) and ASC or NLRC4 and caspase-1.  Canonical 
inflammasomes can recruit multiple NLRs and caspases to the same inflammasome complex to tailor 
a pathogen-specific inflammatory response
5
.  This recruitment occurs through multiple domain 





of inflammasomes formed in response to specific pathogens or cellular insults, and how this affects 
inflammasome activity, is likely to be of major clinical importance in infectious and inflammatory 
disease research.  
CARD9 is a CARD-containing adaptor protein with roles in activating innate immune signalling, 
particularly in response to fungal
6
 and viral infections
7,8
.  CARD9 regulates dectin-1 stimulation of NF-
κB activation9, reactive oxygen species production10 and non-canonical inflammasome assembly3,4, 
as well as activation of p38 and Jnk during nucleotide-binding oligomerization domain-containing 
protein 2 (NOD2) signalling
11
. Mutations in CARD9 are associated with chronic inflammatory diseases 
in humans, including those associated with bacterial rather than fungal infection, such as Crohn’s 
disease and colitis
12–16
.  Little is known about whether CARD9 is important in regulating the host 
response to bacterial infection.  CARD9 up-regulates IL-1β production in fungal infections, but 
whether there is a direct link between this protein and canonical inflammasome activity is unclear. 
Infection with Salmonella enterica serovar Typhimurium (S. Typhimurium) triggers the formation of a 
complex inflammasome that can include NLRC4, NLR family PYRIN domain-containing protein 3 
(NLRP3), ASC, caspase-1 and caspase-8
5,17–19
 .  Caspase-1 drives IL-18 and IL-1β maturation and 
gasdermin D processing, which leads to pyroptosis
20,21
. Caspase-8 is important for IL-1β maturation 
but has no clear role in pyroptosis
17
.  The complex composition of the Salmonella-induced 
inflammasome led us to speculate whether other CARD domain containing proteins, such as CARD9, 
may regulate its activity. CARD9 regulates SYK activity and this kinase phosphorylates the CARD 
domain of ASC when NLRP3, but not NLRC4, is activated to increase IL-1β and IL-18 production22–25.  
We investigated whether CARD9 could regulate canonical inflammasome activation in response to S. 
Typhimurium infection.  Surprisingly, we show that in response to Salmonella infection CARD9 
negatively regulates NLRP3-induced IL-1β production, but not pyroptosis, in murine bone marrow 
derived macrophages (BMDM) by two distinct mechanisms: i) by fine-tuning pro-IL-1β expression; 
and ii) by reducing NLRP3 activation through modulation of SYK and caspase-8 activity.  Importantly, 
we show that CARD9 can negatively regulate canonical NLRP3 inflammasome activity and NOD2-
mediated pro-IL-1β synthesis. Our data identify a negative regulatory role for CARD9 on IL-1β 
production in bacterial infection that contrasts its role in fungal infections in which it drives 
proinflammatory responses.  We propose that CARD9 is a central signalling hub that can negatively 
or positively regulate proinflammatory signalling to coordinate a pathogen-specific host 








CARD9 negatively regulates IL-1β production from inflammasomes 










had reduced IL-1β processing and induction of cell death at all multiplicities of infection (MOI) at 
early time points, consistent with impaired inflammasome assembly (Fig. 1a,b,d,e,g,h). Card9
-/- 
BMDMs, however, showed a slight reduction in S. Typhimurium-induced cell death.  Decreased 
pyroptosis is usually coupled to reduced IL-1β secretion1, but here we observed the opposite effect 
in Card9
-/-
 BMDMs.  At all time points and MOIs studied, there was an increase in IL-1β in the 
supernatant from Card9
-/- 
BMDMs of up to four times that seen from wild-type (WT) cells (Fig. 
1a,d,g). The increased cytokine production could not be explained by increased intracellular 
bacterial load, as both WT and Card9
-/- 
BMDMs had comparable intracellular counts (Supplementary 
Fig. 1a-c). We measured TNF-α production from the same cell supernatant and showed that 
although there is an increase in the production of this cytokine the amount produced is proportional 
to the increase in cell viability whereas the production of IL-1β is disproportionally enhanced from 
the infected Card9
-/-
 cells. (Fig. 1c,f,i). BMDM infection with Escherichia coli also showed increased 
IL-1β production in Card9-/- in comparison to WT macrophages without affecting pyroptosis, 
intracellular bacteria counts and TNF-α production (Fig. 1j-o, Supplementary Fig. 1d-e). It is possible 
that the effects of CARD9 on Salmonella-induced inflammasome activity may be indirect, for 
example by regulating the autocrine production of cytokines such as IL-10 which is reduced in CARD9 
deficient neutrophils infected with Mycobacterium tuberculosis
27
. An IL-10-mediated effect of CARD9 
on Salmonella-induced IL-1β production from macrophages is unlikely, however, as elevated IL-1β 
production occurs within 2 hours of infection, whereas IL-10 production occurs later in 
infection
28
.The increased IL-1β production in vitro is also seen in the production of this cytokine from 
a sub-lethal in vivo model of systemic infection with S. Typhimurium. WT and Card9
-/-
 mice infected 
with S. Typhimurium (strain M525P) had similar bacterial burdens in the spleen at days 1, 3 and 7 
post-infection (Supplementary Fig. 1f-g).  Immunoblotting of cell lysates from isolated spleen cells 
revealed an upregulation of pro-IL-1β in Card9-/- mice at day 7, without an increase in the caspase-1 
p10 subunit (Fig. 1p-q). The mature cytokine could not be reliably measured in mouse sera at this 







One explanation for these data could be the well-known role of CARD9, during fungal infection, in 
regulating NF-κB signalling pathways6 such that enhanced expression of pro-IL-1β could result in an 
overall increase in IL-1β production without effecting inflammasome-induced cytokine processing 
and pyroptosis. BMDM were infected with S. Typhimurium at an MOI 5 for 2h and, following mRNA 
extraction, we performed quantitative PCR analysis for genes involved in inflammasome signalling, 
NF-κB target genes and other genes coding for proteins known to associate with CARD9.  Most NF-κB 
target genes, such as TNF-α and RANTES, were similarly upregulated in WT and Card9-/- BMDMs, 
(Fig. 2c-d).  Levels of pro-IL-1β, however, whilst significantly upregulated in WT cells (around 800 
fold-increase) were even more enhanced in Card9
-/-
 cells (1200 fold-increase, p<0.01) (Fig. 2a).  This 
pattern of enhanced pro-IL-1β was also observed at the protein level (Fig. 2g).   NLRP3 was 
upregulated to a similar level in both WT and Card9
-/-
 BMDMS (Fig. 2b). SYK and caspase-8, proteins 
know to be involved in non-canonical inflammasome activity and NLRP3 activation
18,24
, were also 
found to be slightly upregulated after infection of Card9
-/- 
BMDMs at both the mRNA and protein 
level
 
(Fig. 2e-i).  Several other genes (NAIP5, NLRC4, ASC, caspase-1, FADD, Bcl-10, MALT-1 and Pro-
IL-18) showed no difference in expression between WT and Card9
-/- 
infected BMDMs 
(Supplementary Fig. 2a-h).  None of the analyzed transcripts or proteins showed basal differences 
between uninfected WT and Card9
-/-
 cells (Supplementary Fig. 2i-j).   
To determine whether CARD9 affects inflammasome activation as well as pro-IL-1β expression we 
analyzed, by immunoblotting, the BMDM supernatants for pro-IL-1β and caspase-1 processing. Our 
data show increased IL-1β protein expression in Card9-/- BMDMs at 2 and 6 hours post-infection 
compared to WT cells.  As expected BMDM from ASC knockout mice (Pycard
-/-
) were impaired in the 
production of IL-1β and the mature forms of both caspase-1 and caspase-8. Caspase-1 processing 
was similar in both WT and Card9
-/-
 BMDMs at 2 and 6 hours, suggesting that the increased IL-1β 
production in Card9
-/-
 cells is not due to an increase in caspase-1 activation.  We recently showed 
that caspase-8 plays an important role in canonical inflammasome processing of IL-1β in response to 
S. Typhimurium, but not pyroptosis which is wholly dependent on caspase-1
17
 via cleavage and 
activation of Gasdermin D
20,21
.  The mature form of caspase-8 was increased in Card9
-/-
 BMDMs at 2 
hours (Fig. 2g-h) suggesting that, in the absence of CARD9, increased caspase-8 activity is 
responsible for the increased conversion pro-IL-1β to its mature form.  
CARD9 negatively regulates IL-1β production independently of NLRC4 and AIM2 
S. Typhimurium stimulates IL-1β production via both NLRC4 and NLRP3 activation26. To assess 
whether CARD9 affects IL-1β production by each of these NLRs LPS-primed WT, Nlrc4-/-, Nlrp3-/- and 
Card9
-/-





quantification of IL-1β production.  IL-1β was elevated to similar levels in WT, NLRP3 and CARD9 
knockout macrophages, but, as expected, was below the detection limit for Nlrc4
-/-
 BMDMs (Fig. 3a). 
CARD9 modulation of inflammasome-induced IL-1β production therefore occurs independently of 
NLRC4. 
In order to confirm this observation, we infected WT BMDM with either wild-type S. Typhimurium or 
a mutant strain deficient in NLRC4 activation
5
 (ΔfliCΔfljBΔprgJ).  Both WT and Card9-/- BMDM 
infected with the ΔfliCΔfljBΔprgJ strain had impaired levels of pyroptosis in comparison to cells 
infected with WT bacteria (Fig. 3b-d).  IL-1β secretion was elevated in BMDMs infected with WT S. 
Typhimurium, but markedly reduced, as expected, in BMDMs after infection with the ΔfliCΔfljBΔprgJ 
mutant.  In Card9
-/-
 BMDMs, however, IL-1β production was increased after infecting cells with both 
strains of bacteria (Fig. 3e-g).  At 2 hours post-infection Card9
-/-
 BMDMs produced detectable IL-1β 
after infection with both bacterial strains although the level was much reduced in cells infected with 
the ΔfliCΔfljBΔprgJ mutant. No IL-1β was detected in WT cells at this time point infected with the 
ΔfliCΔfljBΔprgJ strain.  Card9-/- macrophages secreted 2.5 times more IL-1β than WT BMDMs at both 
6 and 24 hours post-infection, time points known to involve NLRP3 activity in response to Salmonella 
infection
5
.  This is consistent with our flagellin data suggesting that IL-1β produced via NLRC4 occurs 
independently of CARD9. 
To determine whether AIM2 inflammasome activity could be regulated by CARD9 LPS primed WT 
and Card9
-/- 
BMDMs were stimulated with the AIM2 ligand poly(dA:dT), but no differences in cellular 
viability or IL-1 secretion were seen (Supplementary Fig. 3). 
CARD9 negatively regulates IL-1β production through NLRP3 
To determine whether the NLRC4-independent impact of CARD9 on IL-1β production resulted from 
activation of NLRP3 we infected BMDMs with S. Typhimurium at an MOI 10 in the presence or 
absence of either glibenclamide or MCC950
29,30
.  At 2 and 6 hours post-infection, both WT and Card9
-
/-
 BMDMs showed similar levels of cellular viability in the presence or absence of glibenclamide (Fig. 
4a-b), while MCC950 slightly inhibited cell death in Card9
-/-
 BMDM (Fig. 4e-f).  Glibenclamide and 
MCC950 did not affect IL-1β production in WT cells, but they did reduce the enhancement of IL-1β 
production in Card9
-/-
 BMDMs to a level comparable to that seen in WT cells.  These data suggest 
that the increased IL-1β production from Card9-/- macrophages after Salmonella infection is driven 
by enhanced NLRP3 activation (Fig. 4c-d,g-h). 












nigericin (10 µM, 1 hour).  Nigericin, as expected, stimulated cell death and IL-1β secretion in WT 
and Nlrc4
-/-
, but not Nlrp3
-/-
, BMDMs (Fig. 4i-j).  Levels of IL-1β produced by Card9-/- BMDMs were 
greatly enhanced in comparison to WT cells after stimulation with nigericin.  Similar levels of cellular 
viability were seen in nigericin-stimulated WT and Card9
-/-





 BMDMs with ATP showed no alterations in cellular viability (Fig. 4k) and a 
significant increase in IL-1 production in Card9-/- cells in comparison to WT cells, while Nlrp3-/- 
BMDMs showed great impairment in IL-1 production (Fig. 4l). These data confirm that the effects 
of CARD9 on inflammasome function are specific for NLRP3-mediated IL-1β production and are 
uncoupled from inflammasome-driven pyroptosis. 
CARD9 inhibits NLRP3 activation upstream of speck formation 
The enhanced production of NLRP3-dependent IL-1β secretion in Card9-/- BMDMs is independent of 
caspase-1 (Fig. 2g).  How then does the presence of CARD9 inhibit processing of IL-1β? We 
investigated first whether CARD9 acts upstream or downstream of the canonical inflammasome 




 LPS-primed BMDMs were stimulated with nigericin 
(5 µM for 30 minutes), fixed, and stained for ASC and CARD9.  Both WT and Card9
-/-
 cells formed ASC 
specks (Fig. 5a).  Immunolocalisation of endogenous CARD9 suggests that this protein forms 
aggregates in stimulated and unstimulated WT and Pycard
-/-
 BMDMs,  but it does not co-localize with 
ASC specks suggesting that CARD9 is not recruited to the ASC speck (Fig. 5a). Card9
-/-
 BMDMs show 




To determine whether CARD9 associates with ASC prior to speck formation co-immunoprecipitation 
analysis of WT BMDM lysate was performed using anti-ASC, anti-CARD9 or anti-SYK antibodies as 
bait.  SYK was targeted because of its involvement in both CARD9 and ASC signalling
22,24
.  Co-
immunoprecipitations confirmed that both ASC and CARD9 interact with SYK in unstimulated or 
uninfected WT BMDMs.  ASC and CARD9 do not, however, directly interact with one another (Fig. 
5b).  After Salmonella infection or nigericin treatment, ASC immunoprecipitated preferentially with 
the phosphorylated form of SYK (p-SYK) confirming previously published data
25
, while CARD9 
predominantly interacted with unphosphorylated SYK (Fig. 5b).  Phosphorylated SYK regulates 
NLRP3 activation
22–25
, so the interaction of CARD9 with unphosphorylated SYK may prevent the its 





 isotype controls IPs (Supplementary Fig. 4). Consistent with this hypothesis we 







 mice in comparison to WT cells (Fig. 5c). This supports the idea that in the absence of CARD9 
there is increased SYK phosphorylation which facilitates NLRP3 activation. 
CARD9 inhibits NLRP3 activation through SYK and caspase-8  
Our immunoblotting (Fig 2g), co-immunoprecipitation (Fig. 5b) and SYK phosphorylation data (Fig. 
5c) all suggest that CARD9 regulates NLRP3 activation by a SYK and caspase-8-dependent 
mechanism.  To investigate this hypothesis LPS-primed BMDMs were infected in the presence or 
absence of R406, a specific SYK inhibitor, and Z-IETD-FMK, a caspase-8 inhibitor.  The expression of 
pro-IL-1β, caspase-8, caspase-1, SYK and CARD9 are similar in LPS-primed WT and Card9-/- BMDM in 
the presence or absence of these inhibitors (Supplementary Fig. 5).  BMDM infection with S. 
Typhimurium (MOI 10) in the presence of the caspase-8 inhibitor Z-IETD-FMK, as expected, had no 
effect on cell viability as measured by LDH activity (Fig. 6a) because caspase-8 does not induce 
pyroptosis in response to infection with this pathogen
17
. It is possible, however, that caspase-8 may 
induce cell death in response to infection by other mechanisms
31
. IL-1β production was reduced in 
both WT and Card9
-/-
 macrophages in the presence of Z-IETD-FMK which is consistent with our data 
suggesting that caspase-8 plays an important role in IL-1β processing during Salmonella infection17.  
Importantly IL-1β secretion in infected Card9-/- macrophages, in the presence of Z-IETD-FMK, was 
now no different to that of infected WT BMDM (Fig. 6b) supporting the hypothesis that the 
increased IL-1β production observed in Card9-/- cells is indeed mediated by caspase-8. Treatment 
with Z-IETD-FMK also reduced IL-1β secretion from nigericin stimulated Card9-/- BMDMs to the same 
level as WT cells (Fig. 6c-d).   
Cell viability in BMDMs infected with S. Typhimurium in the presence of the SYK inhibitor R406 was 
unaffected, as expected, given that SYK activity does not regulate NLRC4 activity  (Fig. 6e)
24
.  SYK 
inhibition decreased the amount of IL-1β secreted by infected Card9-/- BMDMs to similar levels to 
those seen in WT cells (Fig. 6f).  SYK inhibition, however, had less effect on IL-1β production than 
caspase-8 inhibition probably because caspase-8 is activated by both NLRC4 and NLRP3 in response 
to Salmonella infection
17
, whereas SYK only regulates NLRP3 activation
24
.   Stimulation of LPS-primed 
WT or Card9
-/-
 BMDMs with nigericin in the presence of R406 elicited similar levels of IL-1β 
production from both cell types (Fig. 6h).  SYK inhibition led to a small, but statistically significant, 
increase in cell viability in both WT and CARD9 knockout BMDM stimulated with nigericin probably 
due to its effect on NLRP3-induced caspase-1 activation
25
 (Fig. 6g).  
SYK regulates NLRP3 activity in BMDM, but it does not affect NLRP3 activation in bone marrow 
derived dendritic cells (BMDCs)
24





SYK then there should be no difference in NLRP3-stimulated IL-1β production between WT and 
Card9
-/-
 BMDC.  Stimulation of LPS-primed BMDCs with nigericin (5 µM, 1 hour) induced similar 
levels of IL-1β processing and cell death in both Card9-/- and WT BMDCs (Fig. 6i-j).  Similarly, no 
increase in IL-1β processing was observed in unprimed Card9-/- compared to WT BMDCs infected 
with S. Typhimurium (MOI 10) (Supplementary Fig. 6).  Taken together, these data support a role for 
CARD9 in regulating SYK activation of NLRP3 to control caspase-8 processing of IL-1β in the canonical 
inflammasome in BMDMs. 
SYK controls caspase-8 recruitment to the inflammasome 
How does SYK regulate caspase-8 activity in response to NLRP3 activation?  We hypothesized that 





BMDMs with nigericin in the presence or absence of R406, and 
stained the cells for active caspase-8 and caspase-1.  After fixation and counterstaining with DAPI, 
we observed speck-like structures for both caspase-1 and caspase-8 in WT and CARD9 knockout 
macrophages, but not in Pycard
-/-
BMDM (Fig. 7a).  Quantification of the number of cells containing 
specks (1000 cells per treatment, selected from random fields) confirmed that Card9
-/-
 BMDMs had 
more caspase-8 positive specks than WT cells.  The number of WT and Card9
-/- 
BMDM containing 
caspase-1 positive specks were very similar to each other (Fig. 7c).  In the presence of the SYK 
inhibitor R406 the number of cells containing caspase-8 positive specks was reduced compared to 
cells without inhibitor, but was the same for WT and Card9
-/-
 BMDM (Fig. 7b).  These observations 
corroborate the caspase-8 cleavage data (Fig. 2g) and caspase-8 inhibition assays (Fig. 6a-h) 
supporting the concept that SYK and CARD9 regulate the recruitment of caspase-8 to the 
inflammasome after NLRP3 activation to process IL-1β. 
CARD9 is a central signalling hub for inflammatory signalling 
Our data identifies a novel, inhibitory, role for CARD9 in the regulation of NLRP3-induced IL-1β 
production.  CARD9 regulates inflammatory responses downstream of numerous PRRs including 
NOD2, Dectin-1 and RIG-I.  This suggests that CARD9 may function as a signalling hub coordinating 
the cellular response to infection and permitting a rapid integrated inflammatory response to a 
range of PRRs.  To test this hypothesis we investigated whether Salmonella infection alters CARD9 
protein expression and thereby potentially alters the resulting level of inflammasome activation. 
CARD9 is constitutively expressed in many cell types including macrophages
11
 and after infection of 
WT BMDM with S. Typhimurium (MOI 10) a progressive decrease in the expression of this protein 





independent of inflammasome assembly, as similar CARD9 expression profiles were seen in infected 
LPS-primed or unprimed Pycard
-/-
 BMDMs (Fig. 8b).  Nigericin stimulation does not trigger CARD9 
downregulation (Fig. 8c) supporting our hypothesis that the regulation of CARD9 expression in 
macrophages is specifically down-regulated upon Salmonella-infection possibly to maximize the host 
inflammasome response to infection. 
Our data and other published work supports a role for CARD9 as an important regulator of PRR 
signalling where it can up- or down-regulate pro-inflammatory cytokine production in a pathogen 
dependent manner
6,8,32
. If CARD9 is a central regulator of the inflammatory response to pathogens 
then signalling through other CARD9-dependent PRRs that recognize salmonellae should also be 
altered in response to infection.  NOD2 recruits CARD9 to activate p38 and JNK MAPK signalling
11,33
, 
but NF-κB signalling is activated independently of this adaptor protein. Pro-IL-1β expression is 
transcriptionally regulated by NF-κB, p38 and JNK MAPK whereas TNF- transcription is independent 
of p38 and JNK activity
34
.  We investigated whether CARD9 was important in regulating NOD2-




 BMDMs were infected 
with S. Typhimurium (MOI of 10) and the levels of IL-1β and TNF- were determined by ELISA.  
Infection of Nod2
-/-
 macrophages induced a small increase in IL-1β production, but suppressed TNF- 
production (Supplementary Fig. 7a-c). These data are consistent with the NOD2-CARD9 axis 
negatively regulating pro-IL-1 production through an action on MAPK signalling independently of 
NOD2 induction of TNF-. Consistent with this idea, overstimulation of NOD2 at the same time of 
infection with S. Typhimurium leads to a CARD9 and NOD2-dependent decrease in pro-IL-1 
expression (Supplementary Fig. 7d). Functional association network analysis showed that the 
primary interactome of CARD9 consists of key immune and death signalling pathways in both mice 
and humans (Supplementary Fig. 8). Collectively these data support the idea that CARD9 functions 
as a signalling hub to co-ordinate inflammatory responses to pathogens such as Salmonella.  
DISCUSSION 
In this study we have identified a new role for CARD9 as a negative regulator of IL-1β production in 
response to bacterial infection.  This is in stark contrast to the role of CARD9 in fungal signalling 
where this adaptor is important for driving pro-inflammatory signalling responses to infection
3,6
.  
The recognition of infection by host cells triggers a series of complex, pathogen specific, signalling 
events to drive an appropriate inflammatory response.  It is increasingly clear that inflammatory 
signalling pathways do not function in isolation, but form complex networks in which key 
constituents act as nodes or hubs linking apparently distinct pathways.  The data we present here, 





coordinates TLR-dependent and independent NF-κB signalling6,9,11,35, ROS production10, autophagy36, 
non-canonical inflammasome function
3
 and, as we now demonstrate, canonical inflammasome 
assembly in a context dependent manner.  Importantly the specific role of CARD9 differs between 
cell types, thereby contributing a further level of regulatory control in enabling cell specificity in the 
host response to infection 
32,35,37
. 
Our data shows CARD9 fine-tunes IL-1β production in two distinct ways (Supplementary Fig. 9). 
During “signal 1”, CARD9 specifically downregulates pro-IL-1β transcription without affecting other 
NF-κB target-genes.  This occurs following activation of p38 and JNK signalling via NOD2, and is 
consistent with reports that NOD2 can have specific inhibitory roles that are dependent upon the 
context of its activation
38–43
. How CARD9 regulates pro-IL-1β in this context remains to be fully 
elucidated, but is likely to involve the transcription factor AP-1.  AP-1 is a known transcriptional 
regulator of pro-IL-1β44 which is itself regulated by p38 and JNK activity45. There is, therefore, 
increased expression of pro-IL-1 during the “signal 1” phase of inflammasome stimulation in Card9-
/- 
cells. However, in WT and Card9
-/-
 LPS-primed macrophages, which express similar levels of pro-IL-
1 the production of IL-1 is further increased in Card9-/- compared to WT cells. This suggests the 
elevated production of IL-1 from Card9-/- cells is not solely due to the increased pro-IL-1 substrate 
availability, but is also due to an effect of CARD9 during “signal 2” of inflammasome activation. 
During “signal 2”, CARD9 suppresses SYK phosphorylation which consequently reduces ASC 
phosphorylation and the subsequent assembly and activation of the inflammasome.  In 
macrophages, p-SYK phosphorylates ASC, enhancing NLRP3 inflammasome activity
24,25
; whereas in 
dendritic cells SYK has no effect on the canonical NLRP3 inflammasome
24
.  Consistent with these 
studies our data clearly shows that CARD9 negatively regulates the activity of NLRP3 in 
macrophages, but not dendritic cells. Our data suggests that, in addition to the well described 
regulatory role for CARD9 downstream of SYK, it is also possible that CARD9 can act upstream of SYK 
during bacterial infection. The regulation of SYK phosphorylation by CARD9 specifically alters 
caspase-8 recruitment to the inflammasome explaining why we see changes in IL-1β production 
independently of any effect on pyroptosis.  In Salmonella infection caspase-8 processes IL-1β but 
does not affect pyroptosis
17
.  Precisely how ASC phosphorylation enhances caspase-8 recruitment is 
unclear, but as SYK phosphorylates ASC on its CARD domain
24
 it is plausible that altering the pattern 
of ASC phosphorylation could impair the CARD/CARD interaction between ASC and caspase-1
46
 and 
favour interactions between the ASC PYD and Caspase-8 DED
47
. 
Identification of negative regulators of inflammasome activation may have important clinical 







. Genome-wide association studies found strong correlations between loss of function 
CARD9 mutations and an increased likelihood of developing inflammatory diseases
12–16
. In a 
Mycobacterium tuberculosis infection model CARD9 knockout mice have an increased bacterial 
burden and develop exacerbated systemic inflammatory responses
27
, further strengthening the link 
between CARD9 and inflammatory diseases. Similarly, Card9
-/-
 mice are deficient in controlling 
Candida albicans infection, a fungal pathogen capable of stimulating NLRP3
6
. These in vivo and 
clinical observations emphasize CARD9 role as a negative regulator for inflammation, possibly by 
fine-tuning NLRP3-mediated IL-1 production. In conclusion we have identified a novel negative 
regulatory role for CARD9 on IL-1β production in macrophages by modulating pro-IL-1β expression 
and caspase-8 recruitment to the inflammasome in response to bacterial infection.  These data 
support a role for CARD9 as a central signalling hub in co-ordinating innate immune inflammatory 




























 mice on 
a C57BL/6 background were produced by Millenium Pharmaceuticals and obtained from Kate 
Fitzgerald (University of Masschusetts).  Card9
-/-
 mice on a C57BL/6 background, originally produced 
by Xin Lin (University of Texas)
11
, were provided by David Underhill (Cedars-Sinai Medical Center).  
Nod2
-/-
 mice were provided by Peter Murray (St. Jude Children’s Research Hospital).  Mice were 
backcrossed on a C57BL/6 background at least 8 generations. All mice strains were bred 
independently. All work involving live animals complied with the University of Cambridge Ethics 
Committee regulations and was performed under the Home Office Project License number 80/2572. 
In vivo infections 
S. Typhimurium M525P was grown statically for 18 hours at 37 
o
C in LB Broth (Sigma), then washed 
and resuspended in PBS (Sigma). 1.90 to 2.04 x10
4
 CFU/mouse were administered systemically to 8 
to 16 weeks-old mice, both male and female, via the lateral tail vein, while control mice were 
inoculated with PBS only. Mice were euthanized at days 1, 3 and 7 after infection and their spleens 
and livers were aseptically removed. Organs were homogenized in 10 mL sterile water using a 
Colworth stomacher. Organ homogenates were then 10-fold serially diluted in PBS, plated on LB 
agar plates and incubated overnight at 37 °C followed by enumeration of colony-forming units. 
To obtain splenocyte cell suspensions, spleens were disrupted through a 70 µm cell strainer (BD 
Biosciences), washed in RPMI containing 2% Hyclone, resuspended in Red Blood Cell lysis buffer 
(Sigma), and incubated for 10 minutes at room temperature. The suspension was then centrifuged at 
300 G for 10 minutes and the pellet washed twice in RPMI. The purified splenocytes were lysed and 
the proteins probed by immunoblotting as described below. 
All mice were housed in a specific pathogen-free facility and all work involving live animals complied 
with the University of Cambridge Ethics Committee regulations under Home Office Project License 
number 80/2572.  
Cell culture and stimulation 
Primary bone marrow derived macrophages (BMDM) were prepared and cultured for 6-9 days as 
previously described
17
. Bone marrow derived dendritic cells (BMDCs) were prepared and cultured for 
7-10 as previously described
49
. Briefly, mice were killed by cervical dislocation, the skin was sterilized 





muscle and the proximal and distal epiphysis cut away. For BMDMs, the bone marrow was flushed 
out using DMEM supplemented with 10% FCS (Thermo Fisher Scientific), 20% L929 conditioned 
media and 5 mM L-Glutamine (Sigma). For BMDCs, the bone marrow was flushed out using BMDC 
growth media (RPMI 1640 supplemented with 10% FCS, 50 µM 2-Mercaptoethanol and 1000 U/mL 
GM-CSF (Thermo Fisher Scientific). The bone marrow cells were centrifuged (300 x G for 10 minutes 
at 15 
o
C) and ressuspended in appropriate growth media. Cells were cultured at 37 
o
C in 5% CO2 and 
growth media replaced every 2 days.Infection of BMDM with S. Typhimurium strain SL1344 and 
ΔfliCΔfljBΔprgJ was performed as previously described17. For NLRP3 inhibition assay, the cells were 
pre-incubated with glibenclamide (Sigma) 200 µM, MCC950 10 µM (Cayman Chemical) or vehicle 
control (DMSO) for 15 minutes and infection was carried out as described above. For NOD2 co-
stimulation assay, the cells were infected with S. Typhimurium in the presence or absence of 
muramyl dipeptide 10 µg/mL (Invivogen). 
Selected experiments required BMDMs primed with LPS. This was performed by incubating the cells 
in growth media containing 200 ng/mL ultrapure LPS from Escherichia coli O111:B4 (InvivoGen) for 3 
hours at 37 
o
C and 5% CO2, followed by washes in media alone. For stimulation experiments, the 
LPS-primed BMDM were incubated with nigericin 10 µM (Sigma), 5 mM ATP (Sigma) or 60 ng 
ultrapure flagellin from S. Typhimurium (Invivogen), after incubation at room temperature for 20 
minutes with Profect-P1 reagent (Target Systems) for transfection complex formation. AIM2 
stimulation was performed using Poly(dA:dT)/LyoVec (Invivogen) 2 µg/mL for 4 hours. Caspase-8 
inhibition experiments were performed in LPS-primed cells by the addition of the stimuli with or 
without 10 µM Z-IETD-FMK (MBL International). SYK inhibition experiments were conducted by pre-
incubating the LPS-primed cells for 1 hour with or without 1 µM R406 (Invivogen), followed by 
stimulation in presence or absence of 1 µM R406. 
Quantitative PCR 
Following stimulation, cells were treated with RNAprotect Cell Reagent (Qiagen) and total RNA was 
isolated using the RNeasy Mini kit (Qiagen) according to manufacturer’s instructions. Genomic DNA 
was removed using the TURBO DNA-free kit (ThemoFisher Scientific). The primers used 
(Supplementary Table 1) were selected based on data submitted to the primer bank database 
(http://pga.mgh.harvard.edu/primerbank/index.html)
50
. The quantitative RT-PCR was performed 
with the SensiFAST™ One-Step Real-Time PCR kit  (Bioline) using a Rotor-Gene Q real-time PCR cycler 
(Qiagen). Data analysis was carried out using the mean of glyceraldehyde 3-phosphate 








Immunoprecipitation, protein precipitation and immunoblot 
Cell culture supernatant and spleen homogenate proteins were precipitated using methanol and 
chloroform. Briefly, a volume of the sample was vortexed with one volume of ice-cold methanol and 
0.25 volume of chloroform, followed by centrifugation (4 
o
C, 16000 G, 12 minutes). The intermediate 
phase was collected, washed two times in ice-cold methanol, and ressuspended in Pierce
TM
 Lane 
Marker Reducing Sample Buffer (Life Technologies).  
Cells were lysed in lysis buffer containing 10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-
100, 10 mM NaF, 1 mM NaVO4, 20 mM PMSF, Phosphatase inhibitor cocktail 3 (1 in 100 dilution, 
Sigma) and Protease inhibitor cocktail (1 in 100 dilution, P8340, Sigma).  Protein levels were 
quantified using Pierce
TM
 BCA Protein Assay Kit (Life Technologies).  The samples were used for co-




 Lane Marker Reducing 
Sample Buffer (Life Technologies) for immunoblotting. 
For co-immunoprecipitation analysis cells were reversibly cross-linked with 5 mM DTBP (Fisher 
Scientific) for 30 minutes at 4 
o
C then lysed as described above. Protein concentration was adjusted 
to 600 µg/mL and 800 µL was incubated overnight with 2 µL antibody (goat anti-ASC, (sc-33958, 
Santa Cruz); rabbit anti-CARD9 mouse preferred (12283, Cell Signaling); mouse anti-SYK (MA1-
19332, Thermo Scientific)) and 20 µL of Protein A/G PLUS-agarose beads (Santa Cruz).  The 
remainder of the protein sample was stored for immunoblotting. After incubation, the beads were 
washed four times in lysis buffer, ressuspended with Pierce
TM
 Lane Marker Reducing Sample Buffer 
(Life Technologies), incubated for 5 minutes at 100 
o
C, centrifuged for 1 minute at 5000 G and the 
supernatant used for immunoblotting. 
Immunoblots were probed using the following primary antibodies: caspase-1 p10 (mouse) (sc-514, 
Santa Cruz) 1 in 500; cleaved caspase-8 (rabbit) (8592, Cell Signaling) 1 in 500; caspase-8 (rabbit) 
(IG12, Enzo) 1 in 500; IL-1β (goat) (AF-401, R&D Systems) 1 in 1000; SYK (mouse) (MA1-19332, 
Thermo Scientific) 1 in 1000; p-SYK (rabbit) (2711, Cell Signaling) 1 in 1000; ASC (rabbit) (AL177, 
Enzo) 1 in 2000; Β-Actin (mouse) (AB3280, ABCAM) 1 in 2500; CARD9, mouse preferred (rabbit) 1 in 
1000 (12283, Cell Signaling). The secondary antibodies used were: anti-goat IgG-HRP (sc-2922, Santa 
Cruz) 1 in 5000; anti-mouse IgG-HRP (7076, Cell Signaling) 1 in 6000; anti-rabbit IgG-HRP (A24537, 
Thermo Scientific) 1 in 6000 as appropriate. 
Immunofluorescence microscopy 
To label CARD9 and ASC, stimulated cells were fixed in -20 
o
C methanol for 5 minutes, after washing 
with PBS, non specific labeling was blocked by incubation at 37 
o





serum (Dako) containing 0.1% saponin (Sigma).  ASC was labeled with anti-ASC primary (1:500 
dilution, AL177; Enzo) and Alexa-fluor 568 secondary antibody (1:1000 dilution, anti-rabbit Alexa-
fluor 568 (Invitrogen)).  To label CARD9 the cells were subsequently blocked in PBS containing 1% 
BSA and 0.1% saponin.  Immunolabelling was performed with anti-CARD9 (1:300 dilution, sc-49408, 
Santa Cruz) and anti-Rabbit-Alexa 430 (1:1000 dilution, Invitrogen).  Cells were counterstained using 
DAPI mounting medium (Vecta Labs). 
Speck enumeration was performed in cells stimulated with nigericin in presence of FAM-FLICA™ 
Caspase 8 Assay Kit, green (1:150, Immunochemistry Technologies) and FAM-FLICA™ Caspase 8 
Assay Kit, red (1:150, Immunochemistry Technologies), followed by fixation with 4% 
paraformaldehyde for 15 minutes at room temperature.  Non-specific labeling was prevented by 
incubating cells with 10% normal goat serum (Dako) and 0.1% saponin (Sigma) for one hour.  1000 
cells per treatment were selected from random fields and the specks counted. 
Cellular viability assays and intracellular bacteria counts 
Cytotoxicity was quantified by measuring LDH activity after being released from live cells. Uninfected 
BMDMs (ranging from 12.500 to 200.000 cells/well) were used as standards. After treatment, the 
cells were washed three times with pre-warmed PBS and the intracellular LDH was released by lysing 
the cells with Triton X-100 1.2% for 1 hour at 37
o
 C. LDH activity was them measured using CytoTox 
96 Non-Radioactive Cytotoxicity Assay (Promega)
17
. Cellular viability was them calculated in relation 
to the uninfected control containing 200.000 cells (100% viability). Intracellular bacteria counts were 
performed using LB agar plates after overnight incubation. 
Cytokine quantification 
Secreted cytokines were measured in the culture supernatants. All cytokines were measured 
according to the manufacturer’s instructions. For IL-1β OptEIA Mouse IL-1β Set (BD Biosciences) was 
used and TNF-α using the DuoSet ELISA kit (R&D Systems). 
Computational analysis 
Functional association network analysis was performed using STRING v10
52
 and either murine or 
human CARD9 as search proteins. Primary interactomes were initially established using a high 
confidence cut-off score of 0.7 and a maximum of 50 fifty interaction partners. These interactomes 
were further expanded by relaxing the inclusion criteria to a cut-off value of 0.4. Data are presented 
with the thickness of the line between protein nodes representing the confidence level associated 






Statistical significance was determined by one-way analysis of variance (ANOVA) with Tukey post-
comparison tests using a confidence interval of 95%. In vivo data was analyzed by two-way ANOVA 
with Bonferroni post-test using a CI of 95%. 
 
Data availability 
The data presented in this study have been deposited in the University of Cambridge data repository 
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Figure 1: CARD9 negatively regulates IL-1β production in vitro and in vivo. (a,d,g) IL-1β secretion (as 
measured by ELISA), (b,e,h) cellular viability (as measured by LDH release) and (c,f,i) TNF-α (as 









at MOIs 1, 10 and 50 for 2 (a-c), 6 (d-f) and 24 (g-i) hours. (j,m) IL-1β secretion, (k,n) cellular viability 
and TNF-α (l,o) after infection of WT and Card9-/- BMDMs with E. coli P19A at MOIs 1, 10 and 50 for 2 
(j-l) and 6 (m-o) hours. (p) Immunoblot analysis of pro-IL-1β, caspase-1 and β-actin in spleen cells 
isolated from infected WT and Card9
-/-
 C57BL/6 mice after intravenous infection with S. 
Typhimurium M525P (4x10
3
 CFU) (q) densitometric analysis of this immunoblot. * p<0.05 (one-way 
analysis of variance (ANOVA) with Tukey’s multiple comparisons test). (a-i) Data from five 
independent experiments (mean and s.e.m.). (j-o, q) Data from two independent experiments (mean 
and s.e.m). (p) Representative data from two independent experiments, using cells pooled from four 
to six mice per genotype, plus two negative controls per genotype. Mice were from 8 to 16 weeks 








Figure 2: CARD9 modulates pro-IL-1β expression. (a-f) qPCR analysis of WT and Card9-/- BMDMs 
infected with S. Typhimurium (MOI 5) for 2 hours, compared to uninfected controls. (a) pro-IL-1β, (b) 
NLRP3, (c) TNF-α, (d) RANTES, (e) Caspase-8 , (f) SYK. (g) Expression of pro-IL-1β, SYK, pro-caspase-8, 
pro-caspase-1, CARD9, ASC, β-actin in cell lysates and caspase-1 p10, caspase-8 p18 and IL-1β in 




 BMDMs after 2 or 6 hours of infection  with S. 
Typhimurium (MOI 5) and relative densitometry (Card9
-/-
/WT) in culture supernatants (h) or cell 
lysates (Card9
-/-
/WT, actin-normalized) (i). * p<0.05 in comparison to uninfected control, unless 
stated in the graph (one-way ANOVA with Tukey’s multiple comparisons test). (a-f, h-i) Data from 








Figure 3: CARD9 does not control IL-1β produced via NLRC4. (a) IL-1β production from LPS-primed 
BMDMs after transfection with ultrapure flagellin. (b-d) Cellular viability and (e-g) IL-1β production 
from unprimed BMDMs after infection with S. Typhimurium WT or ΔfliCΔfljBΔprgJ (deficient in 
NLRC4 activation) at an MOI 10 for 2 (c,f), 6 (d,g) and 24 (e,h) hours. * p<0.05 in comparison to WT 
(one-way ANOVA with Tukey’s multiple comparisons test). (a-h) Data from three independent 







Figure 4: CARD9 selectively negatively regulates NLRP3-induced IL-1β production. (a-b, e-f) Cellular 
viability and (c-d, g-h) IL-1β secretion from unprimed WT and Card9-/- BMDMs infected with S. 
Typhimurium at MOI 10 for 2 (a,c,e,g) and 6 (b,d,f,h) hours in presence or absence of NLRP3 
inhibitors glibenclamide (a-d) and MCC950 (e-h). (i-j) Cellular viability (i) and IL-1β secretion (j) from 
LPS-primed BMDMs after nigericin stimulation (10 µM, 1 hour). IL-1β from LPS-primed cells without 
nigericin stimulation was below the level of detection. (k-l) Cellular viability (k) and IL-1β secretion (l) 
from LPS-primed BMDMs after ATP stimulation (5 mM, 30 minutes). * p<0.05 in comparison to WT 
(one-way ANOVA with Tukey’s multiple comparisons test). (a-f) Data from three independent 







Figure 5: CARD9 and SYK regulates NLRP3 activation upstream to speck formation. (a) CARD9 and 




 LPS-primed macrophages after nigericin 
stimulation (5 µM, 30 minutes). Green arrows indicates CARD9 aggregates. Red arrows indicates ASC 
specks. (b) Co-immunoprecipitation of ASC, CARD9 and SYK from cell lysates of uninfected, S. 
Typhimurium (MOI 10, 30 minutes) infected or nigericin (10 µM, 30 minutes) stimulated LPS-primed 
BMDMs. (c) Immunoblot analysis of LPS-primed WT and Card9
-/- 
uninfected, S. Typhimurium (MOI 
10, 2 hours) infected or nigericin (10 µM, 30 minutes) stimulated BMDMs. (a-c) Images are 







Figure 6: SYK and Caspase-8 activity are important for CARD-9 regulation of NLRP3 activity in 
BMDMs, but not BMDCs. (a-d) Effects of caspase-8 inhibition by Z-IETD-FMK on LPS-primed WT and 
Card9
-/-





Typhimurium infection (MOI 10, 1 hour) (a-b) or nigericin (10 µM, 1 hour) stimulation (c-d). (e-h) 
Effects of SYK inhibition by R406 on WT and Card9
-/-
 LPS-primed BMDMs on cellular viability (e,g) and 
IL-1β secretion (f,h) in response to S. Typhimurium infection (MOI 10, 1 hour) (e-f) or nigericin 
stimulation (5 µM, 1 hour) (g-h). (i-j) Stimulation of WT or Card9
-/-
 BMDCs with Nigericin (5 µM, 1 
hour).  Cellular viability (i) and IL-1β secretion (j). *p<0.05 (one-way ANOVA with Tukey’s multiple 
comparisons test. (a-j) Data from three independent experiments (mean and s.e.m.). 
 
 
Figure 7: SYK activity increases the number of caspase-8 specks in response to NLRP3 stimulation 
in Card9
-/-




 LPS-primed BMDMs were incubated with nigericin 
(5 µM, 30 minutes) in the presence of caspase-1 and caspase-8 FLICA substrates, with or without the 
SYK inhibitor R406. (a) Pattern of caspase-1 and caspase-8 specks observed by immunofluorescence 
labelling of this protein. (b) Percentage of cells containing caspase-8 or (c) caspase-1 specks. * 
p<0.05 (one-way ANOVA with Tukey’s multiple comparisons test). (a) Image is representative of 
three independent experiments. (b-c) Data from three independent experiments (mean and s.e.m.). 






Figure 8: CARD9 acts as a regulatory switch during infection. (a) Immunoblotting of CARD9 and ASC 
in cell lysates from unprimed WT BMDMs after infection with S. Typhimurium (MOI 5) for 0, 30, 60 





) after infection with S. Typhimurium (MOI 5) for 0, 2 and 6 hours. (c) 
Immunoblotting of CARD9 and ASC in cell lysates from uninfected, S. Typhimurium infected (MOI 5 










Supplementary Figure 1: CARD9 does not influence bacteria counts in vitro and in vivo. (a-c) 




 BMDMs after infection with S. Typhimurium 
SL1344 at MOIs 1, 10 and 50 for 2 (a), 6 (b) and 24 (c) hours. (g-h) Bacteria burden in the spleen (g) 
and liver (h) after C57BL/6 WT and Card9
-/-
 infection with S. Typhimurium M525P (4x10
3
 CFU). * 
p<0.05 in comparison to WT (one-way ANOVA with Tukey’s multiple comparisons test). (a-e) Data 
from two independent experiments (mean and s.e.m.). (g-h) Data from two independent 
experiments using from four to six mice per genotype, plus two negative controls per genotype. 







Supplementary Figure 2: Transcription and expression analysis of WT and Card9
-/-
 BMDMs. (a-h) 
qPCR analysis of WT and Card9
-/- 
BMDMs infected with S. Typhimurium (MOI 5) for 2 hours, in 
relation to their respective uninfected controls. (a) ASC, (b) Bcl-10, (c) FADD, (d) Caspase-1, (e) NAIP5 
, (f) Malt-1, (g) NLRC4, (h) pro-IL-18. (i) Basal transcriptional levels in uninfected Card9
-/-
 BMDMs in 
relation to uninfected WT cells. (j) Basal expression of pro-IL-1β, SYK, Caspase-8 Full Length, Caspase-





comparison to uninfected control (one-way ANOVA with Tukey’s multiple comparisons test). (a-i) 






Supplementary Figure 3: CARD9 does not control IL-1β produced via AIM2. (a) Cellular viability and 
(b) IL-1 from LPS-primed BMDMs after transfection with poly(dA:dT) for 4 hours. Data from three 












were primed with LPS (200 ng/mL) for 3 hours and incubated with S. Typhimurium (MOI 10, 30 
minutes) or with Nigericin (10 µM, 30 minutes). IPs were then performed as indicated using anti-
CARD9 (for Card9
-/-
 BMDMs) or anti-ASC (for Pycard
-/-
 BMDMs), followed by immunoblotting. No IPs 








Supplementary Figure 5: LPS-priming by itself or use of Z-IETD-FMK and R406 do not cause 
different expression in WT and Card9
-/-
 BMDMs. Expression of pro-IL-1β, SYK, pro-caspase-8, pro-
caspase-1, CARD9, β-actin in of cell lysates from WT and Card9-/- BMDMs incubated for 3 hours with 
LPS (200 ng/mL) or 3 hours with LPS with and additional hour of incubation with Z-IETD-FMK (10 µM) 







Supplementary Figure 6: CARD9 plays no role in controlling IL-1β production in BMDCs. (a) cellular 
viability (as measured by LDH release) and (b) IL-1β secretion (as measured by ELISA), of WT and 
Card9
-/-
 BMDCs after infection with S. Typhimurium SL1344 at MOI 10 for 2, 6 and 24 hours. (a-b) 







Supplementary Figure 7: NOD2 up- and down-regulates the expression of different cytokines 
during S. Typhimurium infection. (a) Cellular viability (as measured by LDH release) (b) IL-1β 
secretion (as measured by ELISA) and (c) TNF-α (as measured by ELISA) of WT and Nod2-/- BMDMs 





 BMDMs infected with S. Typhimurium (MOI 10) with or without MDP co-
stimulation (10 µg/mL) (a-c) Data from two independent experiments (mean and s.e.m.). (d) Figure is 








Supplementary Figure 8: CARD9 interfaces with multiple inflammatory and death-related 
signalling pathways. Functional association network analysis of the primary CARD9 interactome was 
performed using STRINGv10. High confidence interaction partners (score > 0.7) for murine (a) and 





interaction partners (score > 0.4) confirms the expansive signalling network in which CARD9 is 






Supplementary Figure 9: Simplified model for CARD9 regulation of IL-1β production. Infection by S. 
Typhimurium triggers the assembly of the NLRP3 inflammasome in the cytoplasm of BMDMs with 
subsequent processing of pro-IL-1β to mature IL-1β. CARD9 negatively regulates inflammasome 






Supplementary Table 1: Pairs of primers used for the qPCR experiments. 
 
 
 
